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Abstract 
Aims and objectives 
This thesis aimed to assess the efficacy of percutaneous tibial nerve stimulation (PTNS) 
in the treatment of adults with faecal incontinence (FI). The objectives were (1) to 
perform a systematic review of the evidence base for tibial nerve stimulation (TNS) to 
treat FI, (2) to assess the short term efficacy of PTNS in the treatment of FI (the 
CONFIDeNT Trial), (3) to identify factors predictive of successful PTNS and (4) to 
analyse the 1-year outcomes of all patients in the CONFIDeNT Trial. 
Methods 
Objective 1: A systematic review of the current literature on TNS in the treatment of FI 
was performed. Objective 2: A multi-centre double blind randomised sham-controlled 
trial comparing PTNS to sham electrical stimulation in the treatment of adults with FI 
was performed. Objective 3: Logistic regression analysis to identify factors predictive 
of successful PTNS from the CONFIDeNT Study data was performed. Objective 4: A 1-
year follow-up study of patients enrolled in The CONFIDeNT Study was performed.  
Results 
Data supporting the use of PTNS in the treatment of adults with FI was encouraging, 
however data quality was poor. In the short term, PTNS did not offer significant clinical 
benefit over sham electrical stimulation in the treatment of adults with FI, based on the 
primary outcome (treatment success was defined as ≥50% reduction in weekly FI 
episodes). Logistic regression analysis demonstrated the absence of any difficulty with 
rectal evacuation was the only factor predictive of successful PTNS in the short term 
(directly after treatment). The follow-up study demonstrated the continued benefit of 
treatment in the proportion of patients followed to 1-year.   
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Conclusions 
PTNS should not be recommended as a first-line treatment for unselected adults with 
FI (the population in CONFIDeNT Trial). However, subgroups of patients, e.g. those 
with FI uncomplicated by problems with rectal evacuation, may benefit more. In 
patients gaining benefit, this appears to be sustained.  
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1 Introduction 
1.1 Definitions 
Faecal incontinence (FI) is described as the ‘recurrent uncontrolled passage of faecal 
material, for at least three months’1. The loss of wind (flatus) can also be a problem, 
and this, in addition to FI as described above, is often called anal incontinence2-4. FI 
occurs when one or more of the mechanisms that maintain continence is disrupted, and 
the other mechanisms are unable to fully compensate5.  
FI is often sub-divided in an attempt to classify symptomatology and determine 
pathophysiology. Passive FI occurs without the patients’ knowledge that their bowels 
have opened; post-defaecation leakage is defined as passive FI temporally related to 
defaecation and urge FI occurs with the patient’s awareness, causing them to rush to 
the toilet6.  
1.2 Applied anatomy of the anorectum 
The rectum and anus comprise the most distal portion of the large bowel. The rectum, 
which serves as a reservoir for faecal material, is more proximal to the anus, begins at 
the upper level S3 and extends 12-15cm distally7. It is distinguishable from the sigmoid 
colon above, as the incomplete outer muscle layer or taenia on its surface have 
coalesced from three distinct bands to form a single longitudinal layer marking its 
surface7. Underlying this, the longitudinal muscle interlaces with circular muscle5. 
Below the rectum, the anal canal extends from the pelvic floor muscles to the anal 
verge, and is approximately 2.5 – 5cm in length (slightly longer in males than females)7, 
8. The anal canal is surrounded by two muscles, the internal and external anal 
sphincters7. The internal anal sphincter is 0.3-0.5 cm thick and is a continuation of the 
inner circular smooth muscle surrounding the rectum, and the external anal sphincter 
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is 0.5-1cm thick and comprises an extension of the pelvic floor muscles5, 7. The two 
sphincters are separate and distinguishable morphologically9. The pelvic floor (levator 
ani muscle) is a striated muscle layer surrounding a central tendon, with openings for 
the urethra, vagina and rectum8. The levator ani muscle is comprised of 3 separate 
muscles; the iliococcygeus muscle, the pubococcygeus muscle and the puborectalis 
muscle, which work as one to support the pelvic organs, maintain continence and help 
co-ordinate defaecation7. This broad thin sheet of muscle originates from the inner 
surface of the lower pelvis7. At rest, there is a natural angle of approximately 90 
degrees between the anus and rectum, maintained in part by the puborectalis muscle, 
which is considered the most significant portion of the levator ani in terms of 
continence, as it slings around the upper anal canal, inserting onto the pubis5, 7. Figure 
1 is a schematic representation of the anatomy described.  
 
Figure 1: Schematic coronal representation of anorectal anatomy  
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1.3 Innervation of the anorectum 
Innervation of the anorectum is via the enteric, somatic, autonomic and central 
nervous systems10. The enteric nervous system is the intrinsic innervation of the GI 
tract, which comprises an outer myenteric plexus (which regulates smooth muscle 
activity) and an inner submucosal plexus (which influences secretory and absorptive 
functions, and local blood flow), and is modulated by the autonomic (sympathetic and 
parasympathetic) nervous system10. Afferent nerve fibres, located in GI tract 
epithelium and mucosa, which respond to distension, mucosal irritation and chemicals, 
are involved in local reflexes as well as conveying information centrally, via the enteric 
nervous system, prevertebral ganglia and vagus nerve11. Parasympathetic innervation 
to the hindgut i.e. descending colon, sigmoid colon and anorectum is via the pelvic 
nerves 10. The pelvic nerves originate from the caudal S2, S3 and S4 nerve roots 
(forming nervi erigentes) which increase colonic motor activity and blood flow as well 
as providing an integral role in defaecation7, 10. Sensation of rectal distension is likely 
parasympathetically mediated5. Sympathetic innervation to the GI tract is from the 
thoracolumbar outflow (T5-L2), and fibres leave the spinal cord, pass through the 
paravertebral ganglia and relay to the coeliac and mesenteric ganglia, with most 
postganglionic sympathetic fibres terminating on the enteric nervous system10. 
Maintenance of anal tone, by internal anal sphincter contraction, is mediated by the 
sympathetic nervous system10. The sympathetic nervous system is responsible for 
inhibiting motility through the GI tract, and causing vasoconstriction via noradrenaline 
on enteric nerves10.  
The pudendal nerve provides innervation to the external anal sphincter and cutaneous 
sensation from the perianal area and perineum, but does not convey rectal sensation10, 
12. With regards to the central nervous system, the medial prefrontal area and the 
anterior cingulate gyrus represent two areas that are involved in the timing and 
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initiation of defaecation at an appropriate time, with their effects over voluntary 
control being mediated through spinal pathways10.  
1.4 Physiology of continence and defaecation 
Continence relies on the correct individual functioning of each of the component parts, 
namely the gastrointestinal tract and anal sphincter complex, brain and central 
nervous system and the autonomic and enteric nervous systems, and their correct, 
timely and co-ordinated actions together13. Factors contributing to the maintenance of 
continence are detailed in Table 1. 
  
Table 1: Factors contributing to the maintenance of continence (Scott et al.13) 
 Sphincteric Pelvic Intestinal 
Structural Anal sphincters 
Longitudinal 
muscle 
Vascular anal 
cushions and 
secondary mucosal 
folds 
Levator ani 
Resting perineal 
position 
Rectal capacity 
Intestinal length 
Functional Resting tone 
Squeeze increment 
Anal sensation, 
plasticity and 
motility 
Rectoanal 
inhibitory reflex 
Rectoanal 
contractile reflex 
Levator ani 
contraction 
Anorectal angle 
Rectal tone, 
sensation and 
compliance 
Rectosigmoid 
motility 
Anorectal pressure 
gradient 
Stool consistency 
and volume 
GI motility 
Neurological Satisfactory functioning of relevant nerves (pudendal nerve, 
sympathetic nerves, parasympathetic nerves, sacral somatic 
nerves, spinal afferent nerves, enteric nerves. 
Other Central neurological integrity 
Psycho-behavioural factors 
Normal rectal evacuation 
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The internal anal sphincter is responsible for the majority of the resting anal sphincter 
tone (between 55 and 85%)12. It comprises fatigue-resistant slow-twitch smooth 
muscle, which generates mechanical activity with a frequency of 15-35 cycles per 
minute and ultra-slow waves at 1.5-3 cycles per minute14-17. The external anal 
sphincter is comprised of striated muscle, which contains tonically contracting ‘slow 
twitch’ and phasically contracting ‘fast twitch’ fibres that are fatigable8. Though it 
contributes a little to anal resting tone12 (reported as up to 30%18), its main function is 
to reinforce anal sphincter function during voluntary squeeze5.  Pressures between 50 
and 200mmHg can be generated in health8. The sphincter muscles alone cannot 
entirely close the anal lumen19, but the blood-filled vascular tissue of the anal mucosa is 
thought to provide a further seal for the anus, contributing to a further 10 – 20% of the 
resting anal tone18, and in addition to this the secondary anal mucosal folds provide a 
better seal3. Another feature that contributes to the maintenance of continence at rest 
is the acute angle maintained between the anus and rectum.  
Once an urge is felt, continence is maintained by a combination of voluntary 
contraction of the external sphincter increasing intra-anal pressure, alongside 
contraction of the puborectalis muscle which creates a forward-pull causing the 
anorectal angle to become more acute20.  
The act of defaecation involves a complex interplay of features, which can be described 
as 4 distinct phases: [1] the basal phase, normal motor function of the colon and 
rectum prior to the urge to defaecate; [2] the pre-defaecatory phase, which leads to 
generation of the urge to defecate; [3] the expulsive phase, during which evacuation of 
the bowel contents occurs, and finally [4] the termination of defaecation21. This is 
described in Figure 2. 
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Figure 2: Flowchart to show the principal events during defaecation 21 . 
 
The basal phase: Functions of the colon include water absorption, propulsion of faecal 
material, and the storage of faeces until a socially acceptable time for expulsion21. 
During any normal 24-hour period colonic motor activity is increased during the 
daytime hours, and maximally after waking and after eating22-24. Colonic motor activity 
 
31 
 
comprises brief, tonic contractions and prolonged, phasic contractions, which can be 
either propagating or non-propagating24. Net propagation is antegrade (aboral) though 
there is significant retrograde (oral) colonic activity also21. Faeces are delivered to the 
rectum, in which most motor activity at this point is in a retrograde direction, thought 
to contribute to maintenance of continence by acting as a ‘brake’21. During this phase 
the pelvic floor muscles and external anal sphincter maintain tone in order to support 
the weight of the pelvic contents, and the anal canal is closed as described above21. So 
called ‘anal sampling’ is a physiological process whereby transient relaxation of the 
internal anal sphincter allows rectal contents to briefly enter the upper anal canal in 
order that the nature of the matter can be determined by the anal canal epithelium25. It 
is described as occurring 7 times per hour in health, and less frequently in patients 
with incontinence25, 26.  Few data have been published on this theory since its first 
description in 1988, and some question whether this is an accurate representation of 
true physiology27. A reduction in internal anal sphincter tone occurs in response to 
rectal distension, and this is known as the ‘rectoanal inhibitory reflex’ (RAIR). 
Amplitude and duration of the anal relaxation increase with rectal volume and the 
reflex is mediated by the myenteric plexus28. The RAIR may facilitate the passage of 
flatus, but it is associated with a contractile response of the external anal sphincter, in 
order to prevent accidental passage of rectal contents5.  
The pre-defaecatory phase: This phase involves increasing motor activity of the 
colon, rectum and anus which culminate in a person perceiving the ‘call to stool’: a very 
important sensation in achieving normal defaecation21. The rectum is the predominant 
site that perceives defaecatory urge21; and gradual distension of the rectum causes a 
graded response, which begins with initial awareness of filling, followed by a constant 
sensation which then turns into a sustained urge to defecate and finally to an intense 
urge to defecate as the maximum tolerated pressure or volume is reached29-31. Normal 
defaecation relies on a combination of normal rectal afferent nerves and rectal wall 
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biomechanical properties in order that perception of rectal fullness and subsequent 
defaecatory urge are felt32. The pelvic floor muscles are in a state of continuous 
contraction to preserve continence, though it is thought that these muscles also have a 
role in generation of normal filling sensation and defaecatory urge perception through 
stretch receptors21, 33. During this phase, it is not known whether the ‘anal sampling’ 
reflex alters in any way, though it is likely that as rectal filling increases, the pressure 
exerted on the anal canal thus increases and increased contraction of puborectalis and 
the external anal sphincter are required to maintain continence21. 
The expulsive phase: This phase involves the active and conscious decision to 
evacuate the bowels following on from the presence of a defecatory urge, where a 
normal behavioural response to the urge to defaecate is integral21. During this process, 
a proportion of the colon as well as the rectum, empties34. Evacuation is facilitated by 
several factors; the adoption of an appropriate position; elevation of intra-abdominal 
and therefore intra-rectal pressure by straining; relaxation (or reflex inhibition) of the 
pelvic floor tonic activity resulting in straightening of the anorectal angle and finally 
relaxation of the anal canal21. Expulsion occurs and is maintained due to high intra-
rectal pressure from straining, though it is thought that this is reinforced once 
defaecation has started, by a spinal reflex, which maintains propulsive force until the 
rectum is empty35, 36. Defaecation will continue to occur whilst intra-rectal pressure is 
higher than intra-anal pressure.  
Termination of defaecation: This phase is under semi-voluntary control, with the 
cessation of straining or increased intra-abdominal and rectal pressure following the 
sensation of complete evacuation21. This in turn leads to involuntary contraction of the 
pelvic floor and external anal sphincter, which results in anal pressure again exceeding 
rectal pressure21. The passage of stool through the anal canal results in a traction force 
being applied to the external anal sphincter, which in turn causes a reflex increase in 
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external sphincter pressure. This ‘closing reflex’ is important in terminating 
defaecation and provides sphincter tone whilst the internal anal sphincter recovers 
from relaxation as a result of the RAIR21. Tone resumes in the pelvic floor muscles, 
which in turn increases the anorectal angle to its resting state. Defaecation is thus 
terminated.  
1.5 Epidemiology of faecal incontinence  
FI comprises a significant public health problem and causes much physical and 
psychological disability amongst those worst affected2, 37, 38. Results of clinic-based 
studies of FI cannot be extrapolated to estimate population prevalence of FI, and only 
true community-based studies will allow estimation of this. Unfortunately, due to the 
inherent strategic and economic difficulties associated with such studies, few 
epidemiological studies have been performed, making true estimation of the disease 
burden challenging.  
Adding to this situation is the well-recognised but necessarily ill-defined population of 
‘silent sufferers’, who have significant symptoms and associated physiological and 
psychological disability, but who never consult any medical professional. This may be 
due to any number of factors including embarrassment, failure of acceptance of the 
condition, or lack of knowledge that treatment strategies do exist, and it is estimated 
that this may account for between 55-85% of sufferers4, 39, 40. A study carried out in the 
USA estimated that two thirds of symptomatic patients did not report this condition to 
a physician40, 41, similarly a study of women in the United Arab Emirates suggested that 
60% of multiparous women with FI did not seek medical advice42. This study further 
questioned subjects with FI as to why they did not seek medical advice: 64.7% 
reported that this was due to embarrassment, 47.1% presumed it would resolve 
spontaneously, 31.3% thought this was normal and 23.5% chose self-treatment as they 
had low expectations of medical care42.  
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This situation is not helped by the social taboo surrounding the subject of FI, especially 
in the UK, which has led to a relative paucity of published literature, and a distinct lack 
of media attention in terms of raising awareness and acceptance amongst the general 
public. 
Differences in the reported prevalence of FI between studies may be due to a number 
of reasons. The main reason for differing prevalence seems to be the population 
studied with the most important factors being sex, age, health status and place of 
residence2. Another factor contributing to this is the lack of a standardised definition 
for ‘FI’, with some studies strictly reporting only FI symptoms as defined in 1.1 above, 
and other studies using the definition of ‘anal incontinence’ as in 1.1 above, which will 
clearly provide significantly differing estimations of disease burden.  
Eleven studies have estimated prevalence of FI in the community by sampling all adults 
in a population 2, 38, 43-51. These studies, which included between 500 and 7,196 subject,  
reported the prevalence of incontinence at between 1.9% 49 and 16.8% 51, although 
different definitions of ‘incontinence’, as described above, were used (Table 2).  
1.5.1 Prevalence by country  
The studies described above comprised three studies from the USA, three studies from 
Australia, one from Brazil, one from Germany, one from New Zealand, one from France 
and one from the UK and it seems that there are no substantial geographical 
differences in the prevalence of FI. Many other studies in the literature have estimated 
rates of FI in different countries and these are summarised in Table 2. 
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Table 2: Studies of rates of FI in different countries (adapted from Nelson. (53)). 
Reference Country Population 
Number of 
subjects 
Prevalence 
MacLennan et 
al. 2000 
Australia Household survey 3010 
2.3% men; 3.5% 
women >15 years 
old 
Lam et al. 
1999 
Australia Age >18 yr 618 
15% (M= 20%; F = 
11%) 
Kalantar et al. 
2002 
Australia Age >18 yr 651 
2% solid; 9% liquid 
(F>M) 
Santos et al. 
2014 
Brazil Age >18 yr 2162 3.6% (F>M) 
Siproudhis et 
al. 2006 
France 
Household 
community survey 
7169 16.8% 
Giebel et al. 
1998 
Germany Age >18 yr 500 4.8% 
Lynch et al. 
2002 
New 
Zealand 
Age >18 yr 717 
9.8% for solid; 
12.7% for liquid; 
64% gas 
Thomas et al. 
1984 
UK Community 4844 1.9% 
Drossman et 
al. 1993 
US Market mailing 5430 
7% soiling; 0.7% to 
faeces 
Nelson et al. 
1995 
US 
Wisconsin 
households 
6959 
2.2%; 63% of whom 
were women 
Whitehead et 
al. 2009 
US Household survey 4308 
8.3% (M=F); 1.6% 
solid stool 
Denis et al. 
1992 
France Age>45 years 1100 
11%, 6% to faeces; 
60% of whom were 
women 
Perry et al. 
2002 
UK Age >40 yr 10 116 1.4% (M=F) 
Talley et al. 
1999 
US Age >65 yr, at home 328 3.7% (M>F) 
Bharucha et 
al. 2006 
US 
Olmsted County 
women >20 years 
old 
2800 
12.1% in females; 
increasing with age 
Melville et al. 
2005 
US 
HMO population 30-
90 years. 
Washington State 
3536 7.7% in females 
Quander et al. 
2005 
US 
Chicago Health and 
Ageing Project >65 
years old 
6158 
6.9%; associated 
with age (M=F) 
Varma et al. 
2006 
US 
Population based 
study of females >40 
years 
2109 24% in females 
Nygaard et al. 
2008 
US Survey of women 1961 9% in women 
Matthews et 
al. 2013 
US 
Women aged 62-87 
years 
64, 396 11.5% 
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1.5.2 Prevalence by sex 
There is on-going debate regarding the differences in prevalence of incontinence 
between males and females. Perry et al. have suggested differences may exist due to 
the age of the population studied, may represent differences in referral pattern and 
consultation behaviour, indeed it has been shown that women are more likely to report 
symptoms than men2, or may represent differences in aetiology52, 53. The differences 
between sexes may also be accounted for by considering the definition of incontinence 
used. The suggestion being that in those studies that define ‘anal incontinence’ 
prevalence, a higher preponderance of women can be explained by the association 
between childbirth and a higher rate of flatus incontinence53. Alternatively, Maddoff et 
al. have suggested that the differences may be explained as most reported clinical 
series have a female preponderance whereas epidemiological studies are those which 
report equal distribution between the sexes, and this points more towards consultation 
behaviour than any other reason4.  
With regard to FI, some studies found equal prevalence in both sexes, for example the 
UK based study of 10,116 adults over the age of 40 years, calculated the prevalence of 
FI to be 6.2% in men and 5.7% in women, i.e. with no differences between sexes53. 
Other studies have found a higher prevalence in women, for example the Australian 
study of 3,010 adults found higher rates of flatus and FI in women than men (10.9% vs 
6.8% and 3.5% vs 2.3% respectively)43. Another Australian study of 651 subjects found 
that 55% of those suffering FI were women (although no significance was attached to 
this)45. A US study of 6, 959 individuals found 63% of those suffering FI were women, 
and indeed this was an independent risk factor for incontinence2. Conversely, other 
studies have found higher rates of faecal incontinence in men, for example the 
Australian study of 618 subjects (259 males) found prevalence significantly higher in 
men than women (20% vs. 11% (p=<0.015)44. Other studies have found equal 
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prevalence in both sexes 54-57, higher prevalence in men55, 57, 58 and higher prevalence in 
women39, 59, 60. However all of these studies have concentrated only on the elderly 
population, which is a separate epidemiological factor in itself.  
1.5.3 Prevalence by age 
Many studies have concentrated on the prevalence of incontinence amongst older 
individuals who are not institutionalised. Prevalence of FI in 6 studies with subjects 
over the age of 50 years ranges from 3% to 16.9%39, 54, 55, 57, 59, 61. Of these studies, 3 
found an increased prevalence of FI with age54, 57, 61 (although one of these studies only 
included women61), one found an increased prevalence with age in men but not 
women59 and the other reported no significant change with age39. Of the studies 
considering the whole population, the UK based study of 10, 116 adults over the age of 
40 years found a steady increase in prevalence with age in terms of both frequency of 
leakage and severity of leakage episodes (0.9% adults between 40-64 years and 2.3% 
adults aged 65 years or over)53. Similarly an American community based study that 
estimated the prevalence of anal incontinence in 6, 959 adults to be 2.2%, found a 
majority of sufferers over the age of 65 years (greater than two thirds)2. A further 
epidemiological study of 3, 010 subjects in Australia found an association between all 
types of pelvic floor disorders and age in both males and females43. 
Most studies seem to agree that prevalence and severity of FI increase with age, and as 
populations age, comorbid disease becomes a significant component of incontinence 
risk39, 53.  
1.5.4 Prevalence amongst institutionalised individuals 
The prevalence of FI amongst the institutionalised elderly population is undisputedly 
higher than the general elderly population, with four studies quoting prevalence 
estimates between 46% and 54.4% in sample sizes ranging from 447 to 18, 170 
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subjects62-65. Indeed FI prevalence is disproportionately high amongst those with 
severe mental and physical disability, and although FI is often attributed as the reason 
for older people becoming institutionalised53, 66, 67, it seems the evidence to back up this 
claim is limited68-70. The reasons for such high prevalence amongst institutionalised 
elderly may be attributed to poor functional status, impaired cognitive ability or 
dementia and limited mobility60, 71. There is also evidence to suggest rates of 
incontinence correlate with length of time spent in a nursing home 63. 
1.5.5 Prevalence by ethnicity 
There is some literature regarding FI and race. Varma et al., reported no difference in 
prevalence of FI in women by race in a large population based study in the US72, 
however another community-based US study of women has reported that FI is almost 
twice as common in white women as opposed to black women73. This may, at least in 
part, be explained by the apparent reduced risk of anal sphincter injury amongst Afro-
Caribbean women as compared to Caucasian or Hispanic women reported in two 
studies74, 75.  Another study found Asian, Indian and Pilipino women to have an 
increased risk of obstetric anal injury76.  
1.6 Pathophysiology of faecal incontinence 
Since the maintenance of continence relies on the correct individual functioning of each 
of the anatomical components listed above, and their correct, timely and co-ordinated 
actions,13 failure of the individual functioning of any of these components or of their co-
ordinated action, could result in FI. Many people may exhibit more than one 
pathophysiological mechanism. Pathophysiological mechanisms for FI can be 
physiological or psychological (Table 3). 
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Table 3: Pathophysiological mechanisms for faecal incontinence. 
Physiological Factors 
Failures of internal anal sphincter, external anal sphincter or puborectalis muscle 
Abnormal rectal sensation or rectal compliance 
Abnormal stool consistency e.g. diarrhoea  
Impaired mental faculties 
Impaired mobility 
Psychological Factors 
Anxiety and depression 
 
1.6.1 Physiological factors 
1.6.1.1 Failures of anal sphincter complex and puborectalis muscle 
Controlled studies report anal sphincter weakness as the most commonly identified 
abnormality in incontinent patients. In older women with FI, a study reported 
approximately 40% had reduced anal resting pressure and 80% had reduced squeeze 
pressure 77.  
Internal anal sphincter dysfunction may be characterised by exaggerated spontaneous 
relaxation of the internal anal sphincter (sampling reflex)78 or decreased resting 
pressure 77, 78. Decreased anal resting pressure may be as a result of a discrete defect in 
the internal anal sphincter (e.g. following traumatic vaginal delivery) or a generalised 
thinning of the muscle (e.g. with age). External anal sphincter weakness may result 
from sphincter damage (e.g. by surgery), neuropathy (generalised or specific to 
pudendal nerve) or myopathy. Failure of puborectalis to maintain continence may 
occur in patients with excessive perineal descent, who have a more obtuse anorectal 
angle, impairing the flap valve that normally maintains continence when intra-
abdominal pressure increases.79   
Few studies have evaluated the pathophysiology of FI in men, 80-82 which indeed is 
often associated with normal sphincter function.81, 83 In the presence of iatrogenic 
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injury to the sphincters, pathophysiology is similar to that in females, however where 
this has not occurred, FI may be associated with dyssynergic defaecation,84 high anal 
resting pressure trapping stool which is subsequently expelled without the usual 
control, causing soiling,85 or isolated weakness of the internal anal sphincter.  
1.6.1.2 Abnormal rectal sensation or rectal compliance 
Abnormalities of the rectum, including sensation and compliance can lead to FI. If 
rectal sensation is reduced, an episode of FI may have occurred before the external 
sphincter has contracted 30, 78, 86. Alternatively, if a patient has decreased rectal 
sensation and increased rectal compliance the resultant faecal retention may then lead 
to overflow incontinence.  Conversely, increased rectal sensation may result in 
symptoms of urgency, and associated urge faecal incontinence 77, 87.  
1.6.1.3 Other factors 
In addition to the problems listed above, FI may also be a result of abnormal stool 
consistency e.g. diarrhoea, impaired mental faculties or immobility (resulting in an 
inability to reach the toilet at the correct time). 
1.6.2 Psychological factors 
FI has a profound effect on emotional, social and psychological function, and is 
significantly associated with anxiety and depression 88. Higher depression scores are 
associated with more severe quality of life impairment in patients with FI 89. Other 
functional gastrointestinal disorders have shown an association between psychological 
stress and alteration of the brain-gut axis, and this is likely to also occur in FI.  
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1.7 Risk factors for faecal incontinence 
In a minority of cases, there is a clear and direct cause for a person to suffer FI, for 
example internal anal sphincter division during a lateral sphincterotomy for non-
healing fissure. For many people however, there is no obvious temporal relationship.  
FI may come on years after an apparently uneventful vaginal delivery; the association 
between the event and the symptoms is less clear, and indeed the event may be just 
one component of a multifactorial aetiology.  Structural sphincteric causes for FI are 
relatively easy to investigate, however in many people who suffer FI no structural 
problem is evident. Risk factors are definable entities that place one individual at 
greater risk of developing a condition than another individual who has not been 
exposed to that same factor13. Many risk factors for FI have been identified (Table 4). 
Unfortunately, there are few epidemiological studies that have systematically reviewed 
all potential risk factors for FI, with most studies instead being clinic-based and so not 
generalisable to a whole population. In truth, it is likely that most patients (up to 80%) 
have a combination of factors, the sum total of which has contributed to their 
symptomatology78, 90.   
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Table 4: Risk factors for faecal incontinence 
Anal sphincter weakness 
Traumatic: Obstetric, surgical (e.g. haemorrhoidectomy, internal sphincterotomy, 
fistulectomy) 
Non-traumatic: Scleroderma, internal sphincter degeneration of unknown aetiology 
Neuropathy 
Peripheral (e.g. pudendal) or generalised (e.g. diabetes mellitus) 
Pelvic floor deficiency 
Rectal prolapse 
Increased perineal descent 
Diarrhoea 
Irritable bowel syndrome, post-cholecystectomy diarrhoea 
Faecal retention with overflow 
Inflammatory bowel conditions and anorectal surgery as listed below 
Problems of rectal capacity 
Inflammatory conditions: Radiation proctitis, Crohn’s disease, ulcerative colitis 
Anorectal surgery (e.g. ileo-anal pouch or anterior resection) 
Central nervous system disorders 
Dementia, stroke, brain tumour, multiple sclerosis, spinal cord lesion 
Psychiatric diseases, behavioural disorders 
 
1.7.1 Faecal incontinence in women 
1.7.1.1 Obstetric injury 
Obstetric injury is  a major contributor to FI in women, indeed obstetric trauma is often 
cited as the most common cause of anal sphincter injury91-94. Obstetric anal sphincter 
injuries (OASIS) are classified by the Thakar and Sultan Classification of Perineal 
Trauma from first to fourth degree tears95 (Table 5).  
Table 5: Classification of perineal tears95  
Tear classification Description 
First degree Only vaginal epithelium or perineal skin involved 
Second degree Involves perineal muscles but not anal sphincter 
Third degree Disruption of the anal sphincter muscles. Divided into: 
 3a: <50% thickness of external sphincter torn 
 3b: >50% thickness of external sphincter torn 
 3c: Internal sphincter also torn 
Fourth degree tear 3c tear in which anal epithelium also disrupted 
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It is reported that 85% of women sustain some perineal trauma during vaginal 
delivery96, and the mechanisms for this are twofold, namely structural i.e. direct 
sphincteric damage via third and fourth degree tears, or neurological i.e. injury to the 
pudendal nerve from the foetal head97-99. More recently it has been postulated that it 
may not just be injury to the pudendal nerve that results in subsequent 
symptomatology, but that the inferior hypogastric plexus may indeed be damaged. This 
would result in damage to intrinsic and extrinsic nerves innervating pelvic viscera thus 
resulting in pelvic floor dysfunction (and the development of faecal urgency and 
altered sensory function)100. Most patients were thought to have ‘neurological’ FI101 
until the advent of endoanal ultrasound scanning (EAUS) which enabled morphological 
study of the sphincter. It is now believed that isolated neuropathy as a cause of 
incontinence only occurs in about 10% of cases102 whereas a structural sphincteric 
injury is identified in the majority93, 103, 104, however in truth it is likely that in most 
patients there is a combination of both.  
Many studies have shown a strong association between OASIS and symptomatic FI, 
although some women who suffer no occult sphincter injury do seem to suffer FI105. 
Nine studies92, 106-112 in which sphincter integrity postpartum was assessed with EAUS 
to assess the relationship between new sphincter defects and symptoms of FI have 
been summarised13. The median study size was 96 (range 35 – 197), and a new 
sphincter defect was observed in a median of 29% (range 20-45%) of women. A 
median of 44% (range 0-75%) women had a newly symptomatic defect compared to a 
median of only 1.3% (range 0-6.8%) women who were newly symptomatic with FI but 
had no sphincter defect identified. This summary reports that the studies show a 
median of 8.5% (range 0-46%) of the sphincter defects are isolated to the internal anal 
sphincter, a median of 68.5% (range 18-85%) are isolated to the external anal 
sphincter and a median of 24% (range 5-36%) involve both the internal and external 
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anal sphincters. A summary of 8 studies92, 106, 107, 109-113 confirms that it is most 
commonly the external anal sphincter that is disrupted during childbirth114. 
Meta-analysis of 5 studies92, 106, 108, 113, 115 which report the incidence of new OASIS 
(third and fourth degree tears) following vaginal delivery in a total of 717 women 
calculated the incidence as 26.9% after first vaginal delivery and 8.5% after subsequent 
vaginal deliveries, estimating that a total of 35.4% of multiparous women have 
OASIS116. Thirty per cent of the women with sphincter injury in these studies reported 
symptoms of anal incontinence. Conversely 3.4% of women who had no discernible 
sphincter injury still experienced symptoms of anal incontinence116. Therefore the 
incidence of anal sphincter defects and symptoms of FI is 29.7% and the calculated 
probability of postpartum FI being due to sphincter defect is 76.8% in primiparous 
women and 82.8% in multiparous women116. This said, it is worth noting that the 
length of follow-up for the women in all these studies was short (<1 year after 
delivery). 
A prospective study by Pollack et al. involved 242 nulliparous women whose medical 
history, bowel habits and symptoms of anal incontinence were ascertained during the 
puerperal period, and who were asked again about bowel habits and anal incontinence 
at 5 months, 9 months and 5 years following vaginal delivery98. Fifteen per cent of 
women (36 women) had a recognised and treated sphincter injury at their index 
delivery and 44% (16 women) of these had anal incontinence at 9 months follow-up, 
which by 5 years had increased to 53% (19 women). Of the 206 women who had no 
sphincter injury detected at index delivery, 52 (25%) reported some degree of anal 
incontinence at 9 months, and at 5 years this had increased to 66 women (32%). Nine 
of the 36 women with a sphincter tear at first delivery, who had no additional 
childbirths, reported an incidence of incontinence of 44% (4 women) at both 9 months 
and 5 years follow-up. Of the remaining 27 women who did have subsequent 
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childbirths, 12 (44%) reported incontinence at 9 months and this had increased to 15 
(56%) at 5 years. Of the 205 women who had no sphincter injury initially, 44 had no 
subsequent childbirths, and at 9 months 9 (20%) reported anal incontinence which 
increased to 11 (25%) at 5 years. Of the 162 women who did have subsequent 
childbirths, the rate of incontinence reported at 9 months was 27% (44 women) at 9 
months and 34% (70 women) at 5 years. On multivariate logistic regression this study 
found maternal age, sphincter tear at first delivery and subsequent childbirth were 
independent risk factors for developing anal incontinence. The presence of anal 
incontinence after first delivery was the strongest risk factor with the odds ratio of 
incontinence at 9 months leading to incontinence at 5 years being 4.3 (95% CI 2.2 – 
8.2); this increased to an odds ratio of 7.8 (95% CI 1.6 – 8.8) in the presence of a 
sphincter tear at the first delivery. This study did not assess for the presence of anal 
sphincter injury by EAUS, which may indicate an underestimate of the number of occult 
injuries and may account for the rate of incontinence in those without diagnosed 
sphincter injury. Alternatively this rate may be due to neurological injury sustained 
during uncomplicated childbirth92, 117.  
Many further studies have shown other factors which increase the likelihood of FI 
following vaginal delivery, and these include all forms of instrumental-assisted 
delivery118, 119, unassisted delivery at home, prolonged second stage of labour (indeed 
one third of women who have a second stage of labour lasting greater than 4 hours will 
sustain an OASIS)120, 121 large birth weight (>4kg)76, 118, 122, large head circumference, 
maternal obesity123, 124 and increasing maternal age92, 122, 125.  Factors which have been 
identified as increasing risk of OASIS, and therefore also increasing likelihood of FI 
include midline episiotomy, first vaginal delivery, shoulder dystocia and persistent 
occipito-posterior presentations92, 122, 126-128. Epidural anaesthesia has also been linked 
to an increased risk of OASIS102, 129.  It is worth noting that although many studies find 
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overlap in the risk factors associated with subsequent FI and/or OASIS, there is rarely 
agreement that all of these are factors in all studies.  
Women often present with FI some 2-3 decades following the vaginal delivery in which 
they sustained an OASIS, increasing the likelihood that the involvement of another 
factor or factors is required to cause overt symptoms99. It may be that neuropathy 
sustained during childbirth may be worsened by other factors, such factors may be for 
example multiparity108, 130-132, chronic straining at stool133-135, or advancing age136.    
1.7.1.2 The effect of Caesarean section 
It is interesting at this point to consider whether elective Caesarean section (CS) is 
protective against the risks of FI, given vaginal delivery, especially complicated vaginal 
delivery, is a risk factor. Whilst significant literature exists in this area, often 
comparisons between vaginal delivery and CS do not consider that elective and 
emergency CS should not be categorized together.  
A recent Cochrane review found no demonstrable benefit of elective primary CS in the 
preservation of anal incontinence137. This review was based on 21 reports, all of which 
were non-randomised, and included over 31 000 women. The report acknowledges 
that the evidence in this area is ‘less than optimal’ and that a study to randomise 
average risk pregnancies into vaginal vs CS deliveries would significantly improve this.  
A further study from Sweden, published in 2014, found the prevalence of late FI and 
anal incontinence (20 years after delivery) were higher after vaginal delivery 
compared to CS delivery, offering some evidence of a protective effect of CS138.  
In truth, a properly designed RCT of elective CS vs vaginal delivery would be the only 
way to answer this question, however it is likely that huge crossover would exist 
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between groups, based on medical decision making and personal choice, making 
interpretation of results difficult.  
1.7.1.3 Other factors in women 
A study of 475 females with FI explored the relationship between symptoms and the 
occurrence of four previously proposed risk factors: obstetric events, anal surgery, 
pelvic surgery and neurological factors6 . It found that although the overwhelming risk 
factor was indeed childbirth (91%), with at least one vaginal delivery reported as 
complicated in 338 (78%) (perineal trauma [episiotomy or tear], forceps or ventouse 
extraction), 67% women did report more than one risk factor, namely pelvic surgery 
(most commonly hysterectomy) in 153 and anal surgery in 90 (19%)6. However in the 
150 females reporting only a single risk factor, obstetric history was by far the most 
common (124 or 86%) and of those, whilst most had complicated vaginal deliveries 
(105), 16 patients reported that these vaginal deliveries were completely 
uncomplicated6 .  
A population-based study of over 2, 000 females over the age of 40 years showed that 
independent risk factors to developing FI in the previous year included obesity, COPD, 
irritable bowel syndrome, urinary incontinence and colectomy72. In the same study, 
risk factors associated with women having FI episodes on a monthly or more frequent 
basis included (in addition to those above), age, diabetes, parity and cholecystectomy72. 
Previous studies have linked obesity to FI139, 140. Diarrhoea has also been previously 
been established as an independent risk factor for FI141, with this often linked to other 
medical conditions in which an association with FI has been made, for example 
diabetes66, 142, 143, irritable bowel syndrome144 previous cholecystectomy145 and 
colectomy144. Urinary incontinence has been found an independent risk factor for FI in 
women, which increases the likelihood that childbirth and associated damage to the 
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pelvic floor is a factor in FI, since it is believed that urinary and faecal incontinence 
share an aetiology72.  
Hysterectomy, oestrogen use and menopause were also found to be independently 
associated with FI72. At odds however with other literature, this study by Varma et al. 
found hysterectomy to confer a decreased risk of FI. Another group found an increased 
risk of FI after hysterectomy with oophorectomy141 and one other study found no 
link139. Certainly within our practice, a significant number of women seem to make this 
association, but this does not necessarily correlate with direct causation. The large 
population based study found a 30% increased risk of FI in women using oestrogen 
replacement therapy72, and this is in agreement with published randomised controlled 
trial data regarding an association with oestrogen and worsening of urinary 
incontinence146, 147. The mechanism for this is, however, unclear. The increased risk in 
post-menopausal women found in the population study has not been replicated by 
others, however it is difficult to know whether this is due to a lack of awareness of this 
as a potential risk factor72. 
It is likely that all of the above associations are explicable and link to one of the 
pathophysiological classification discussed in Section 1.5. For example, chronic cough 
(COPD) and obesity cause increased pressure on the pelvic floor; diabetes, colectomy, 
cholecystectomy and irritable bowel syndrome may increase intestinal motility, 
resulting in diarrhoea; and diabetes, age, and parity may all have an effect on the 
neurological system, causing generalised or specific pudendal neuropathy72. It is 
difficult however to know whether many of the specific (e.g. diabetes) and non-specific 
(e.g. ageing) associations made with increased risk of FI result through their general 
effect on mobility and ability to carry out the activities of daily living, and this too 
makes cause-effect associations even more difficult to define114.   
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1.7.2 Faecal incontinence in men 
Since the primary cause of FI in women is often cited as childbirth, aetiological factors 
associated with FI in men have to be different. Fewer data exist to address specific 
aetiological factors in men, however, it is likely that many factors are overlapping with 
females.  
A study by Kim et al. reviewed the medical notes of 404 male patients with FI in two 
groups, namely those under the age of 70 years (Group A) and those aged 70 years or 
over (Group B), in order to ascertain likely aetiological factors148. Of these patients, 321 
(79.5%) had a history of at least one anorectal disease that may affect continence, (167 
(82.3%) in group A and 154 (76.6%) in group B). 234 (57.9%) of the group had 
undergone at least one procedure that might affect faecal continence (which comprised 
121 patients (59.6%) from group A and 113 patients (56.2%) from group B). The most 
common prior anorectal diagnoses amongst patients in group A which may have 
affected anal continence included perianal sepsis, perianal trauma, congenital 
disorders, HIV infection and anal cancer. However, in group B the most common prior 
diagnoses were prostate cancer, neurological diseases and colon cancer. In group A, the 
most common procedures which might have affected continence were prostatectomy 
or proctocolectomy, fistulotomy, pull through operation for imperforate anus, anal 
wide excision and radiation therapy for anal cancer, whereas in group B, the most 
common procedure was radiation therapy for prostate cancer. These results may seem 
as one would expect given the prevalence of certain diseases at a given age. This study 
did, however, fail to consider any other factors that may be associated with FI.  
One of the above mentioned publications also considers the aetiological risk factors 
associated with FI in male patients by screening the medical history for the presence of 
three proposed risk factors (anal surgery, pelvic surgery, neurological factors)6. Of the 
154 males included in the study, 120 (79%) had histories which contained volunteered 
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potential risk factors and of those, the most commonly reported factor by far was anal 
surgery (50%), which comprised mostly haemorrhoidectomy followed, in terms of risk, 
by fistula surgery and sphincterotomy for anal fissure. In incontinent males, usually 
only a single risk factor was volunteered (76 males or 50%), which was anal surgery in 
45 (59%). This study did not document the presence or absence of other more general 
risk factors, for example diabetes or obesity, since these were not routinely screened 
for.  
1.7.3 Faecal incontinence and its association with defaecatory disorders 
Faecal impaction is an important risk factor in FI, and this is a well-described 
phenomenon in the elderly population4, 66 and amongst children66, 103, 149. Faecal 
impaction may result from incomplete rectal emptying or as a consequence of other 
factors such as physical immobility, poor diet and fluid intake, and constipating 
medications4. Such faecal impaction may result in overflow incontinence as liquid stool 
seeps around the stool bolus150. More recently, an association has been made between 
co-existent defecatory disorder and FI in the absence of faecal impaction151. Defecatory 
disorder refers to difficulty evacuating stool from the rectum in a patient with chronic 
or recurring symptoms of constipation152. Causes can be structural (e.g. due to 
rectocoele or intussusception) or functional (e.g. inadequate defaecatory propulsion 
and/or dyssynergic  defaecation). This link is also described amongst post-partum 
women, where up to 40% of patients suffer with coexistent symptoms153. Although the 
mechanism underlying this is not completely clear, it is possible that FI and defecatory 
disorder share a common pathophysiology.  
1.7.4 Summary 
The difficulty with attribution of aetiology to any individual suffering from FI is that it 
is often impossible to say with any degree of certainty why this pathophysiology has 
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arisen. Maintenance of continence relies on a complex interplay between many sensory 
and motor functions, and there is often a degree of compensation by different 
mechanisms to maintain continence in the event of dysfunction of one aspect of 
continence. Whether the balance tips towards symptoms, i.e. FI, involves a combination 
of one or more aetiological factors interplaying with inability of other mechanisms to 
compensate.  
Although there is much published literature in this area, no study could consider every 
possible risk factor to define a relative risk, especially since direct causation can rarely 
be allocated. Studies which only use univariate analysis are particularly susceptible to 
this, since possible confounding factors such as age, BMI, parity and common medical 
conditions are not included in the analysis72. Long-term prospective detailed studies of 
large cohorts of patients are required in order to improve the strength of evidence, 
however with such studies being hugely costly and impractical the reality of the 
situation may be that the literature in this area will continue to have limitations.  
1.8 Unmet clinical need associated with faecal incontinence 
FI is not a life threatening condition, but the personal impact of incontinence is 
profound. It can cause medical morbidity (decubitus ulcers, urinary tract infections) 
and involve significant cost to those involved, causing many to withdraw from society 
and remain in close proximity to a toilet at all times to avoid incontinent episodes4, 154. 
The impact that FI has on quality of life cannot be underestimated as it causes social 
and psychological disability, and often leads to people suffering from stigmatisation 
and social exclusion52, 155-158.  
Quantifying FI can also be troublesome, as can assessment of disease progression or 
improvement. Whilst bowel diaries (Appendix 1) and scoring systems are the most 
commonly used methods, each has its limitations. These are discussed in later chapters. 
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The most commonly used scoring systems for FI are the St Marks’ Continence Score159 
(Appendix 2)  and the Cleveland Clinic Incontinence Score160(Appendix 3).  
1.8.1 Quality of Life 
Impact of FI on quality of life (QOL) has most often been studied in the clinic, rather 
than in the community154, 161 and many studies are focused on a particular patient 
population, resulting in minimal data being available to help understand the personal 
and economic impact of FI on the population as a whole154. One US based population 
survey assessing effect of FI on quality of life amongst 2, 800 women found that in the 
503 symptomatic patients, FI had a moderate or severe impact on one or more QOL 
domains (activities at home, activities away from home and travel) in 23% of women, 
with the impact of QOL related to symptom severity i.e. 6% of women with mild 
symptoms, 35% of women with moderate symptoms and 82% of women with severe 
symptoms reported a moderate or severe impact on one or more QOL domain162. 
Similarly, this study found that self-reported health status was also associated with the 
prevalence of FI (p<0.001), the severity of FI (P<0.0001) and the impact of FI on QOL 
averaged across all domains (p<0.001). Similarly, a UK population-based study 
reported that 51.7% of those reporting major FI found this problem to have ‘a lot’ of 
impact on their quality of life, compared to a rate of 16% in those with minor FI and 
only 2.9% in those with rare or no FI53. Indeed FI remained significantly associated 
with a large impact on quality of life even when adjustment for other bowel symptoms 
had been made53. A large impact on quality of life was significantly more frequent in 
both those with major incontinence (odds ratio 12.4) and minor incontinence (odds 
ratio 2.5) compared to those with rare or no FI53. Another UK based study of 2, 818 
individuals over 65 years old found a 4-fold increase in anxiety and a 5-fold increase in 
depression in those who had FI compared to those who did not. The same study also 
reported that 59% of those with FI described themselves as severely disabled 
compared to 16% of the study population without FI39. There seems little doubt that FI 
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has a huge impact on the quality of life of those who suffer, and this effect worsens with 
severity of symptoms.  
1.8.2 Health Economics 
In order to estimate healthcare costs, many health economists will calculate direct 
costs, indirect costs and consequent costs154. Direct costs include those for delivering a 
treatment, for example healthcare provider costs, hospital fees, medications, 
continence pads or appliances, and transport costs154. Indirect costs are those to the 
individual and ultimately society as a whole from work absenteeism, impaired 
performance at work, and those who seek alternative professions due to symptoms154. 
Consequent costs involve those involved with treating sequelae of a condition, for 
example the costs associated with treating skin breakdown arising due to FI154. 
Estimation of the direct economic costs of FI is difficult due to the few data available. It 
is estimated that combined urinary and FI in adults account for 2% of the total UK 
healthcare budget with an annual NHS spend in excess of £500 million163. One study of 
FI amongst institutionalised patients in Ontario Canada has calculated the mean time 
spent each day dealing with FI is 52.5 minutes per patient and the total annual cost of 
incontinence per patient to be $9, 77162. Another study of urogynaecological patients in 
Minnesota estimated lifetime charges to patients with FI secondary to obstetric injury 
at $17, 166164. Although medical and surgical costs associated with interventions are 
easily determined, calculating the economic impact of FI on a whole population is 
difficult due to differing study populations, for example differing ages and living 
arrangements, variations in treatment strategies between physicians and institutions 
and differences in associated costs between different regions and countries165. 
Indirect costs associated with FI are even more difficult to calculate, but are believed to 
be large. In the USA these extend to hundreds of millions of dollars per year154. A 
survey of 5, 400 US adults found that compared to 4.2% of asymptomatic individuals, 
 
54 
 
13.2% of those with any FI and 29.4% of those with large-volume FI considered 
themselves too sick to attend work or school, with those suffering large-volume FI 
missing an average of 50 days in the past year compared to 4.9 days in asymptomatic 
individuals38. 
It is clear that FI represents an area of unmet clinical need with attendant high 
economic costs to patients, the NHS and the economic function of the country as a 
whole163.   
1.9 Management of faecal incontinence 
Management of FI can be challenging due to a combination of its high prevalence, 
aetiological heterogeneity and a lack of widespread expertise. NICE have published a 
‘NICE Pathway’ for the management of FI amongst adults, which brings together all 
NICE guidelines. In addition to this, there is guidance from the International 
Consultation on Incontinence166 and the Rome Foundation167. Our department has 
devised a basic algorithm of care for FI patients, which encompasses guidance from all 
three sources. It consists of initial basic assessment and treatment of patients (Level I) 
(Figure 3) and followed by appropriate management strategies for specific conditions, 
the use of specialist tests and more specialist conservative therapy (Level II) (Figure 4). 
Patients should be managed in a dedicated unit equipped with the appropriate 
facilities, expertise and full multidisciplinary team.  Following thorough and detailed 
history, examination and appropriate investigations, all patients suffering with faecal 
incontinence should follow an initial pathway of condition-specific first line 
conservative interventions, singly or in combination, prior to specialised treatment 
including any invasive or surgical options 168, 169.  
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Figure 3: Algorithm of care for Faecal Incontinence: Level I 
 
 
Figure 4: Algorithm of care for FI: Level II 
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1.9.1 Specific treatments 
Prior to these initial management strategies however, each patient should have the 
following excluded, and these will not all be considered here: 
 Lower GI malignancy 
 Acute disc prolapse/cauda equina syndrome 
 Prolapsing 3rd degree haemorrhoids 
 Acute anal sphincter injury secondary to obstetric injury (see below) 
 Rectal prolapse  
Further, the initial assessment of patients with FI includes the exclusion of faecal 
loading and potentially treatable causes of diarrhoea (e.g. infective, inflammatory 
bowel disease, irritable bowel syndrome) (Figure 3). 
1.9.1.1 Management of obstetric injury 
Guidelines updated by the Royal College of Obstetricians and Gynaecologists in March 
2007, recommend that all women who sustain a 3rd or 4th degree perineal tear during 
childbirth should undergo timely repair of this injury in theatre, under regional or 
general anaesthesia, by a practitioner with formal training in anal sphincter repair 
techniques170. The guidelines advise that either an overlapping or end-to-end method 
of repair is acceptable for the external anal sphincter170, however subsequent Cochrane 
review has suggested that at one-year follow up immediate primary overlapping repair 
is associated with lower risk of developing faecal urgency and anal incontinence, 
compared to end-to-end repair; however at 36 months there was no difference in flatus 
or faecal incontinence between the two techniques171. Both sources however 
acknowledge the paucity of high quality studies in this area.  
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Functional outcome following primary repair is often unsatisfactory, with up to 40% of 
women developing anal incontinence despite surgery 122, 172. Long-term outcome after 
sphincter injuries is largely unknown 98. 
1.9.2 Generalised treatments 
1.9.2.1 Level I conservative therapies 
Level I conservative strategies to treat FI aim to address all factors which may be 
involved in order to achieve satisfactory bowel emptying at a predictable time. They 
can be administered together or sequentially, and used appropriately, tailored to each 
patient’s individual needs. 
1.9.2.1.1 Education and ‘lifestyle’ interventions 
In light of the well-documented association between FI and obesity, weight reduction 
may well be helpful in improving symptoms. Weight reduction was shown in one study 
to improve FI in obese women173. Another study reported a significant decrease in FI 
from 19.4% pre-operatively to 8.6% 1 year post-operatively in 101 women who 
underwent laparoscopic Roux-en-Y gastric bypass for morbid obesity174. Physical 
exercise may also be helpful in reducing symptoms, indeed one study of nursing home 
residents found exercise, in combination with increased fluid intake and regular toilet 
visits, significantly improved FI175. Reduction or, where possible, cessation of 
medications which adversely affect bowel function, either by causing diarrhoea or 
constipation, should be attempted. In addition to these measures, improvement of 
toilet facilities and patients’ access to, for example, disabled toilet facilities, may well 
help with FI and the anxiety it is often accompanied by. There is also some evidence 
from a RCT that education and advice improves symptoms of FI, indeed this 
intervention was as effective alone as additional biofeedback or exercises in this study 
176.  
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1.9.2.1.2 Diet and fluid intake 
Common sense supports increasing fluid intake to ameliorate symptoms of 
constipation and the FI which may accompany this, especially in nursing home 
residents, however no data exist to support this recommendation. Diet modification is 
often recommended, in the form of increasing dietary fibre to improve stool 
consistency in those suffering incontinence associated with loose stool. A small 
placebo-controlled RCT of 39 patients found dietary fibre successfully reduced rate of 
FI in these patients177. 
1.9.2.1.3 Bowel management and retraining programmes 
Education regarding the importance of establishing a regular and predictable pattern 
of bowel evacuation is important, as well as encouraging bowel emptying after a meal 
to utilise the gastrocolic reflex. There is, however, no evidence to evaluate or prove the 
effectiveness of this169. Encouraging the adoption of a sitting or squatting position to 
improve defaecation and teaching people techniques to facilitate bowel evacuation 
including stressing the importance of avoiding straining are also useful168.  
1.9.2.1.4 Medications  
Alongside the use of medications to help prevent FI, it is also important to recognise 
and attempt to find alternatives where medications which contribute to FI are being 
used e.g. laxatives. For the pharmacological management of FI, a recent Cochrane 
review summarised 3 approaches: anti-diarrhoeal medications to improve stool 
consistency, medications to enhance sphincter function, and osmotic laxatives to 
improve stool consistency where FI is related to constipation in elderly patients178.  
Antidiarrhoeal medications (namely Loperamide, Diphenoxylate plus atropine, and 
Codeine) were shown to improve symptoms in patients with liquid stool, however, this 
evidence was limited. Loperamide was associated with more side effects than placebo, 
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although dose titration is possible to reduce side effects whilst improving 
continence178. Loperamide has also been shown to improve continence by directly 
increasing anal sphincter tone179. Medications that enhance anal sphincter tone were 
also found to reduce FI however evidence was again limited e.g. Phenylephrine gel. 
Laxative use in elderly patients with constipation-associated FI again reduced faecal 
soiling and the need for help from nurses. All trials, although randomised and placebo 
controlled, included only a small number of patients and had a short duration of follow-
up178.  
1.9.2.2 Level II conservative therapies: Biofeedback and anal sphincter exercises/pelvic 
floor muscle training 
Biofeedback involves the use of equipment to record or amplify body activities in order 
that these can be observed by the patient, using the principle of operant conditioning 
180, 181 to improve function168. Many methods have been used to treat people with FI, 
though the three main modalities described involve rectal sensitivity training, anal 
sphincter strength training, recto-anal co-ordination training or a combination of the 
three181. Pelvic floor muscle training or anal sphincter exercises involve ‘enhancing the 
strength, speed or endurance of voluntary anal sphincter contraction’181. Different 
treatment regimens again exist, and there is no consensus for the best method to treat 
FI. A recent Cochrane review analysed 21 randomised studies involving a total of 1, 525 
patients, however these studies were often small and had methodological 
weaknesses182. The review recommend that it was not possible to definitively assess 
the role of anal sphincter exercises and biofeedback therapy in the management of FI, 
although there was some evidence to suggest that biofeedback and electrical 
stimulation may enhance the outcome of treatment compared to electrical stimulation 
alone or exercises alone. Exercises seem less effective than an implanted sacral nerve 
stimulator. There is some suggestion that some elements of biofeedback and sphincter 
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exercises may have a therapeutic effect, this is not certain, and larger well-designed 
trials are required to confirm or refute this181. 
1.9.2.3 Surgical interventions 
In patients in whom the above conservative strategies have failed to satisfactorily 
resolve symptoms of FI, a specialist surgical opinion can be sought.  
1.9.2.3.1 Sphincter repair 
NICE recommends all patients with a full thickness external anal sphincter defect of ≥ 
90 degrees should be considered for a sphincter repair168. This operation is usually 
performed on patients who have suffered anal obstetric injury182. Various techniques 
are described, however, the most commonly performed procedure is an anterior 
overlapping sphincteroplasty183.  Whilst good results are achieved in the short term (3 
months), a summary of numerous retrospective studies reports long-term continence 
rates ranging from 15% to 60%183.  A review of sphincteroplasty and SNS revealed that 
sphincteroplasty remains a good option for the management of incontinence due to 
sphincter defect, despite new technologies184.  
1.9.2.3.2 Sphincter augmentation 
In patients with major sphincter disruption or after failure of other intervention, e.g. 
SNS, a patient can be considered for a neosphincter, for which the two options are a 
stimulated graciloplasty or an artificial anal sphincter. The level of evidence for both 
procedures is low (small observational case series) and they are both associated with a 
high incidence of morbidity185. They should only be performed in specialised centres 
and patients should be given a realistic picture of the outcomes168.  No randomised 
controlled trial data exist for either procedure186.  
An artificial anal sphincter is placed around the native sphincter via perianal tunnels. It 
remains inflated with fluid until the patient wishes to defecate, at which time it is 
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deflated by a manual pump implanted into the scrotum of men or labia majora of 
women. Like most treatments for FI it was first developed for the treatment of urinary 
incontinence187. Careful patient selection for this procedure is required since a 
successful outcome requires the ability to operate it. Case series report successful 
treatment in 49-83% of patients183. 
Gracilis neosphincter or dynamic graciloplasty has largely been replaced by sacral 
nerve stimulation and the artificial bowel sphincter for the treatment of FI with 
apparently better functional outcomes and quality of life185, 188, 189. It involves 
transposition of the gracilis muscle to function as a neosphincter, with the addition of 
electrical stimulation to maintain tonic contraction. Success rates are reported as 60-
75% for dynamic graciloplasty in one series183, however third party prospective 
evaluation reported less favourable results, however still concluding that this 
technique deserves consideration in patients who have failed other conventional 
treatments 190.   
All data on gracilis neosphincter (GN) and artificial anal sphincter (AAS) are however 
very poor (mostly case series), with variable methods of data collection and differing 
outcome criteria. High incidence of morbidity in the long term are reported for both 
with infection rate AAS vs. GN 21.7% vs. 35.1%, revision rate AAS vs. GN 37.5% vs. 
40.6% and AAS explantation rate of 30%185. 
1.9.2.3.3 Antegrade continence enema 
This procedure was first described in 1990191 and is mostly used in the paediatric 
population. It may however be considered in selected adults with faecal soiling 
secondary to constipation and poor colonic motility183. It involves creating an access 
point for irrigation in the right large bowel (most commonly the appendix), and 
irrigating it, as necessary, with an electrolyte or bowel cleansing solution. Functional 
results are good, with about 75% adults achieving continence with the procedure192-194.  
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1.9.2.3.4 Radiofrequency energy and injectable materials 
The delivery of radiofrequency energy to the internal anal sphincter (the SECCA 
procedure), is thought to improve continence by restructuring of collagen, leading to a 
more robust internal anal sphincter. It is proposed for patients with mild-moderate 
faecal incontinence refractory to conservative management, who are unable or 
unwilling to undergo surgical treatment. Series include between 8 and 50 patients, 
with most showing a significant improvement in incontinence scores after 
treatment183. Long-term outcomes seem variable with one study reporting most 
patients still having treatment success at 5 years195 whilst another reported only 22% 
patients having treatment success at a mean of 40 months196. Adverse events reported 
from this procedure are minor (infection, minor bleeding, haematoma, anal pain)98.  
Injections of various materials into the sphincter complex in order to add bulk and 
treat FI have been trialed. The procedure involves low associated morbidity183. Ideal 
candidates are those with faecal seepage or mild to moderate faecal incontinence who 
have failed conservative management, but are not ready or willing to try more invasive 
surgical procedures. The procedure does not preclude future surgical treatments such 
as SNS or sphincter replacement. Various agents have been trialed and of the five 
randomised trials identified by the recent Cochrane review, most reported a short term 
benefit from injection regardless of the material used, including placebo saline 
injection197. However, no long-term data were available and the quality of most studies 
was poor. One pivotal randomised study of dextranomer in stabilised hyaluronic acid 
(NASHA Dx), based on 206 patients, found it to be significantly better than sham at 6 
months based on 50% FI episode reduction, with a 52% response rate in the active vs. 
31% response rate in the sham arm, yielding a NNT of 4.4 198. Treatment did not 
significantly improve FI quality of life; data for complete continence and effects on 
anorectal physiology or imaging were not provided. Hence, the magnitude of benefit, 
 
63 
 
mechanisms of action and factors that predict response to therapy merit further 
study.199 Sustained long-term benefit (up to 3 years) has also been reported recently.200 
1.9.2.3.5 Stoma 
Creation of a colostomy or ileostomy provides definitive control of FI. It should be 
considered when FI severely restricts quality of life, but only once all appropriate non-
surgical and surgical options, including those at specialist centres, have been offered. 
Such patients should be referred to a stoma care service. Interestingly, quality of life for 
patients with a colostomy for faecal incontinence was shown in one study to be higher 
than that of patients with faecal incontinence201, whilst another study found patients 
with stomas generally reporting a high level of satisfaction with over 80% saying they 
would likely or definitely choose to undergo the procedure again202.  
1.9.2.3.6 Neuromodulation 
1.9.2.3.6.1 Sacral Nerve Stimulation  
NICE advise that a trial of temporary SNS should be considered for people with FI in 
whom sphincter surgery is deemed inappropriate. Those patients may have an intact 
anal sphincter or a disruption. In those with a defect, contraindications to repair may 
include atrophy, denervation, a small defect, absence of voluntary contraction, 
fragmentation of the sphincter or a poor quality muscle (NICE). All patients should be 
informed of the risks vs. benefits and undergo a trial stimulation of at least 2 weeks. 
Patients should be offered SNS on the basis of their response to PNE, and this should be 
performed at a specialist centre that has experience of performing this procedure.  
SNS is a form of neuromodulation (i.e. a technology which impacts on neural interfaces 
to produce benefit), which employs chronic, low-voltage electrical stimulation to 
recruit residual function of pelvic organs by direct or indirect stimulation of the sacral 
spinal nerves. It is growing in popularity due to its minimally invasive technique, 
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avoiding possibly hazardous surgery to the bowel or anal sphincter, well cited success 
rates, minimal morbidity (reported as 5-26%) and no reported mortality203. A recent 
systematic review identified 61 studies of sacral nerve stimulation where the median 
success rates were 63% in the short term, 58% in the medium term and 54% in the 
long-term203.  Quality of life scores also improved in the short and long term following 
SNS203.  Furthermore another study reported women who have undergone SNS for FI 
have also benefitted from improvements in urinary, sexual and vaginal symptoms and 
also a global benefit of pelvic floor health204. Age, gender, aetiology of FI and physiology 
results do not impact efficacy of SNS205. Also, SNS does seem effective in patients with 
sphincter defects, and the success of SNS does not seem to be correlated with degree of 
sphincter defect i.e. sphincter defect is not a contraindication to SNS206, 207. However, 
nearly all studies with SNS have been uncontrolled. Thus, despite the widespread 
popularity of SNS and abundant case series data,208 there has still been no high quality 
randomised trial of efficacy or effectiveness. The only cross-over study to include more 
than 2 patients209 enrolled 34 patients of whom only 27 participated in the crossover 
with significant issues of performance and attrition bias (5 patients were excluded due 
to lack of efficacy or to adverse events). In this study the number of episodes of FI 
declined by 90% during stimulation versus 76% without stimulation.209 Economic 
evaluation of SNS has been carried out, and its incremental cost effectiveness ratio of 
£25 070 per QALY gained falls well within the NICE £30 000 per QALY recommended 
threshold210.  
1.9.2.3.6.2 Tibial Nerve Stimulation  
The benefits of SNS over other surgical techniques to treat FI are evident, since SNS has 
reduced the need for potentially hazardous surgery to the anus itself, whilst producing 
seemingly favourable outcome data203. SNS however, is not successful in all patients, 
and there are others for whom this option is not available (due to comorbidities, 
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patient choice or local expertise). SNS also requires two operations that, despite 
advances in technology and technique, may still lead to complications210. Although it is 
cost effective compared to other surgical options211, SNS does have high equipment 
costs (approx. £10,000 pp) and costs associated with on-going management212.  
In the last ten years, another neuromodulatory technique has been developed; Tibial 
Nerve Stimulation (TNS). Its concept is that, via electrical stimulation of the tibial 
nerve, similar changes in anorectal neuromuscular function can be achieved as with 
SNS, but without the need for a permanent surgically implanted device along with the 
attendant risks. It was first described in 1983 by McGuire et al. in patients with urinary 
incontinence using a transcutaneous electrode over the tibial nerve, producing data 
suggesting long term effectiveness213. The method was adjusted by Stoller in 1999, 
through the use of a percutaneous needle with a ground electrode on the ipsilateral 
extremity214. In 2003, Shafik proposed using PTNS for FI and achieved a reported 78% 
functional success in 32 patients215.  
Two main delivery methods of TNS are described:  
Percutaneous tibial nerve stimulation (PTNS); involving electrical stimulation via a 
needle placed adjacent to the tibial nerve just above the ankle. This is now most 
commonly delivered via the Urgent® PC neuromodulation system (Uroplasty Ltd., 
Minnetonka, MN, USA). Treatment is typically delivered as twelve 30-minute 
treatments, given usually weekly for 12 weeks or sometimes twice weekly for 6 weeks.  
Transcutaneous Tibial Nerve Stimulation (TTNS); electrical stimulation is delivered via 
two pad electrodes placed over the tibial nerve just above the ankle. This is usually 
delivered via a TENS machine (Transcutaneous Electrical Nerve Stimulation). 
Treatment regimens vary considerably though administration is usually in 20-30 
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minute sessions over a period of weeks or months. I have no knowledge of this method 
being used outside of the research setting in the UK. 
 
1.9.2.3.6.2.1 Physiological effects of tibial nerve stimulation 
The possible mechanism of action of TNS in the treatment of FI is not well studied. 
Since TNS was borne from the hypothesis that its shared nerve roots (L1-S3) could 
result in similar effects to the bladder and anorectum (innervated from S2-S4) 
achieved by SNS, there is a presumed similarity to the mechanism of action of the two 
neuromodulatory modalities216.  
SNS and TNS act on the nervous system, but what is unknown is whether the effect is 
mediated by central or peripheral effects, which may be somatic (sensory or motor) or 
autonomic, or a combination of the aforementioned. Investigation of the effects of 
neuromodulation could be carried out either by analysing changes invoked by 
electrical stimulation of a nerve itself, or assessing end organ changes. Due to 
complexities and difficulties of examining the former217 most studies have 
concentrated on end organ effects.  Given the therapeutic use, we would anticipate that 
end organ effects of TNS and SNS would be within the GI tract, and most likely within 
the colon, rectum and/or anus.  
Studies of SNS attest to alteration in rectal sensation, up-regulating the striated muscle 
function of the external sphincter, and reduction in detrimental spontaneous anal 
relaxations and rectal contractions215, 218-223. Data reporting end organ effects following 
TNS are far fewer, however some studies of clinical effectiveness do report changes in 
anorectal physiology tests, most commonly anorectal manometry215, 218, 224-230. Most of 
these studies were non-randomised case series; one showed no change in anorectal 
manometry229, whilst others showed improvements in maximum squeeze pressure218, 
225, 227, 230 or an improvement in both maximum resting and maximum squeeze 
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pressure226, 228. Two of these studies were randomised, and included sham treatment 
arms. It is interesting to note that, although both showed an improvement in anal 
manometric function following treatment in the active treatment arms, these 
responses were also seen in the sham treatment arms, with no significant differences 
between the groups225, 230. 
Experimental studies of PTNS have mainly concentrated on the afferent mediated 
effects. A study of the effect of electrical stimulation over the tibial nerve in the rat 
demonstrated an increase in the peak amplitude of primary cortical evoked potentials 
by 45.1%, findings homologous to those with acute S1 nerve stimulation 231. This was 
supported by a clinical study for the treatment of overactive bladder where treatment 
was associated with an increase in long latency somatosensory evoked potentials, 
whereas placebo was not232. A further study suggested that PTNS inhibited bladder 
activity by depolarising somatic sacral and lumbar afferent fibres233.  
A recent review article into the clinical and experimental literature regarding 
mechanism of action of SNS234 reported that data pertaining to the effects of SNS on 
anorectal and colonic function are extremely heterogeneous, and no constant change 
has been demonstrated. There were also discrepancies between clinical and 
experimental data. Data quality was poor, with most studies comprising case series or 
cohort studies in humans, making them subject to considerable selection and 
performance bias. Six studies used a randomised, double-blind design, the data from 
which, Carrington et al. have assimilated234.  There was strong human evidence (in the 
form of a RCT) to support the theory of colonic motor effects, and strong animal 
evidence to support the theory of central nervous system effects. There was some 
evidence in human studies (RCT data) to support the theory of rectal sensory effects 
and central nervous system effects (cohort study data). There was also some evidence 
from animal studies to support the theory of colonic motor effects.  Conclusions of this 
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study indicated the likely influence of SNS on anorectal function occurs at a pelvic 
afferent or central level.  
Studies into the mechanism of action of TNS are extremely limited, and those into SNS 
do not draw reproducible conclusions. This area is limited somewhat by a lack of tools 
to measure therapeutic effects, for example, whilst attempting to measure effects of 
SNS on gastrointestinal sensation may be straightforward on the anus or rectum, this 
poses more of a problem in the upper GI tract or colon, which are inaccessible. 
Similarly, the measurements of effect in the peripheral nervous system are more 
straightforward than the inaccessible central nervous system. 
1.9.2.3.6.2.2 Clinical effects of tibial nerve stimulation. 
These will be considered in Chapter 3. 
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2 Aims and objectives 
2.1 Knowledge gap 
Neuromodulation is an emerging field in the treatment of FI. It is advantageous in its 
relative ease of application, limited morbidity, low associated cost and apparent 
relative efficacy. SNS is now commonplace, however it is not available everywhere and 
is associated with significant treatment costs, often necessitating regional funding 
requisition on a case-by-case basis.   
TNS is a newer, cheaper and less invasive treatment, which is thought to work on a 
similar pathway, and seems to have similar efficacy. A recent RCT of TTNS vs. sham 
shows no clinical benefit of the active treatment. Whilst there are numerous case 
reports indicating clinical efficacy of PTNS, including one small RCT comparing PTNS to 
TTNS to sham, where PTNS appears superior, no sham-controlled trial has been 
performed. A well-conducted and adequately powered randomised sham-controlled 
trial is required to definitively answer the question regarding efficacy of PTNS to treat 
FI.  
2.2 Objectives 
The aim of this thesis was to definitively investigate the effect of PTNS in the treatment 
of faecal incontinence, with the following specific objectives: 
1. To perform a systematic review of the current evidence base for tibial nerve 
stimulation to treat faecal incontinence (Chapter 3); 
2. To assess the short term clinical efficacy of PTNS compared to sham electrical 
stimulation in the treatment of patients with significant faecal incontinence in the 
CONFIDeNT Study, a large multicentre randomised sham controlled trial (Chapter 
4); 
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3. To identify factors predictive of successful PTNS from the CONFIDeNT Study data 
(Chapter 5); 
4. To follow-up all patients enrolled in the CONFIDeNT Study to assess medium-term 
outcomes (Chapter 6). 
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3 Clinical effects of tibial nerve stimulation: A systematic review 
3.1 Aims 
The aim of this review was to provide a comprehensive and systematic overview of 
PTNS and TTNS in the treatment of FI. The two methods of TNS, described in Chapter 1 
(1.8.2.3.6.2) above will be addressed separately. This chapter represents an update of a 
systematic review published in the British Journal of Surgery in 2014235. 
 
3.2 Methods 
A published systematic review235, using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) framework236 to minimise risk of bias, has been 
updated to include more recently published trials. The protocol developed for review, 
detailing pre-specified methods of the analysis and eligibility for the review, was 
adhered to. The following criteria were used. 
3.2.1 Inclusion criteria 
Studies of any design, including case series, case–control and randomised controlled 
trial (RCT) designs, reporting TNS for FI from January 2003 to November 2014 were 
eligible for inclusion. The study must have provided data for at least ten patients 
treated with PTNS or TTNS. Only studies that clearly reported at least one of the 
selected review outcome measures (baseline and post-intervention) and a clear follow-
up period were eligible for inclusion. No exclusions were placed on study centre or 
patients, in terms of age, sex, ethnicity or aetiology of FI. All eligible studies required a 
definitive intervention by PTNS or TTNS for FI; reports of PTNS or TTNS for primarily 
urinary symptoms, or mixed symptoms, were excluded. 
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3.2.2 Outcomes 
The pre-specified primary outcome was the success rate of therapy, based on a 50% or 
greater decrease in the number of weekly FI episodes. Secondary outcomes were: 
reduction in weekly FI episodes; cure rates of the treatment (100% reduction in 
episodes); improvement in the Cleveland Clinic Incontinence Score (CCIS) or similar 
(including St Mark’s Continence Score)160; improvements in quality of life (QoL) 
measures (generic and condition-specific); and improvements in any other outcomes 
reported by individual studies. 
3.2.3 Methods for quality appraisal 
Critical appraisal of the studies was considered by study type and data collected and 
potential sources of bias were considered. Case series, which comprised most of the 
PTNS and TTNS studies, were assessed using the National Institute for Health and Care 
Excellence (NICE) ‘Quality Assessment for Case Series’ system40, which assesses 
characteristics of methodology, outcomes and interpretation from a possible score of 8. 
The randomised trials were evaluated using the Jadad score237, which awards points 
for randomisation method, blinding and account of all patients. The score is out of a 
possible 5 points, with a score of above 3 indicating good quality. The RCTs were also 
evaluated using the Cochrane Collaboration tool for assessing risk of bias in 
randomised trials238, which evaluates six specific domains and reports on whether 
there is a high, low or unclear risk of bias in each area. 
3.2.4 Search 
A comprehensive re-search of the literature was carried out on 3rd November 2014, to 
update that carried out for a previously published review on 10 February 2013235 using 
PubMed, MEDLINE, Embase and Evidence-Based Medicine reviews (including the 
Cochrane database of systematic reviews and the Cochrane central register of 
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controlled trials). Search terms used were 'tibial nerve stimulation faecal incontinence' 
("tibial nerve"[MeSH Terms] OR ("tibial"[All Fields] AND "nerve"[All Fields]) OR "tibial 
nerve"[All Fields]) AND stimulation [All Fields] AND ("faecal incontinence"[All Fields] 
OR "fecal incontinence"[MeSH Terms] OR ("fecal"[All Fields] AND "incontinence"[All 
Fields]) OR "fecal incontinence"[All Fields]). Full-text copies of all studies deemed to be 
potentially relevant were obtained and assessed for inclusion. Where papers cited 
other potentially important references, these were also assessed. Systematic reviews, 
RCTs and case series of patients with FI who had undergone TNS were searched for 
relevant data sets. There was no blinding as to the names of studies, authors, 
institutions or publications. Search results were cross-referenced with bibliographies 
of relevant papers. 
3.2.5 Study selection 
Eligibility assessment was performed in an un-blinded but standardised manner. 
Methodological quality of included studies was assessed independently using the 
PRISMA assessment criteria 236. Exact duplicate data sets generated from the same 
cohort of patients were excluded where possible, or highlighted where this was 
uncertain.  
3.2.6 Summary measures and analysis 
Formal data synthesis was not possible owing to heterogeneity between study designs 
and outcome measures. Summary measures for individual outcome variables across 
broadly homogeneous studies were limited to descriptions of percentages, medians 
and ranges. 
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3.3 Results 
The re-search revealed seven further studies which met the inclusion criteria, giving a 
total of 20 studies. Studies were published between 2003 and 2014, and included 10 
case series of PTNS 215, 218, 224, 226-228, 239-242, a comparative case matched study of PTNS 
vs. SNS 243, a prospective clinical audit of SNS and PTNS244 , five case series of TTNS229, 
245-248 , a randomised controlled trial of TTNS vs. sham230 , a randomised study of PTNS 
vs. TTNS vs. sham225 , and a randomised study comparing daily with weekly TTNS249. A 
total of 773 patients (range 10-146) underwent active treatment for FI of various 
aetiologies, with 565 undergoing PTNS (this does include 2 publications from one 
institution and 4 publications from a second institution where likely duplication of 
patient data has occurred) and 208 undergoing TTNS (two of these studies are again 
from one institution). Results are presented as those from randomised studies, those 
from PTNS studies (including the PTNS arm of a randomised studies), and those from 
TTNS studies (including the TTNS arms of randomised studies). 
3.3.1 Quality of studies 
3.3.1.1 Randomised studies 
Using the Jadad score 237, two RCTs scored 4, and the other scored 3 out of a possible 5 
marks, indicating good quality (Table 6). Appraisal of RCTs using the Cochrane 
Collaboration tool for assessing risk of bias (Table 7) identified two area of potential 
bias, in the forms of incomplete outcome data and the risk of performance bias as 
patients were self-treating at home, in the larger RCT comparing TTNS with sham 
stimulation230. In the smaller RCT comparing PTNS versus TTNS versus sham225, two 
areas of potential bias were identified (blinding and conduct of sham). In the final RCT 
comparing two treatment protocols for TTNS249, four areas of potential bias were 
identified: The trial was only single blinded; analysis was not on intention to treat 
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basis, since one patient was excluded as outcome data were not available; patients self-
treated at home with no consideration for performance bias; and no comparison 
between the two groups were made (all analysis was per group compared to baseline).  
Table 6: Critical appraisal of randomised controlled trials using Jadad Score 
Study Randomisation Blinding Account of all 
patients 
Score 
Leroi et al. 
(2012) 
2 1 1 4 
George et al. 
(2013) 
2 1 1 4 
Thomas et al. 
(2013) 
2 0 1 3 
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Table 7: Critical appraisal of randomised controlled trials using the Cochrane 
Collaboration tool for assessing risk of bias in randomised studies.  
Domain Description 
Judgement 
of risk of 
bias 
Leroi et al. (2012)    
Sequence generation Random number table stratified based on 
CCIS score 
Low 
Allocation concealment Random number table stratified based on 
CCIS score – unclear whether allocation 
central, web-based or other 
Unclear 
Blinding of participants, 
personnel and outcome 
assessors 
Double-blinded – patient and evaluating 
physician blinded to treatment 
Low 
Incomplete outcome 
data 
13 patients dropped out and therefore not 
analysed 
High 
Select outcome 
reporting 
All outcomes reported Low 
Other sources of bias Performance bias – patients treated at home High 
George et al. (2013)    
Sequence generation Sealed-envelope randomisation Low 
Allocation concealment Sealed, windowless envelopes used Low 
Blinding of participants, 
personnel and outcome 
assessors 
Single-blinded – patient blinded only High 
Incomplete outcome 
data 
No missing outcome data Low 
Select outcome 
reporting 
All outcomes reported Low 
Other sources of bias Paper reported that sham arm was suitable 
only for comparison with TTNS arm, and not 
for PTNS arm 
High 
Thomas et al. (2013)     
Sequence generation Sealed-envelope randomisation Low 
Allocation concealment Sealed, opaque envelopes used Low 
Blinding of participants, 
personnel and outcome 
assessors 
Single blinded – assessor only  High 
Incomplete outcome 
data 
Outcome data missing for one patient who 
was excluded 
High 
Select outcome 
reporting 
All outcomes reported Low 
Other sources of bias No comparison between groups made 
Performance bias – patients treated at home 
High 
CCIS, Cleveland Clinic Incontinence Score; TTNS, transcutaneous tibial nerve stimulation; PTNS, 
percutaneous tibial nerve stimulation. 
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3.3.1.2 Non-randomized studies 
 Critical appraisal of the case series, using the NICE quality assessment form, is shown 
in Table 8. All studies scored between 3 and 6 out of 8. The median score for TTNS 
studies was 5 (range 3–6) and that for PTNS studies was 4 (3–5). 
Table 8: Critical appraisal of case series using the National Institute for Health and Care 
Excellence Quality Assessment for Case Series form. 
Reference Score 
PTNS series  
Shafik et al. (2003) 3 
De la Portilla et al. (2009) 4 
Govaert et al. (2010) 5 
Boyle et al. (2010) 4 
Findlay et al. (2010) 4 
Hotouras et al. (2012) 5 
Arroyo et al. (2014) 4 
Al Asari et al. (2014) 5 
Hotouras et al. (2014) 4 
De la Portilla et al. (2014) 5 
Hotouras et al. (2014) 4 
Lopez Delgado et al. (2014) 3 
Median (range) 4 (3-5) 
TTNS series  
Queralto et al. (2006) 3 
Vitton et al. (2009) 4 
Vitton et al. (2010) 6 
Eleouet et al. (2010) 5 
Thomas et al. (2013) 6 
Median (range) 5 (3-6) 
 
3.3.2 Results of randomised studies 
The three randomised studies of PTNS and TTNS included a large multicentre RCT of 
TTNS vs. sham containing 144 patients,230 a smaller single-centre study of PTNS vs. 
TTNS vs. sham containing 30 patients225, and a further small single-centre study 
comparing twice weekly vs. daily TTNS. The outcomes of these RCTs are summarised in 
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Table 9, with further details of secondary outcomes and treatment protocols in 
Appendix 1 (Table 39 and Table 40). 
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Table 9: Faecal incontinence episodes and Cleveland Clinic Incontinence Score outcomes in trials of percutaneous and transcutaneous tibial nerve 
stimulation 
Reference n* 
Initial 
treatment 
period in 
months ‡ 
Follow-up 
(months from 
start of 
treatment) 
FI episodes/week CCIS 
Median 
(range)§ P 
≥ 50% 
reduction 
(%) 
100% 
continence 
(%) 
Improvement in 
CCIS (% of 
patients) 
≥ 50% 
improvement in 
CCIS (% of 
patients) 
Median 
CCIS§ P 
Leroi et 
al.  
           
 TTNS 73 
(68) 
3 (180) 3 1.7 (0–23) to 
1.0 (0–14.3)  
(−0.7)# 
0.004 0 0 n.r. 47¶ 11 to 8  
(−3) 
< 0.001** 
 Sham 71 
(63) 
3 (180) 3 2.9 (0–25) to 
1.6 (0–23.6)  
(−1.3)# 
0.06 0 0 n.r. 27¶ 11 to 9  
(−2) 
< 0.001** 
George et 
al.  
           
 PTNS 11 
(n.r.) 
1.5 (12) 1.5 8.2(5.2) to 
1.8(0.8)  
(−6.4)†# 
n.r. 82*** 82 – – – – 
 TTNS 11 
(n.r.) 
1.5 (12) 1.5 7.4(5.9) to 
5.1(4.2)  
(−2.3)†# 
n.r. 45*** 45 – – – – 
 Sham 8 
(n.r.) 
1.5 (12) 1.5 6.5(3.5) to 
4.7(3.5)  
(−1.8)†# 
n.r. 13*** 13 – – – – 
Thomas 
et al.  
           
TTNS 
(Daily) 
14 
(14) 
1.5 (42) 1.5 5 (11.1) to 
3.5 (4.3) 
(-1.5) 
0.025 n.r.+ 21 - - - - 
TTNS 
(Weekly) 
15 
(12) 
1.5 (12) 1.5 6.5 (5) to  
3 (6.5) 
(-3.5) 
0.31 n.r.+ 0 - - - - 
*Values in parentheses are numbers of women. †Data reported as mean(s.d.). ‡Number of initial treatments shown in parentheses; there were no top-up treatments in either study. 
§From baseline to start of treatment; difference is shown in parentheses. ¶More than 30 per cent improvement in Wexner score. FI, faecal incontinence; CCIS, Cleveland Clinic 
Incontinence Score; TTNS, transcutaneous tibial nerve stimulation; n.r., outcome measured but not reported; n.s., not significant; PTNS, percutaneous tibial nerve stimulation. #Leroi 
et al.36, no significant difference between groups; George et al.37, P = 0.042 (PTNS versus TTNS and sham, ANCOVA test) Thomas et al. significance between groups not reported. 
**Leroi et al.36, no significant difference between groups. *** statistically significant across all groups. + reported as ‘about half’ in each group. 
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3.3.2.1 Primary outcome 
In the TTNS vs. sham study230, no patient in either group had a 50% or greater 
reduction in weekly FI episodes. In the PTNS vs. TTNS vs. sham study225, 82% of 
patients in the PTNS group, 45% of patients in the TTNS group and 13% of those in the 
sham group had treatment success based on this outcome. This was statistically 
significant across all groups: there were significantly more patients with treatment 
success in the PTNS group than in the TTNS group, and in the TTNS group compared 
with the sham group (p = 0.035) (Table 9). In the TTNS study249 it is commented that 
‘about half’ of the patients in each group achieve this outcome, though no further detail 
is given. 
3.3.2.2 Secondary clinical outcomes 
In the TTNS vs. sham study230, there was a significant reduction in median number of 
weekly FI episodes, from 1.7 (range 0–23) to 1 (0–14.3) in the TTNS group (p = 0.004), 
and in median CCIS in both TTNS (from 11 to 8) and sham (from 11 to 9) groups 
(p < 0.001) (Table 9). However, there were no significant differences between the two 
groups. In the three-arm study225, there was a reduction in the mean number of FI 
episodes in the PTNS group (from 8.2 to 1.8), in the TTNS group (from 7.4 to 5.1) and in 
the sham group (from 6.5 to 4.7). However, significance within the groups was not 
reported. Statistical analysis demonstrated a significantly greater reduction in the 
PTNS group (p = 0.042). CCIS was not collected in the three-arm study. In the TTNS 
study249, there was a statistically significant reduction in the median number of weekly 
FI episodes from 5 (SD 11.1) to 3.5 (SD 4.3) (p=0.025) in the daily TTNS group, 
however there was no significant reduction in the twice weekly TTNS group. CCIS was 
not collected in this study.  
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3.3.2.3 Quality of life 
In the TTNS vs. sham study230, both TTNS and sham groups had significantly improved 
scores in all four Faecal Incontinence Quality of Life Scale (FIQL) domains compared 
with baseline, but there were no significant between-group effects. In the three-arm 
study225, all groups demonstrated improvement in the FIQL and Short Form 36 (SF-
36®; QualityMetric, Lincoln, Rhode Island, USA) scores; however, there were few 
statistically significant differences between groups.  In the TTNS study249 there was no 
improvement in any domain of the FIQL or SF-36® scores in the twice weekly group, 
however, there was a significant improvement in the lifestyle and embarrassment 
domains of the FIQL and in the physical functioning domain of the SF-36® score in the 
daily TTNS group. No comparisons between groups were made. (Table 39 Appendix 1).  
3.3.3 Results of studies of percutaneous tibial nerve stimulation 
PTNS studies included ten case series 218, 224, 226-228, 239, 240, 250, 251 (one study215 included a 
‘control’ group for comparison), one comparative case matched study of PTNS vs. SNS 
243, one prospective clinical audit of SNS and PTNS 244 and one small single-centre 
randomised single-blind trial (PTNS vs. TTNS vs. sham)225, comprising a total of 565 
patients who received active treatment. All studies treated patients in 12 or 14 30-min 
sessions, with nine studies performing weekly treatments for 12 weeks 218, 224, 226, 228, 240-
242, 244, three studies 225, 239, 243 performing twice-weekly treatments for 6 weeks and one 
study performing treatment every other day for 4 weeks 215. The median length of 
follow-up was 5 (range 1.5–29) months from start of treatment, indicating that three 
studies 225, 241, 242 followed up patients only immediately after treatment had ended. 
Nine studies 215, 218, 224, 226-228, 239, 242, 243 then offered ‘top-up’ treatments to those who 
perceived treatment benefit (range 3–72 top-ups). Outcomes of patients receiving 
PTNS are summarised in Table 10, with further secondary outcomes and details of 
treatment protocols shown in Appendix 1 (Table 41 and Table 42). 
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Table 10: Faecal incontinence episodes and Cleveland Clinic Incontinence Score outcomes in studies of percutaneous tibial nerve 
stimulation. 
Reference n 
No. of 
initial 
weekly 
treatments 
in weeks 
No. 
of 
top-
ups 
Follow-up 
(months 
from start 
of 
treatment) 
FI episodes/week CCIS 
Median 
(range)† P 
≥ 50% 
reduction (%) 
100% 
continence 
(%) 
Improvement 
in CCIS (% of 
patients) 
≥ 50% 
improvement 
in CCIS (% of 
patients) 
Median 
CCIS† P 
Shafik et 
al.‡ 
32 
(32) 
14 (4) 8 22* n.r. n.r. n.r. n.r. n.r. n.r. –  
De la 
Portilla 
et al. 
16 
(11) 
12 (12) 8 3 n.r. n.r. n.r. n.r. 81 38 13 to 9  
(−4)* 
< 0.001 
8 63 44 13 to 8  
(−5)* 
0.001 
14 63 31 13 to 9  
(−4)* 
0.001 
Govaert et 
al. 
22 
(16) 
12 (6) > 72 1.5 7 to 3  
(−4) 
0.082 63 n.r. n.r. n.r. 
12 to 8  
(−4)* 
< 0.001 
12 7 to 1  
(−6) 
0.029 59 12 to 6  
(−6)* 
0.001 
Boyle et al. 31 
(30) 
12 (12) 3 5 4 to 0  
(−4) 
< 0.001 71 39 65 n.r. 13 to 7  
(−6) 
< 0.001 
Findlay et 
al. 
13 
(13) 
12 (12) 0 4 n.r. n.r. n.r. n.r. – – –  
Hotouras 
et al. 
88 
(88) 
12 (12) 0 3 5 to 1  
(−4) 
< 0.001 n.r. n.r. n.r. n.r. 12 to 9  
(−3) 
< 0.001 
George et 
al. 
11 
(?) 
12 (6) 0 1.5 8 to 2  
(−6)* 
n.r. 82 82 – – –  
Arroyo et 
al.** 
16 
(15) 
12 (12) 12 3 n.r. 
 
n.r. 
 
n.r. 
 
n.r. 
 
n.r. 
 
n.r. 
 
n.r. 
 
- 
 
6 n.r. n.r. n.r. n.r. n.r. n.r. 10 to 5 
(-5) 
0.006 
Al Asari et 
al.^^^ 
21 
(21) 
12 (6) >3+ 6 - - - - n.r. 47 15 to 8 
(-7)* 
< 0.001 
12 n.r. 31 15 to 9 
(-6)* 
< 0.001 
Hotouras 
et al.^ 
146 
(128) 
12 (12) 0 3 4 to 1 
 (-3) 
n.r. n.r  n.r  n.r n.r 12 to 
10  
(-2)* 
n.r. 
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De la 
Portilla 
et al. 
30 
(21) 
12 (12) 12 
 
3 - - - - 80 43 14 to 
10 
(-4)* 
<0.005 
8 77 40 14 to 7 
(-7)* 
<0.005 
14 77 37 14 to 9 
(-5)* 
<0.005 
27 77 43 14 to 9 
(-5)* 
<0.001 
Hotouras 
et al. 
115 
(103) 
12 (12) *** 3 5 to 1 
 (-4) 
<0.001 n.r. n.r. 
 
n.r. n.r. 12 to 9 
(-3) 
<0.001 
29^^ 5 to 1  
(-4) 
<0.001 52 12 to 
10 (-2) 
<0.001 
Lopez-
Delgado 
et al. 
24 
(19) 
12 (12) 6 3 n.r. n.r. n.r. n.r. n.r. n.r. 15 to 
14 (-1) 
0.389 
6 15 to 
10 (-5) 
0.018 
Summary 
(median 
(range)) 
565 
(497) 
12 (12-14) 6 (0-
>72) 
6 (1.5-29) 5 (4-8) 
to 1 (0-
3) 
(-4) 
 63 (52-82) 61 (39-82) 77 (63-81) 40 (31-47) 13 (10-
15) to 9 
(5-14) 
 
All values have been calculated to the nearest integer. *Mean values. †From baseline to end of treatment; difference is shown in parentheses. ‡Outcome 
data reported in groups only. +Once per week for 3 weeks, once every 15 days followed by once every 3-4 weeks and then 5-6 weeks as required. ^this 
study contains 88 patients from the previously reported study in this institution. **All patients had sphincter defect of 90-1800. ^^^ Comparative case-
matched study of PTNS vs SNS. ^^ median value. *** 3 weaning sessions plus median 2 (range 1-27).  FI, faecal incontinence; CCIS, Cleveland Clinic 
Incontinence Score; n.r., outcome measured but not reported; n.s., not significant. 
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3.3.3.1 Primary outcome of PTNS 
Four studies224, 225, 239, 242 reported a 50% or greater reduction in the number of FI 
episodes immediately after treatment, in 52–82% of patients. In the single study239 that 
reported on this outcome after 1 year, 59% of patients still experienced treatment 
success (Table 10). 
3.3.3.2 Secondary clinical outcomes of PTNS 
Two studies 224, 225 reported rates of ‘complete continence’ following treatment of 39% 
and 82%. Statistically significant reductions in median weekly FI episodes were 
reported in four studies224, 239, 241, 242. These reductions were between 4 and 6 episodes 
per week (Table 10). 
The CCIS was used as an outcome measure in all but two studies 225, 240, with five224, 226, 
228, 241, 242 reporting a significant reduction in the median CCIS and five 218, 227, 239, 242, 243 in 
the mean score (all P ≤ 0.006) (Table 10). 
3.3.3.3 Quality of life outcomes of PTNS 
Eight studies 218, 225, 227, 228, 239, 240, 242, 243 reported changes in quality of life after 
treatment, with some reaching statistical significance, especially in the domains of 
depression, coping/behaviour, embarrassment and lifestyle. Different methods were 
used to collect these data. Other outcome measures are also shown in Appendix 1 
(Table 41). 
3.3.4 Studies of transcutaneous tibial nerve stimulation 
TTNS studies included five non-randomised case series 230, 245-248 and three RCTs (one 
of TTNS vs. sham230 a second of PTNS vs. TTNS vs. sham225 and the third to compare 
two treatment protocols of TTNS249), comprising a total of 208 patients who received 
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the active treatment. All studies used different treatment protocols, with a median 
treatment duration of 1.5 (range 1–3) months involving a median of 42 (12–180) 
treatments. All studies, apart from one248, used unilateral stimulation. Follow-up was 
for a median of 3 (1.5–15) months. Two studies229, 245 offered top-up treatments to 
patients who had perceived benefit from treatment. Outcomes of patients receiving 
TTNS are summarised in Table 11 with further secondary outcome data and details of 
treatment protocols in Appendix 1 (Table 43 and Table 44). 
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Table 11: Faecal incontinence episodes and Cleveland Clinic Incontinence Score outcomes in studies of TTNS 
Reference n* Initial 
treatment 
period in 
months ‡ 
Length of 
top-up 
treatment 
(months) 
Follow-up 
(months 
from start 
treatment) 
FI episodes/week CCIS 
Median 
(red)§ 
P ≥ 50% 
reduction 
(%) 
100% 
continence 
(%) 
Improvement 
in CCIS (% of 
patients) 
≥50% 
improveme
nt in CCIS 
(% pts) 
Median 
CCIS§ 
P 
Queralto et 
al. 
10 
(10) 
1 (20) 2 1 – – – – 80 60 13 to 3  
(−10) 
n.r. 
4 
80 70 13 to 1.5  
(−11.5) 
n.r. 
Vitton et 
al.** 
12 
(9) 
3 (90) Nil 3 – – – – 33 8 13.5 to 13  
(−0.5) 
n.s. 
Vitton et al. 24 
(22) 
3 (90) Nil# 3 – – – – 42 4 14 to 12  
(−2) 
0.025 
15† 29 8 12 to 10  
(−2) 
n.r. 
Eleouet et 
al. 
32 
(30) 
1 (56) Nil 1 – – – – †† 16 14.5 to 11  
(−3.5)† 
< 0.001 
3 
6 
Leroi et al. 73 
(68) 
3 (180) Nil 3 1.7 to 
1.0 
(−0.7) 
0.004 0 0 n.r. 47¶ 11 to 8  
(−3) 
< 0.001 
George et 
al. 
11 
(n.r.
) 
1.5 (12) Nil 1.5 7.4 to 
5.1  
(–2.3)† 
n.r. 45 45 – – – – 
Thomas et 
al. 
14 
(14) 
1.5 (42) Nil 1.5 5 to 3.5 
(-1.5) † 
0.025 n.r.+ 21 _ _ _ _ 
Thomas et 
al. 
15 
(12) 
1.5 (12) Nil 1.5 6.5 to 3 
(-3.5) 
0.31 n.r.+ 0 _ _ _ _ 
Thomas et 
al. 
17 
(15) 
1.5 (42) Nil 1.5 6 to 2  
(-4) 
0.029 59 12 _ _ _ _ 
Summary 
(range) 
208 1.5 (1-3) Nil 3 (1.5–15) (−0.7 to 
–4) 
 45 
(0–59) 
12 
(0–45) 
42 (29–80) 16 (4–70) (–0.5 to 
−11.5 
 
*(women) †Mean values. ‡(Number of initial treatments). §From baseline to end of treatment; (difference). ¶ >30% improvement in CCIS. #Therapy continued at home. **Patients with stable 
inflammatory bowel disease. ††Mean score improved. FI, faecal incontinence; CCIS, Cleveland Clinic Incontinence Score; n.r., not reported; n.s., not significant, +  ‘about half’ in each group. 
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3.3.4.1 Primary outcome of TTNS 
Three studies225, 230, 248 reported on the primary outcome; immediately after treatment 
0% of patients in the first study, 45% in the second and 50% in the third had a greater 
than 50% reduction in the number of weekly FI episodes (Table 11). A further study249 
commented that ‘about half’ of patients achieved this outcome. 
3.3.4.2 Secondary clinical outcomes of TTNS 
Complete continence following treatment was reported by four studies225, 230, 248, 249 
with a median of 12% (range 0-45) experiencing complete continence immediately 
after treatment.  A significant reduction in the median number of weekly FI episodes 
was reported in two studies230, 248, from 1.7 to 1 (P = 0.004) in the first, and 6 to 2 
(p=0.03) in the second. The mean reduction in weekly FI episodes in another study225 
reporting this outcome was 2.3 (from 7.4 to 5.1), although this study did not report 
significance, the final study reporting this outcome249 found a significant reduction in 
the mean weekly FI episodes in the group having daily treatment (-1.5 episodes (5 to 
3.5), p=0.025), but no significant reduction in the group having twice weekly 
treatment.  The CCIS was used as an outcome measure in five studies229, 230, 245-247; the 
median reduction in CCIS ranged from -0.5 to -11 immediately after treatment and was 
reported as significant in three studies230, 245, 247 (Table 11). 
3.3.4.3 Quality of life outcomes of TTNS 
Seven studies225, 230, 245-249 reported quality of life data before and after TTNS treatment, 
although different outcome measures were used. All studies showed significant 
improvement in some quality of life domains immediately after treatment. This effect 
tended to reduce over time. Other outcome measures are also shown in Appendix 1 
(Table 43). 
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3.4 Summary of the evidence 
The current TNS literature contains mostly non-randomised observational studies of 
PTNS and TTNS. In terms of high quality evidence, there is only one large RCT230 and 
this compares TTNS with sham.  
3.4.1 Evidence for PTNS 
There is no high quality evidence for PTNS in the treatment of FI. From this review, the 
success rate of PTNS in the treatment of FI is in the region of 52–82%, for the primary 
outcome measure chosen (patients achieving at least a 50% reduction in weekly FI 
episodes).  
3.4.2 Evidence for TTNS 
There is an adequately powered and well conducted trial in the literature indicating 
that TTNS is not superior to sham electrical stimulation in the treatment of faecal 
incontinence230. Using the chosen primary outcome measure, no patients in either arm 
of the trial achieved treatment success.  
3.4.3 Discussion of the evidence 
It is clear that the evidence surrounding PTNS in the treatment of FI is limited, and 
current studies are inadequate to draw conclusions about the effectiveness of PTNS 
compared with sham. This systematic review highlights the ongoing problems 
concerning trials of therapies for faecal incontinence.  
There is a lack of standardised and universally accepted outcome measures. Moreover, 
this problem includes not only what outcome measure is chosen, but also the way in 
which this measure is presented and interpreted. Most studies used the CCIS or bowel 
diary data (or both) as their primary outcome. The presentation and interpretation of 
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bowel diary data has made comparison between studies difficult. Many of the included 
studies compared the group mean or median number of pre-treatment and post-
treatment FIE to assess for significant improvement. Weekly FIE, as a count, has an 
over-dispersed Poisson distribution i.e. greater variability than expected. Therefore 
attempting to define a clinically significant mean reduction in FIE per week in a 
population of patients with widely dispersed starting FI frequencies is very difficult. 
Therefore, although a significant result has been demonstrated in these studies, this 
does not necessarily correlate with a clinically significant result. Other studies have 
chosen to counter this problem by adopting a categorical measure of percentage 
reductions i.e. the proportion of patients who have a ≥50% reduction in FIE per week, 
which is likely to be a much more realistic indication of success, but was unfortunately 
not universally reported. It is also important to remember that bowel diary data has 
only been collected for a short (usually 2-week) period at the beginning and end of 
treatment, and just because a patient scores ‘zero’ on a bowel diary this does not 
necessarily signify their incontinence is cured (a point ignored in some studies where 
terms such as ‘complete continence’ are used to describe this occurrence). 
CCIS have been compared by testing for statistical differences between the mean or 
median pre-treatment and post-treatment scores. Analysis in this way gives no 
indication of individual patient experiences i.e. percentage that has experienced 
improvement or deterioration, or the magnitude of individual improvement. Since this 
outcome denotes a score, it also indicates nothing about how many are actually ‘better’ 
or ‘cured’. A better way to interpret this data may be to indicate the proportion of 
patients with a certain or significant improvement (e.g. improved by 25%, 50%, 75% 
or 100%), which some studies have done, but again this was not universal.  
Studies were generally hampered by a lack of common treatment indication, protocol 
denoting treatment timing and duration, and follow-up period. Whilst some studies 
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reported patients had failed conservative treatment strategies, others did not. Similarly 
in those which required patients to have failed conservative treatment, those 
treatments were not discussed or standardised. Treatment protocols for PTNS were 
fairly standardised. All used one of two sets of equipment discussed above; the number 
of treatments was fairly constant throughout studies and was always performed once 
or twice weekly. The presence, frequency and duration of top-ups however were 
different across all studies. No conclusions can therefore be drawn regarding which 
treatment protocol is most efficacious. For TTNS therapy, whilst similar equipment was 
used in all studies, each treatment protocol differed significantly in terms of the 
number of treatments, frequency and duration, as well as top-up treatment protocols. 
TTNS patients had up to 180 treatments, which is obviously a factor of 10 greater than 
most PTNS treatment protocols included in this systematic review.  
One potential advantage of TTNS over PTNS is the simplicity of treatment 
administration, resulting in the possibility of patient-administered home treatments; 
indeed, some studies of TTNS discussed here involved patient-administered home 
treatments. This impacts upon the potential patient acceptance of the treatment along 
with the associated costs, which again have to be borne in mind when comparing the 
two. No study evaluated costs or cost effectiveness.  
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4 The CONFIDeNT Study 
4.1 Introduction 
There are serious limitations, as noted in Chapter 2, regarding the current published 
evidence for PTNS in FI. No double blind placebo-controlled trial of PTNS in patients 
with FI has been performed, and this is important, as the effect of PTNS over and above 
that of attendance alone, is still unknown. Although PTNS is available in several centres 
in the UK, some are using it with speculation that it is little more than an expensive 
form of acupuncture. 
4.1.1 Study Aims 
The aim of this study was to assess the clinical effectiveness of PTNS compared to sham 
electrical stimulation, in the treatment of patients with significant faecal incontinence 
who have already failed conservative management strategies.  
We also planned to test the effect of PTNS versus sham electrical stimulation on: 
1. improvements in validated incontinence scores; 
2. patient-centred FI-related symptoms; 
3. disease-specific and generic quality of life measures 
4.1.2 Hypothesis 
A 12-week course of PTNS results in a clinical response rate of 55% compared to a 
sham response rate of 35%, with clinical response defined as the proportion of patients 
in whom the weekly number of faecal incontinence episodes is reduced by 50% or 
more. 
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4.2 Methods 
4.2.1 Overview: Study design 
The CONFIDeNT study was a UK based, multicentre, pragmatic, parallel arm, double-
blind, randomised controlled trial comparing PTNS with sham electrical stimulation in 
the treatment of faecal incontinence. There was equal allocation to the two groups, 
with stratification by sex and centre. Outcomes were assessed following a standard 12-
week treatment schedule.  
4.3 Study outcomes 
Clinical outcomes:  
These were assessed at baseline (prior to therapy) and two weeks following 
completion of a 12-week course of treatment. Clinical outcomes were derived from 2-
week bowel diaries and a series of validated, investigator-administered questionnaires.    
Primary outcome:  
Responder vs. non-responder: Defined as a patient achieving ≥ 50% reduction in total 
FI episodes per week, as recorded on a 2-week self-completed bowel diary. 
Secondary outcomes:  
 Percentage change FI episodes per week (i.e. patients achieving ≥ 25%, ≥ 75% 
or 100% reduction in weekly FI episodes); 
 Change in FI episodes per week as a continuous measure; 
 Change in symptom severity score: St Mark’s Continence Score (SMCS). A score 
from 0 (best) -24 (worst) with >5 indicating significant symptoms 252; 
 Change in disease specific quality of life scores:  
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o Gastrointestinal Quality of Life Index (GIQOL)253. A score from 0 
(worse) to 180 (best); and  
o Faecal Incontinence quality of life scale (FIQOL) 161. A score with 4 
domains scored from 1 (worst) to 4 (best); 
 Change in general quality of life measures: SF-36254. A score with 8 domains 
with scores given as percentages; 
 Change in patients’ health status and overall health using EQ-5D255 
questionnaire; 
 Change in patient-centred outcomes questionnaire. A derivative of the ICIQ-B256 
questionnaire with a score from 1 (best) to 80 (worst); 
 Likert scale of patients global impression of success (scale 0-10); 
 Qualitative data: 
o Patient perceived impression of change in use of incontinence pads and 
constipating medications; 
o Patient perceived impression of change in urinary symptoms; 
o Patients’ impression of the treatment in general; 
o Patients’ perceived allocation (PTNS or sham);  
Other outcomes recorded at each visit: 
 Stimulation parameters 
 Adverse events and concomitant medications 
4.3.1 Clinical centres 
Centres with specialist expertise in faecal incontinence, including nurse-led (or 
equivalent) continence services, were invited to participate in the study. Centres had to 
demonstrate experience with PTNS; having previously completed a full set of 12 
treatments in a minimum of three patients. Each centre also required a minimum of 2 
staff to run the trial and ensure satisfactory blinding.  
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4.3.2 Study population  
All adult patients attending the specialist continence or pelvic floor clinics at each of 
the centres were considered for participation in the study. This included patients with 
FI symptoms sufficiently severe to warrant intervention, in whom medically 
supervised conservative therapies had failed (a combination of diet, pelvic floor 
exercises, biofeedback and anti-diarrhoeal medication). Specialist investigations 
including structural and functional anorectal assessment were not mandatory, and anal 
sphincter injury was not a contra-indication.  
4.3.3 Inclusion criteria 
 Faecal incontinence sufficiently severe to warrant intervention (as 
recommended by the PI at each site) 
 Failure of appropriate medically supervised conservative therapies 
 Age ≥ 18 years 
4.3.4 Exclusion criteria 
 Inability to provide informed consent for the research study 
 Inability to fill in the detailed bowel diaries required for outcome assessments 
(including patients who do not speak / read English) 
 Significant neurological diseases, such as diabetic neuropathy, multiple 
sclerosis and Parkinson's disease (including any patient with painful peripheral 
neuropathy) 
 Anatomical limitations that would prevent successful placement of needle 
electrode  
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 Other medical conditions precluding stimulation: e.g. bleeding disorders, 
certain cardiac pacemakers, peripheral vascular disease or ulcer, lower leg 
cellulitis 
 Congenital anorectal anomalies or absence of native rectum due to surgery  
 A cloacal defect 
 External full thickness rectal prolapse  
 Previous rectal surgery (rectopexy / resection) done < 12 months prior to the 
study (24 months for cancer) 
 Stoma in situ  
 Chronic bowel diseases such as inflammatory bowel disease leading to chronic 
uncontrolled diarrhoea 
 Pregnancy or intention to become pregnant 
 Previous experience of SNS or PTNS 
4.3.5 Data collection 
We planned that each patient should attend for 14 visits and events occurred as follows 
at each visit: 
Visit 1: Interest - eligibility: At this appointment, eligibility was determined on the basis 
of defined inclusion and exclusion criteria, listed above. Eligible subjects were provided 
with adequate explanation of the aims, methods, anticipated benefits and risks of 
participating in the study and given a patient information sheet containing this 
information.  Patients were allowed at least one week to consider their participation. 
Patients who remained interested were provided with a bowel diary to complete over 
2 weeks, and counselled on how to fill this diary in. Appointments were then booked 
for Visits 2-14, with Visit 2 being at least 2 weeks later to allow time for diary 
completion. 
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Visit 2: Consent – confirm eligibility - baseline assessment – randomisation – first 
intervention: At this appointment consent was confirmed, and patients were reminded 
of the need to be logistically able to complete the full protocol of 12 sessions at weekly 
intervals. Urine pregnancy tests were performed to exclude pregnancy in all females of 
childbearing potential.   
The researcher then recorded all baseline data of faecal incontinence history, past 
medical history and medication usage, and the patient completed the baseline 
questionnaires. They also handed in the completed bowel diary, which was checked for 
completeness. If the patient failed to complete the bowel diary properly, they were 
given another 2-week bowel diary to complete and returned 2 weeks later for the trial 
to commence. If they failed a second attempt, they were withdrawn. Another patient 
was recruited in their place.  
The researcher then performed the randomisation, recorded this information, and 
(now unblinded) delivered the first 30-minute intervention (real PTNS or sham). 
Parameters of stimulation were recorded. A GP letter, informing the GP of the patient’s 
involvement in the trial, was sent out. 
Visit 3-13: intervention – interim information: At appointments 3-13, an unblinded 
researcher (who may have been same person as in Visit 2) delivered the 30 minute 
intervention, before first checking randomisation allocation. They enquired about 
adverse events, concomitant medication usage and pad usage, and recorded this 
information.  
At Visit 7, patients were given a one-week interim bowel diary to fill in between Visits 7 
and 8. This bowel diary was collected and checked at Visit 8.  
At Visit 13, patients were given a two-week bowel diary to complete prior to attending 
Visit 14, two weeks later. 
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Visit 14: final study visit: The final study visit was performed by a blinded member of 
the research team (i.e. somebody who was not present at visits 2-13). At this 
appointment, the bowel diary was collected and checked for completeness. The patient 
was then asked to complete the questionnaire document and the post treatment 
questionnaire.  
The researcher then ensured all documents were present and filled in correctly, and 
the patient was then unblinded as to their treatment allocation and further follow-up 
was arranged as necessary. 
Patients who failed to complete the Interim Bowel Diary between Visits 7 and 8, 
attempted this again the following week, and this was recorded as a protocol deviation. 
Patients who failed to complete the Final Bowel Diary were again asked to complete 
this after Visit 14, and they returned for another final study visit 2 weeks later. This 
was also a protocol deviation.   
After completion of trial: After Visit 14, patients who received ‘sham’ stimulation were 
offered PTNS on an open label basis. Patients who received real PTNS and who derived 
significant benefit were offered ‘top-up’ sessions as per local departmental protocols. 
Patients who received real PTNS who derived no significant benefit were offered 
further treatments on an ‘open-label’ basis, following local departmental protocols. 
4.3.6 Study procedures: Delivery of PTNS and SHAM 
PTNS was delivered via the Urgent® PC neuromodulation system (Uroplasty Ltd., 
Minnetonka, MN, USA) according to manufacturer’s instruction. Sham electrical 
stimulation was delivered by transcutaneous electrical nerve stimulation (TENS) to the 
lateral forefoot (i.e. distant and contralateral to the tibial nerve) by modification of the 
validated sham technique used in the pivotal RCT of PTNS for overactive bladder.257 
Both groups used the recommended 12 weekly 30-minute outpatient stimulations.235 
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Treatments were tailored to patients’ needs but protocol tolerance stipulated a 
minimum of ten treatments, with no two treatments less than five days or greater than 
ten days apart, to be completed in 13 weeks. Treatments given outside these windows 
were classified as a protocol deviation. 
Treatments were given in individual treatment rooms, with patients lying, bare-legged, 
supine on a couch. All patients had identical equipment set-up, and this was hidden 
from patients’ view using a stool covered with a sheet (Figure 5). Once the patient was 
comfortable but prior to equipment set-up, each researcher read a standardised 
paragraph to the patient, informing them of what to expect. This read “I am now going 
to start the nerve stimulation treatment. I will be inserting a small electrode needle, like 
an acupuncture needle, into your leg and putting sticky electrodes onto your foot. When I 
turn the machine on you will be asked when you can first feel an electrical sensation in 
your ankle or foot. I will carry on increasing the intensity of this until it is slightly 
uncomfortable, then I will turn it down a little if necessary. Occasionally you may also feel 
numbness or slight movement of your toes. This is normal. I will set the machine up and 
leave it running for 30 minutes. You may or may not continue to feel the stimulation 
during this time – this is normal also. After 30 minutes have elapsed I will remove the 
needle and sticky electrodes (the machine automatically turns off at this time). If the 
treatment becomes uncomfortable at any point please let me know and I will turn it down 
or stop the machine.”  
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Figure 5: Photograph of equipment set-up 
 
All patients then had an Urgent® PC machine and a TENS machine set up on their right 
foot, unless there was a reason why the right foot could not be used, under which 
circumstances the left foot was used (equipment set up can be seen in Figure 6). In the 
true PTNS arm, the Urgent ® PC was utilised as normal, and the TENS machine left 
turned off (Figure 6a). In the sham arm, the TENS machine was used to provide the 
electrical stimulation and the Urgent® PC was only turned on to provide the auditory 
stimulus (Figure 6b). Following satisfactory treatment commencement, the sheet was 
draped fully over the patient’s feet, ensuring accidental unblinding could not take 
place. The researcher then filled in the paperwork for this visit and left the room, 
returning after 30 minutes to remove the equipment. 
Treatment group: The site of needle insertion was identified and cleaned (5cm 
cephalad to and 2cm behind the medial malleolus). The needle was inserted, advanced 
2cm, and connected to the lead wire, which in turn was connected to the stimulator. 
The calcaneal reference electrode was attached. The lead wire was then taped to the 
patient’s leg (to mimic sham equipment set-up). The TENS machine was connected to 
two electrodes placed one under and one on top of the 5th toe but was not turned on. 
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The setting for PTNS therapy was determined by increasing the current whilst 
observing the patient’s sensory response (appropriate response being in great toe or 
sole of foot) or motor response (plantar flexion of foot or great toe).  
Figure 6: PTNS and sham equipment set up 
(a) PTNS needle and calcaneal electrode.  (b) TENS surface electrode placements 
 
Sham group: the same protocol was followed as above, however the needle was 
inserted only 2mm into the skin. The lead was taped to the patient’s leg near to the 
needle. Following equipment set up, the practitioner picked up the Urgent® PC 
machine and the TENS machine (Biostim M7 TENS unit, Biomedical Life Systems, Vista, 
California), and turned both machines on. The TENS machine was set to a pulse 
frequency of 10Hz and a pulse width of 200 microseconds. Then, pressing buttons 
simultaneously on both machines, the practitioner increased the current setting for 
TENS therapy by observing for any sensory or motor response in the toe or ankle. The 
TENS machine was used to provide the electrical stimulation and the Urgent® PC used 
only to provide the auditory stimulus. 
This sham was shown in a departmental pilot to be both more acceptable and more 
realistic than that described by Peters et al, involving placement of a Streitberger 
needle. We also confirmed that this sham, using TENS to deliver the electrical 
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stimulation, does not stimulate the posterior tibial nerve (proven in a 
neurophysiological pilot by Consultant Neurophysiologist).  
4.3.7 Treatment quality control 
The importance of quality control and standardisation of technique between 
individuals and centres was recognised. In order to keep the quality high, each 
researcher was taught and certified to give PTNS by a Uroplasty-approved trainer. Each 
researcher also underwent a personal training session at the site initiation visit by the 
trial Research Fellow, on how to deliver PTNS and sham according to the CONFIDeNT 
protocol. Each researcher was then observed delivering both treatments. Six monthly 
site visits throughout the duration of the trial involved assessment of technique. Re-
training was undertaken where necessary. 
4.3.8 Withdrawal criteria 
Patients were withdrawn from the treatment or the trial if they fulfilled any of the 
criteria below at any point following delivery of the first treatment. 
Withdrawn from treatment only (follow up data still collected): 
 Patient no longer wished to be involved in trial treatments 
 Patient developed medical condition listed in exclusion criteria 
 Patient became pregnant or intended to become pregnant 
 Unblinding occurred 
 Intercurrent illness 
Withdrawn from the trial (no follow up data collected) 
 Patient lost to follow up (could not be contacted by telephone or other means) 
 Patient no longer wished to be involved in the trial 
 Death 
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Early withdrawal was documented carefully and all patients were followed up in the 
NHS in the usual way. Permission was sought from each patient to use the data that had 
already been collected.  
4.3.9 Randomisation 
Patients were randomly assigned to receive either PTNS (active treatment) or sham 
electrical stimulation. Allocation was on an equal basis (1:1) with initial stratification 
by sex and then stratification of females by centre. Stratification by sex was used to 
reduce the potential confounding effects of variation in outcomes between male and 
female patients. Since males represent only 10% of patients and only 1 or 2 male 
patients were expected from each centre (due to differing pathophysiologies6), 
randomisation stratified on centre would increase the probability that all the males 
were allocated to PTNS or sham by chance. To avoid this situation, only females were 
stratified by centre, so achieving a near balance of PTNS and sham arms and allowing 
comparability by centre. Randomly permuted block sizes of randomly varying length 
(2, 4 and 6) were used to preserve allocation concealment. Allocation was managed 
with an automated, real-time, central web-based system, and performed by a local 
researcher following baseline data collection, immediately prior to delivery of first 
treatment. 
For the duration of each patient’s involvement in the trial (14 weeks) the patients and 
investigators performing clinical outcome assessments were masked to treatment 
allocation; investigators who delivered the treatment were not masked. After final data 
collection, patients were unmasked, and those in the sham group offered active 
treatment on an ‘open-label’ basis.   
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4.3.10 Blinding 
Blinding of patients: Patients were blinded to allocation, but had knowledge of the 50% 
chance of receiving sham treatment. For both PTNS and sham interventions: (1) a 
standardised description of the technique was read from a card prior to each 
treatment, which described what the patient should expect: an electrical sensation 
variably in the ankle or foot with or without motor responses in the foot (note: there is 
significant variability in conscious sensation and motor responses even between 
patients undergoing only PTNS); (2) the lower extremity was draped from view, 
ensuring patients had no knowledge of equipment set-up; and (3) the audible sounds 
present during PTNS and sham treatments were identical. 
Performance bias considerations: In order to avoid either arm receiving more advice or 
reassurance, the interaction of the administering researcher was standardised and 
limited to a general welcome, answers to any concerns (whilst recording adverse 
events), questions regarding Loperamide dosages and incontinence pad use (both 
recorded in outcome variables). The standardised description of the technique (as 
stated above) was then read to the patient, equipment set up and then fully covered, 
and then patient left to receive the 30-minute treatment.  
Blinding of trial staff: At least two researchers were available at each site to run the 
study, one of whom performed the randomisation and all treatments and was 
necessarily unblinded, and the other remained blinded and carried out the final data 
collection.  
4.3.11 Sample size calculation 
Data published at the time of sample size calculation 218, 229, 239, 258 and our own data on 
50 patients suggested a 60% success rate for PTNS based on our chosen primary 
outcome measure. There were no RCT data for PTNS in FI, however the pivotal level I 
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SumiT trial of PTNS in overactive bladder symptoms (OAB) 257 which used a similar 
global response assessment of urinary incontinence and intention to treat analysis 
observed a moderate or marked improvement in symptoms in 55% in the PTNS arm 
and only 21% in the sham arm. On the basis that placebo responses are frequently 
higher for bowel rather than bladder symptoms 259-261 we selected a sham response 
rate of 35% whilst keeping this more conservative estimate of treatment response of 
55% (the difference of 20% we believe remains clinically important in relation to other 
therapies such as SNS). 212 patients were required to detect this difference with 80% 
power at the 5% significance level. We expected to screen 235 patients at baseline to 
allow for a 10% failure to attend for randomisation, baseline data collection and first 
treatment. 
4.3.12 Statistical methods 
All patients randomised were included in the intention-to-treat analysis. A statistical 
analysis plan was agreed prior to unmasking and analysis. Analysis was conducted 
using Stata version 12·1, interfacing with Realcom Impute for multiple imputation of 
missing outcome and baseline covariate data.262 For all outcomes, mixed effects models 
were used, adjusting for outcome measured at baseline, sex and with a random effect 
for study centre.263 Linear or logistic models were used, depending on the nature of the 
outcome, with results presented as effect sizes (odds ratios or differences in means) 
with 95% confidence intervals. Sensitivity analyses were performed (i) including only 
those patients who had ten treatment sessions within 13 weeks with no less than five 
and no greater than ten days between sessions (per protocol analysis), (ii) excluding 
any patients who had reported no episodes of FI in the baseline bowel diary, and (iii) 
excluding those centres who randomised less than five patients. Pre-planned subgroup 
analyses for the primary outcome were performed by sex, severity of FI (those with at 
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least seven weekly FIE vs. those with fewer than seven weekly FIE), age (<40, 40-60, 
>60 years) and type of FI (urge FI only vs. passive FI only vs. both). 
4.3.13 Ethical arrangements and research governance 
This trial was granted ethical approval in June 2010 (REC Reference: 10/H0703/25).  
The trial was conducted in compliance with the principles of the Declaration of Helsinki 
(1996), and in accordance with all applicable regulatory requirements including but 
not limited to the Research Governance Framework, Trust and Research Office policies 
and procedures and any subsequent amendments. The trial was compliant with the 
approved protocol and REC conditions of approval, and in line with Good Clinical 
Practice Guidelines. 
Information regarding study patients was kept confidential and managed by each study 
site in accordance with the Data Protection Act, NHS Caldicott Guardian Agreements, 
The Research Governance Framework for Health and Social Care and Research Ethics 
Committee Approval. 
4.3.14 Trial oversight 
The trial was under the auspices of the Chief Investigator and the Pragmatic Clinical 
Trials Unit (PCTU), Barts and The London School of Medicine and Dentistry. It was 
sponsored by Queen Mary University London and registered with the ISRCTN, 
registration number: 88559475. It was funded by the NIHR Health Technology 
Assessment programme (Ref: HTA 09/104/16).  
The project was overseen by a Trial Steering Committee (TSC). The TSC comprised an 
independent chair, and met 6 monthly throughout to provide overall supervision and 
ensure the trial was conducted to the rigorous standards set out in the Medical 
Research Council’s (MRC) Guidelines for Good Clinical Practice.  
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The Trial Management Group (TMG) was responsible for day-to-day project delivery in 
each participating centre. It met monthly and was answerable to the TSC.  
A data and safety monitoring committee (DSMC) was appointed to monitor unblinded 
comparative data and make recommendations to the TSC. The DSMC initially met 
together with the TSC, and subsequently two weeks prior to the TSC to enable any 
findings / recommendations to be submitted to the TSC. A DAMOCLES DSMC charter 
was adopted and an independent PCTU statistician provided the DSMC with an 
unblinded comprehensive report prior to each meeting.  
4.4 Results 
4.4.1 Patient flow 
The CONSORT (Consolidated Standards of Reporting Trials) diagram, below, shows the 
flow of patients through the trial (Figure 7). Non-completing patients either withdrew 
from treatment (and remained in the trial), or withdrew from the trial, in which case 
no further data were collected from them. Permission was however sought to use the 
data which had already been collected.  
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Figure 7: Flow of patients through the study 
373 patients screened
146 failed screening        
        1 withdrew consent     
        3 lost to follow up     
      96 declined to participate
      46 failed eligibility criteria  
           13 no faecal incontinence
             9 previous sacral nerve stimulation
             8 neurological disease
             5 symptoms not severe enough
             4 unable to speak English
             3 sphincter repair < 12 months
             1 conservative management
             1 heart problem
             1 unable to complete bowel diary 
             1 ulcerative colitis    
      
227 patients randomised
112 sham115 PTNS
111 completed six treatments
111 mid-treatment data collected
110 completed six treatments
109 mid-treatment data collected
2 withdrawals      
   1 loss to follow up      
   1 adverse event
4 withdrawals      
    1 lost to follow up      
    1 commitment of  
        weekly treatment*      
    2 perceived lack of 
       efficacy
108 completed treatment 
110 follow up data collected
115 analysed
107 completed treatment
109 follow up data collected
112 analysed
3 withdrawals    
   2 commitment of    
      weekly treatment*      
    1 adverse event
3 withdrawals
   1 lost to follow up     
   2 commitment of 
     weekly treatments *
* withdrawal from treatment only  
4.4.2 Trial Recruitment 
Seventeen of the 18 UK centres recruited patients for the trial between 23rd January 
2012 and 31st October 2013 (Figure 8). The remaining centre was unable to participate 
due to staff shortages. Trial centres were: Barts Health NHS Trust, London; Aintree 
University Hospital, Liverpool; University Hospital Southampton NHS Foundation 
Trust; Sandwell General Hospital, Birmingham; Sheffield Teaching Hospital; Ching Way 
Medical Centre, London; Leicester Royal Infirmary; Queen’s Medical Centre, 
Nottingham; Castle Hill Hospital, Hull; University College Hospital, London; Bristol 
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Royal Infirmary; St. Mark’s Hospital, London; St Thomas’ Hospital, London; Poole 
Hospital NHS Foundation Trust; Leeds General Infirmary; Pilgrim Hospital, 
Lincolnshire; University Hospital of South Manchester.  
373 patients were screened and of these, 227 (61%) were randomised.  The overall 
recruitment rate is shown in Figure 9. The number of patients per site ranged from 1-
45. There were 12 patient withdrawals, 7 from the trial and 5 from treatment (Figure 
7). 
Figure 8: Recruitment of sites 
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Figure 9: Patient recruitment 
 
 
4.4.3 Data quality 
Data return was generally very high and quality very good. Data from bowel diaries 
was 97.7% complete. This was probably a consequence of bowel diary training for each 
patient prior to completion diary and vigilant checking of bowel diaries upon return. 
Questionnaire completion was also very good (mean 90.4%, range 77.6 – 100%). For 
all data, percentages were calculated from the corrected denominator; however, since 
data return was so high individual ‘n’ values for each outcome have not been recorded 
in the tables.  
4.4.4 Baseline data 
227 patients were randomised; 115 to receive PTNS and 112 to receive sham electrical 
stimulation.  
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Baseline Findings  
Ninety per cent of patients were female with mean age 57 years (range 20 to 85 years). 
Mean symptom duration was 8 years (range 5 months to 50 years). Baseline 
demographics and clinical data, previous treatments and relevant past medical history 
are summarised in Table 12. Demographics of the two arms were evenly matched for 
age and sex as per stratification. Of note approximately 40% of patients appear to have 
concomitant symptoms of FI and evacuatory difficulties (39% in PTNS arm and 44% in 
sham arm), and approximately 60% have concomitant urinary symptoms (61% in 
PTNS arm and 64% in sham arm). 
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Table 12: Baseline demographic and clinical data  
 PTNS  Sham  
Sex (female) 104 (90%) 101 (90%) 
Age (years) 58 (50, 67) 58 (48, 65) 
Duration of symptoms  (months) 60 (24, 168) 48 (24, 108) 
Obstetric history 
Parous* 95 (91%) 96 (95%) 
Vaginal deliveries only*  90 (95%) 96 (100%) 
C-Sections only* 5 (5%) 0 (0%) 
Episiotomies or tears* 78 (87%) 82 (85%) 
Bowel function history 
Passive FI 88 (77%) 86 (77%) 
Urge FI 94 (82%) 93 (83%) 
Flatus incontinence 74 (64%) 83 (74%) 
Evacuatory difficulties 44 (39%) 49 (44%) 
Straining 34 (30%) 37 (33%) 
Digitation 12 (10%) 15 (13%) 
Bladder function history 
Urinary symptoms 70 (61%) 72 (64%) 
Urinary urgency 50 (43%) 49 (44%) 
Urinary urge incontinence 39 (34%) 42 (38%) 
Previous treatments for FI   
Anti-diarrhoeal medications 77 (67%) 67 (60%) 
Biofeedback 56 (49%) 59 (53%) 
Pelvic floor exercises 37 (32%) 36 (32%) 
Fibre supplementation 18 (16%) 30 (27%) 
Laxatives / suppositories / Irrigation 20 (17%) 16 (14%) 
Anal sphincter repair 4 (3%) 4 (4%) 
Other anal surgery 11 (10%) 8 (7%) 
Defecatory advice 9 (8%) 7 (6%) 
Other 5 (4%) 8 (7%) 
Relevant medical history   
Hysterectomy* 30 (29%) 24 (24%) 
Vaginal operation*  3 (3%) 2 (2%) 
Pelvic operation * 19 (18%) 16 (16%) 
Abdominal operation  28 (24%) 30 (27%) 
Anal operation 6 (5%) 9 (8%) 
Neck or back pain  15 (13%) 21 (19%) 
Overactive bladder 15 (13%) 7 (6%) 
Diverticular disease 4 (3%) 6 (5%) 
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Irritable bowel syndrome 1 (1%) 4 (4%) 
Data are n (%) and median (interquartile range). *females only (% calculated from only females) 
Bowel diary data at baseline 
Baseline bowel diaries demonstrated a median of 6.0 FI episodes per week in PTNS 
patients, comprising a median of 3.0 urge faecal incontinent episodes and a median of 
2.0 passive episodes. In the sham arm there was a median of 6.9 FI episodes per week, 
but with a slightly higher rate of passive FI (median 3.0 episodes) compared to urge 
episodes (median 2.5 episodes) (Table 13). 
Table 13: Descriptive statistics of bowel diary data at baseline 
 PTNS Sham 
Bowel diary data 
FI episodes/week [median (interquartile 
range)] 
6·0 (2·0, 14·0) 6·9 (2·5, 16·0) 
[mean (standard deviation)] 9·9 (11·2) 10·4 (10·9) 
Urge FI episodes/week 3·0 (0·9, 8·0) 2·5 (0·5, 7·0) 
 5·3 (7·2) 4·8 (5·9) 
Passive FI episodes/week 2·0 (0·0, 7·5) 3·0 (0·0, 8·0) 
 4·6 (6·0) 5·7 (7·6) 
Data are median (interquartile range) and mean (standard deviation). 
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Other baseline outcome measures 
Baseline St Mark’s Continence Scores (SMCS) were similar between the arms, with a 
mean of 14.4 (standard deviation 3.7), in the PTNS arm and 15.4 (standard deviation 
4.1) in the sham arm. All 211 patients who completed their SMCS had significant FI, on 
the basis of their score being greater than 5 (Table 14). 
Table 14: Descriptive statistics of other outcome measures at baseline 
 PTNS Sham 
St. Mark’s Continence Score (0 [best]-24 [worst]) 
 
14·0 (12·0, 17·0) 16·0 (13·0, 18·0) 
14·4 (3·7) 15·4 (4·1) 
St. Mark’s Continence Score >5 110 (100%) 101 (100%) 
Faecal incontinence quality of life scale scores 
Lifestyle (1[best] to 4 [worst]) 2·7 (1·8, 3·4) 2·5 (1·7, 3·6) 
2·6 (0·9) 2·6 (1·0) 
Coping and behaviour (1[best] to 4 [worst]) 1·7 (1·2, 2·3) 1·6 (1·1, 2·6) 
1·9 (0·7) 1·9 (0·9) 
Depression and self-perception (1[best] to 4·4 
[worst]) 
3·1 (2·0, 3·4) 2·6 (2·0, 3·7) 
2·8 (0·9) 2·7 (0·9) 
Embarrassment (1[best] to 4 [worst]) 2·0 (1·7, 2·7) 2·0 (1·3, 2·7) 
2·2 (0·8) 2·1 (0·8) 
Patient centred outcomes (1 [best] to 10 [worst]) 
 8·9 (7·8, 9·8) 9·2 (8·3, 10·0) 
8·5 (1·6) 8·7 (1·7) 
Gastrointestinal quality of life (36 [worst] to 180 [best]) 
 
130·0 (113·0, 
41·0) 
126·5 
(109·0,39·0) 
126·7 (18·8) 123·8 (20·2) 
SF-36 scores (%) 
Physical functioning  70·0 (45·0, 90·0) 65·0 (40·0, 85·0) 
65·7 (27·4) 61·4 (28·4) 
Role-physical functioning 50·0 (0·0, 100·0) 25·0 (0·0, 75·0) 
46·4 (42·1) 36·4 (41·4) 
Bodily pain  60·0 (40·0, 90·0) 57·5 (32·5, 90·0) 
61·3 (30·0) 58·2 (31·5) 
General health  50·0 (35·0, 70·0) 50·0 (30·0, 70·0) 
51·2 (23·4) 50·3 (23·8) 
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Vitality  45·0 (30·0, 57·5) 50·0 (30·0, 60·0) 
43·9 (22·1) 42·7 (22·8) 
Social functioning  62·5 (37·5, 75·0) 62·5 (37·5, 87·5) 
58·4 (28·8) 59·3 (31·6) 
Role-emotional function  66·7 (0·0, 100·0) 33·3 (0·0, 100·0) 
58·4 (28·8) 59·3 (31·6) 
Mental health  60·0 (44·0, 76·0) 64·0 (48·0, 76·0) 
60·3 (21·0) 60·8 (21·6) 
EQ-5D index score (-0·594 [worst] to 1 [best]) 
 0·73 (0·62, 0·85) 0·73 (0·62, 0·85) 
0·69 (0·27) 0·63 (0·34) 
Data are n (%) , median (interquartile range) and mean (standard deviation). 
4.4.5 Primary outcome 
The proportion of patients achieving a ≥50% reduction in weekly FI episodes (FIE) was 
similar in both arms at 38% (39/103) for PTNS compared to 31% (32/102) for sham 
(unadjusted odds ratio 1.333; adjusted odds ratio 1.283, 95% CI 0.722-2.281, p=0.396)  
(Table 15 and Table 16). 
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Table 15: Results of intention to treat analysis (n=227) 
Outcome   Odds ratio 95% confidence 
interval 
p- 
value 
Percentage reduction in weekly FIE 
≥ 50% (primary outcome) 1.283 0.722, 2.281 0.396 
≥25% 1.264 0.730, 2.190 0.404 
≥75% 1.615 0.770, 3.388 0.205 
100% 1.635 0.592, 4.514 0.344 
Outcome   Difference in 
means 
95% confidence 
interval 
p- 
value 
Change in weekly FIE 
Total -2.262 -4.185, -0.339 0.021 
Urge -1.456 -2.693, -0.219 0.021 
Passive -0.635 -1.668, 0.397 0.228 
 Faecal Incontinence Quality of Life 
Embarrassment 0.036 -0.151, 0.223 0.706 
Coping 0.013 -0.171,0.197  0.889 
Lifestyle 0.086 -0.075, 0.248 0.290 
Depression 0.014 -0.297, 0.324 0.927 
SF-36 
Physical functioning -1.854 -6.992, 3.284 0.479 
Role-physical 1.113 -8.866, 11.092 0.826 
Bodily pain -1.026 -6.815, 4.764 0.728 
General health -0.158 -4.749, 4.433 0.946 
Vitality -3.142 -8.129, 1.845 0.215 
Social functioning 5.209 -0.740, 11.157 0.087 
Role emotional -4.815 14.802, 5.171 0.343 
Mental health -0.509 -4.831, 3.814 0.817 
Other outcomes 
St. Mark's continence score -0.047 -1.033, 0.939 0.925 
Patient centred outcomes -0.545 -1.081, -0.008 0.047 
EQ-5D index score -0.017 -0.078, 0.044 0.583 
Gastrointestinal quality of life -1.300 -5.168, 2.568 0.506 
Likert scale of success 0.808 -0.055, 1.672 0.068 
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Table 16: Descriptive statistics for bowel diary outcomes at baseline and end of 
treatment 
 Baseline End of treatment 
 PTNS  Sham PTNS  Sham  
FI episodes/week 
6.0 (2.0, 14.0) 6.9 (2.5, 16.0) 3.5 (1.0, 10.0) 4.8 (1.5, 12.8) 
9.9 (11.2) 10.4 (10.9) 6.4 (7.6) 9.1 (10.7) 
UFI 
episodes/week 
3.0 (0.9, 8.0) 2.5 (0.5, 7.0) 1.5 (0.0, 4.5) 1.5 (0.5, 5.5) 
5.3 (7.2) 4.8 (5.9) 3.0 (4.2) 4.4 (6.5) 
PFI 
episodes/week 
2.0 (0.0, 7.5) 3.0 (0.0, 8.0) 1.5 (0.0, 5.0) 1.5 (0.0, 6.5) 
4.6 (6.0) 5.7 (7.6) 3.4 (4.6) 4.7 (6.6) 
Data are median (interquartile range) and mean (standard deviation). UFI = Urge Faecal Incontinence; PFI = Passive 
Faecal Incontinence. 
4.4.6 Secondary outcomes 
4.4.6.1 Percentage change in FI episodes 
No significant difference was observed between the PTNS and sham arms in the 
number of patients achieving ≥25%, ≥75% and 100% reduction in weekly FI episodes 
(Table 15 and Figure 10). 
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Figure 10: Categorical reductions in mean weekly FIE (adjusted odds ratios and 95% 
confidence intervals) for PTNS vs. sham group at 14 weeks. 
 
 
4.4.6.2 Change in FI episodes as a continuous measure 
There was a greater decrease in total weekly FI episodes in the PTNS compared to the 
sham arm (difference in means -2.3, 95% CI (-4.2 to -0.3) episodes per week, and this 
was significant (p=0.02). This comprised a reduction in urge FI episodes (-1.5, 95% CI 
(-2.7 to -0.2), p=0.02) but not passive FI episodes (-0.64, 95% CI (-1.67 to 0.40), 
p=0.23) per week (Table 15, Figure 11 and Figure 12). There was very little continued 
improvement from mid-treatment to end treatment (Figure 12), indicating that those 
who are likely to respond to treatment will have done this by week 6. 
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Figure 11: Adjusted difference in mean weekly FIE (95% CI) for PTNS vs. sham groups 
at 14 weeks.  
 
Figure 12: Frequency of FIE at baseline, after six treatments and at 14 weeks for PTNS 
vs. sham groups.  
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4.4.6.3 Change in symptom severity score: St Marks Continence Score 
No significant difference in SMCS was observed between the PTNS and sham arms 
following treatment (difference in means -0.047, 95% CI (-1.033 to 0.939), p=0.93) 
(Table 15 and Table 17. 
Table 17: Descriptive statistics for St. Mark’s continence score at end of treatment. 
 Baseline End of treatment 
 PTNS Sham PTNS  Sham  
SMCS  14.0 (12.0, 17.0) 16.0 (13.0, 18.0) 14.0 (11.0, 17.0) 15.0 (11.0, 18.0) 
14.4 (3.7) 15.4 (4.1) 13.9 (4.3) 14.6 (4.6) 
SMCS >5 110 (100%) 101 (100%) 104 (100%) 101 (100%) 
Data are n (%), median (interquartile range) and mean (standard deviation). 
4.4.6.4 Change in Quality of Life Measures 
No significant differences were seen in the disease specific (FIQOL and GIQOL) or 
generic (SF-36) quality of life measures between the PTNS and sham arms following 
treatment (Table 15, Table 18, Figure 13 and Figure 14).  
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Table 18: Descriptive statistics for quality of life outcomes at baseline and end of 
treatment 
 Baseline End of treatment 
 PTNS Sham PTNS Sham 
Faecal incontinence quality of life scale scores 
Lifestyle  
(1[best] to 4 [worst]) 
2.7 (1.8, 
3.4) 
2.5 (1.7, 
3.6) 
3.0 (2.2, 
3.7) 
2.9 (1.9, 
3.7) 
 2.6 (0.9) 2.6 (1.0) 2.8 (0.9) 2.8 (1.0) 
Coping and behaviour  
(1[best] to 4 [worst]) 
1.7  
(1.2, 2.3) 
1.6  
(1.1, 2.6) 
1.9 
(1.3, 2.6) 
1.7  
(1.2, 2.9) 
 1.9 (0.7) 1.9 (0.9) 2.0 (0.8) 2.0 (1.0) 
Depression and self-
perception (1[best] to 4 
[worst]) 
3.1  
(2.0, 3.4) 
2.6  
(2.0, 3.7) 
3.1 
(2.2, 3.7) 
2.6  
(2.0, 3.9) 
 2.8 (0.9) 2.7 (0.9) 2.9 (1.0) 2.8 (1.0) 
Embarrassment  
(1[best] to 4.4 [worst]) 
2.0  
(1.7, 2.7) 
2.0  
(1.3, 2.7) 
2.7  
(1.7, 3.0) 
2.3  
(1.7, 3.0) 
 2.2 (0.8) 2.1 (0.8) 2.4 (0.8) 2.3 (0.9) 
Gastrointestinal quality of life (36 [worst] to 180 [best]) 
 
130.0  
(113.0, 
141.0) 
126.5  
(109.0, 
139.0) 
135.0  
(115.0, 
148.0) 
134.0  
(120.0, 
146.0) 
 126.7 (18.8) 123.8 (20.2) 132.0 (20.6) 131.6 (20.5) 
SF-36 scores (%) 
Physical functioning  
70.0  
(45.0, 90.0) 
65.0  
(40.0, 85.0) 
75.0  
(47.5, 90.0) 
70.0  
(45.0, 90.0) 
 65.7 (27.4) 61.4 (28.4) 67.1 (27.7) 63.8 (29.0) 
Role-physical  
50.0  
(0.0, 100.0) 
25.0  
(0.0, 75.0) 
62.5  
(0.0, 100.0) 
25.0  
(0.0, 100.0) 
 46.4 (42.1) 36.4 (41.4) 54.4 (44.1) 46.2 (44.8) 
 Bodily pain  
60.0  
(40.0, 90.0) 
57.5  
(32.5, 90.0) 
67.5  
(45.0, 90.0) 
67.5  
(35.0, 90.0) 
 61.3 (30.0) 58.2 (31.5) 64.3 (28.3) 62.1 (31.0) 
General health  
50.0  
(35.0, 70.0) 
50.0  
(30.0, 70.0) 
55.0  
(30.0, 75.0) 
50.0  
(35.0, 70.0) 
 51.2 (23.4) 50.3 (23.8) 52.8 (24.6) 50.6 (23.9) 
Vitality  
45.0  
(30.0, 57.5) 
50.0  
(30.0, 60.0) 
50.0  
(25.0, 60.0) 
50.0  
(35.0, 65.0) 
 43.9 (22.1) 42.7 (22.8) 45.6 (22.2) 46.7 (23.1) 
Social functioning  
62.5  
(37.5, 75.0) 
62.5  
(37.5, 87.5) 
75.0  
(50.0, 87.5) 
62.5  
(37.5, 87.5) 
 58.4 (28.8) 59.3 (31.6) 66.4 (28.6) 60.6 (31.7) 
 Role-emotional function  
66.7  
(0.0, 100.0) 
33.3  
(0.0, 100.0) 
100.0  
(0.0, 100.0) 
83.3  
(0.0, 100.0) 
 58.4 (28.8) 59.3 (31.6) 61.7 (45.3) 60.2 (44.1) 
Mental health  
60.0  
(44.0, 76.0) 
64.0  
(48.0, 76.0) 
64.0  
(48.0, 84.0) 
64.0  
(52.0, 76.0) 
 60.3 (21.0) 60.8 (21.6) 62.7 (25.1) 63.0 (21.4) 
Data are n (%), median (interquartile range) and mean (standard deviation). 
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Figure 13: Adjusted difference in means (95% CI) for FIQoL: PTNS vs. sham 
 
Figure 14: Adjusted difference in means (95% CI) for SF-36: PTNS vs. sham 
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4.4.6.5 Change in patient-centred outcomes score 
Improvement in patient-centred outcomes (i.e. a reduction in score) was significantly 
higher in the PTNS arm than the sham arm (difference in means -0.545, 95% CI (-1.081 
to -0.008), p=0.047 (Table 15, Table 19 and Figure 15).  
Table 19: Descriptive statistics for patient-centred outcomes at end of treatment 
 Baseline End of treatment 
 PTNS Sham PTNS Sham 
Patient centred outcomes  8.9  
(7.8, 9.8) 
9.2  
(8.3, 10.0) 
8.4  
(6.9, 9.4) 
9.3  
(7.6, 10.0) 
8.5 (1.6) 8.7 (1.7) 7.8 (2.0) 8.4 (2.1) 
Data are median (interquartile range) and mean (standard deviation).  
 
Figure 15: Adjusted difference in means (95% CI) for other outcomes (SMCS, PCO, 
GIQoL, Likert scale of success and EQ-5D) 
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4.4.6.6 Likert scale of patients’ global impression of success (scale 0-10) 
No significant difference existed in patients’ global impression of success between the 
PTNS and sham arms (difference in means 0.808, 95% CI (-0.055 to 1.672), p=0.068) 
(Table 15, Table 20 and Figure 15).  
 
Table 20: Descriptive statistics for Likert scale of success outcome at end of treatment 
 PTNS Sham 
Likert scale of success  4.8 (0.0, 6.8) 2.1 (0.0, 4.9) 
4.0 (3.3) 3.2 (3.1) 
Data are median (interquartile range) and mean (standard deviation) 
4.4.6.7 EQ-5D analysis 
There were virtually no differences between the two arms either at baseline or post 
treatment in respect of EQ-5D Index and VAS scores, with scores on both scales 
remaining unchanged over time (Table 15, Table 21 and Figure 15).  
  
Table 21: Descriptive statistics for EQ-5D outcome at end of treatment 
 Baseline End of treatment 
 PTNS Sham PTNS Sham 
EQ-5D Index  0.69 (0.27) 0.63 (0.34) 0.68 (0.28) 0.65 (0.34) 
EQ-5D VAS 64.50 (21.72) 64.04 (21.24) 64.25 (22.32) 63.69 (23.66) 
Data are  mean (standard deviation). 
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4.4.6.8 Other outcomes 
In the PTNS arm, 57/107 (54%) patients thought they had received PTNS and 48/107 
(46%) thought they had received sham.  In the sham arm of the trial, 32/103 (31%) 
patients thought they had received PTNS and 71/103 (69%) patients thought they had 
received sham. Of the 208 patients who completed this question, 56% of these 
perceived correctly (Figure 16). This proves that the sham arm was of a good standard. 
 
 
Figure 16: Patients’ perception of treatment. 
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Only 13% (8/61) of patients in the PTNS arm had slight or substantial improvement in 
urinary symptoms and similarly 11% (7/64) reported this in the sham arm. Most 
symptomatic patients reported no effect, 39% in the PTNS arm and 50% in the sham 
arm. Indeed more patients in the PTNS arm reported a worsening of urinary symptoms 
10% vs. 5% in the sham arm (Figure 17). 
 
Figure 17: Effect of treatment on urinary symptoms 
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Of patients who used Loperamide at baseline, the majority in both PTNS (33/49=67%) 
and sham (32/38=84%) arms reported no change in use throughout the trial. Similar 
proportions in each arm (4% in PTNS vs. 5% in sham) reported increasing Loperamide 
use. A higher proportion of patients reduced their Loperamide use in the PTNS arm 
compared to the sham arm (29% vs. 11%, p=0.06) (Figure 18). 
There was minimal concomitant medication usage and this has not been considered 
significant. 
Figure 18: Effect of treatment on Loperamide use 
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Of the patients who used incontinence pads, the majority (56% (44/79) in PTNS arm 
and 49% (35/72) in sham arm) reported no change in use over the period of the trial. 
Similar proportions of patients reduced their pad usage through the course of the trial 
(15% in PTNS arm and 14% in sham arm), whilst 4% patients in the sham arm had to 
increase their pad usage compared with none in the PTNS arm (Figure 19). 
Figure 19: Effect of treatment on incontinence pad usage 
 
4.4.7 Per protocol analysis 
Per protocol analysis was carried out subsequent to the intention-to-treat analysis. To 
be included in these analyses, patients were required to have at least 10 treatments 
within 13 weeks, with 10 treatments no less than 5 and no greater than 10 days apart. 
This was to ensure patients attended for treatments regularly and in a timeframe 
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unchanged apart from the Likert scale of success, which shows that those in the PTNS 
arm felt treatment was more successful than those in the sham arm; this was 
statistically significant. 
Table 22: Results of per protocol analysis (n=197) 
 
 
Outcome Odds ratio 95% confidence 
interval 
p-
value 
Percentage reduction in weekly FIE 
≥ 50% (primary 
outcome) 
1.269 0.688, 2.341 0.446 
≥25%  1.247 0.698, 2.228 0.456 
≥75%  1.631 0.781, 3.409 0.194 
100%  1.658 0.590, 4.655 0.338 
Outcome Difference in 
means 
95% confidence 
interval 
p-
value 
Change in weekly FIE 
Total -2.233 -4.275, -0.191 0.032 
Urge -1.486 -2.778, -0.194 0.024 
Passive -0.600 -1.663, 0.463 0.268 
    
St. Mark's continence 
score 
0.202 -0.855, 1.258 0.708 
 
GI QoL -1.750 -5.864, 2.364 0.401 
 
Faecal Incontinence Quality of Life 
Embarrassment 0.059 -0.141, 0.260 0.563 
Coping -0.007 -0.211, 0.196 0.944 
Lifestyle 0.093 -0.079, 0.266 0.286 
Depression 0.030 -0.302, 0.361 0.853 
 
SF-36 
Physical functioning -0.601 -5.964, 4.761 0.826 
Role-physical 1.562 -9.062, 12.186 0.772 
Bodily pain -2.933 -8.975, 3.108 0.341 
General health 0.612 -3.989, 5.213 0.794 
Vitality -2.872 -7.967, 2.224 0.268 
Social functioning 5.665 -0.518, 11.848 0.074 
Role emotional -6.562 -16.988, 3.863 0.216 
Mental health -0.300 -4.633, 4.033 0.892 
 
Patient centred outcomes -0.593 -1.141, -0.044 0.034 
EQ-5D index score -0.020 -0.082, 0.042 0.524 
Likert scale of success 0.934 0.037, 1.831 0.042 
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4.4.8 Subgroup analyses 
Pre-planned subgroup analyses were performed for the primary outcome only. The 
following subgroups were selected: 
 Sex (male vs. female) 
 FI severity (>7 episodes per week vs. <7 episodes per week on initial bowel 
diary) 
 Age (<40 years, 40-60 years, >60 years) 
 Both urge and passive incontinence, only urge, only passive. 
The primary outcome was negative for each of these subgroup analyses (Appendix 2).  
4.4.9 Sensitivity analysis 
Sensitivity analysis was carried out, removing the patients who scored ‘zero’ on their 
initial bowel diaries (Appendix 3). This excluded 16 patients, 9 from PTNS and 7 from 
sham arms. The primary outcome was negative for this analysis (odds ratio 1.325, 95% 
confidence interval (0.736 to 2.385), p=0.348). 
Further sensitivity analysis was carried out excluding patients who were recruited 
from poorly recruiting centres (defined as centres recruiting fewer than 5 patients) 
(Appendix 3). This excluded 4 patients from 2 centres, 2 from each arm. The primary 
outcome was negative for this analysis (odds ratio 1.234, 95% confidence interval 
(0.693 to 2.196), p=0.476). 
4.4.10 Centre effect 
Data were analysed to allow for a centre effect i.e. that outcomes amongst patients 
being treated by the same study centre may be correlated; indicating treatment at 
some centres may be more effective. The intra-centre coefficient (ICC) for the primary 
outcome based on the raw data was 0.01, 95% CI (-0.06 to 0.08) i.e. the variation in the 
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primary outcome between centres was very small indeed. In the results of the model 
where centre was included as a random effect and other variables as fixed effects the 
ICC was even smaller (<0.001). This indicates no significant centre effect. 
4.4.11 Serious adverse events 
There were four serious adverse events (SAEs) during the trial (Table 23). None were 
related to the trial treatment and all were resolved.  
Table 23: Serious adverse events 
SAE Allocation Grade Duration 
(days) 
Actio
n 
Relatednes
s 
Outcom
e 
Flexible cystoscopy 
for botox PTNS 
Moderat
e 3 H U R 
Sleeve gastrectomy Sham Severe 1 H U R 
Pilonidal abscess Sham 
Moderat
e 26 H U R 
Shoulder 
manipulation PTNS Severe 1 H U R 
H=hospitalisation, U = unrelated, R = resolved 
4.4.12 Adverse events 
A total of 204 adverse events were noted in the trial, 107 in the PTNS arm and 97 in the 
sham arm. Table 24 reports severity by relatedness in each arm.  There were 7 mild 
related adverse events in each arm.  
Table 24: Adverse events - severity by relatedness 
 PTNS Sham 
 Related 
Possibly 
related Unrelated Total Related 
Possibly 
related Unrelated Total 
Mild 7 25 40 72 7 18 33 58 
Moderate 0 13 17 30 0 14 21 35 
Severe 0 4 1 5 0 1 3 4 
 
Related and possibly related adverse events can be seen in Table 25.  
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Table 25: Related and possibly related adverse events 
 Adverse event PTNS Sham 
Related Pain at needle site 4 3 
 Bruising at needle site 2 1 
 Altered sensation at needle site 1 0 
 Bleeding at needle site 0 2 
 Altered sensation in toe 0 1 
Possibly related Pain in abdomen 4 2 
 Pain in back 1 0 
 Pain in leg or foot 13 10 
 Pain in perineum 0 1 
 Altered sensation in leg or foot 4 0 
 Altered sensation in perineum 0 1 
 Weakness in leg 0 1 
 Constipation 0 1 
 Diarrhoea 8 3 
 Faecal incontinence 0 1 
 Urinary symptoms 0 4 
 Headache/migraine 6 7 
 Dizziness 5 0 
 Nausea/vomiting 0 1 
 Anxiety/depression 1 1 
 Skin disorder 1 0 
 
  
      
 
 
132 
 
4.5 Discussion 
4.5.1 Summary of results 
No clinically significant benefit of PTNS over sham electrical stimulation was 
demonstrated in the treatment of adults with faecal incontinence. This was manifest by 
the primary outcome, with 38% patients in the PTNS arm and 31% in the sham arm 
achieving at least a 50% reduction in weekly FIE.  
However, although there was no significant difference in the proportion of patients 
achieving this 50% or greater benchmark, PTNS did result in a significant reduction in 
mean total weekly FIE and mean urge weekly FIE compared to sham. Whilst 
statistically significant, the clinical interpretation of these findings is uncertain, since a 
reduction from a mean of 6.0 (IQR 2.0-4.0) to 3.5 (IQR 1.0-10.0) weekly FIE may or may 
not be helpful to patients. The clinical significance of a seemingly beneficial effect of 
PTNS compared to sham, of urge over passive FIE is also complex, since only a minority 
(in trial 23%) of patients had isolated urge FI. 
Whilst PTNS also resulted in an improvement in the patient centred outcomes (a short-
form derivative of the validated ICIQ-B264), this was not supported by the St. Mark’s 
Continence Score, in which there was no significant improvement in the PTNS 
compared to the sham arm. There was also no significant improvement in disease-
specific or generic quality of life measures.   
This study was generally conducted to a high standard and there were no major 
methodological flaws or protocol violations. The effect of sham stimulation was 
correctly predicted at 35%. It would have been difficult to predict such a marginal 
treatment effect based on the previous literature, however the effect of treatment was 
still less than our conservative estimate of 55%. The data however indicate the sample 
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size was adequate as the 95% CI of the primary outcome analysis precludes a clinically 
significant reduction in the odds of success. 
4.5.2 Comparison of results to previously published studies 
Results of this study may seem surprising when considered in the context of other 
published studies of PTNS in the treatment of FI, as discussed in Chapter 3, which 
include six case series, 235 one small single-centre randomised single-blind trial (PTNS 
vs. TTNS vs. sham),225 one comparative case-matched study (PTNS vs. SNS)265 and one 
prospective clinical audit comparing PTNS and SNS266 and allude to a 52-82% response 
rate using the same primary outcome, which is considerably higher than the 38% 
reported here (Figure 20). The effect size seen in the treatment arm is nearer to that 
reported by a recent pilot randomised study (n=40) of PTNS vs. SNS, where 47% of 
patients had treatment success in the PTNS group at 3 months.267 It also mirrors results 
from a large RCT of transcutaneous tibial nerve stimulation (TTNS) vs. sham electrical 
stimulation for the same indication, in which no superiority of TTNS was observed. 260 
These findings highlight the necessity of conducting well-designed randomised 
controlled trials to answer clinical questions.  
Figure 20: Percentage success rates of PTNS in published studies 
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In order to directly compare results of the CONFIDeNT Study with the previous 
literature, post hoc calculation of changes in mean weekly FIE and SMCS before vs. 
after treatment has been performed. In the PTNS arm, there was a significant reduction 
in mean weekly FIE after vs. before treatment (p<0.001), however there was no 
significant reduction in mean SMCS (p=0.171). Comparison of these findings to the 
previous literature is in agreement in terms of the weekly FIE however almost all 
studies demonstrated a reduction in the CCIS (which is similar to the SMCS). It is not 
clear why no improvement in SMCS was seen in The CONFIDeNT Study. Consideration 
has been given to the differences between the SMCS and the CCIS (CCIS does not 
include urgency or the use of constipating agents). The CCIS can be derived from the 
SMCS, and basic analysis of the SMCS (raw un-imputed data) with the omission of the 
final 2 questions (i.e. leaving the 5 questions covered by CCIS) results in an identical 
conclusion i.e. pre-intervention score (mean 11.3, SD 3.3) vs. post-intervention score 
(mean 10.6, SD 3.7).  
Changes in quality of life measures, both in the previously published literature, and in 
the CONFIDeNT Study, showed no significant or reproducible improvement. This is 
interesting and merits discussion, since in the published case series literature, the lack 
of apparent improvement in quality of life is at odds with the other positive outcomes 
reported. One might have expected that if weekly FIE were reducing and CCIS 
improving, quality of life would follow suit. This was not observed. My hypothesis is 
that either the QOL tools used were not sensitive to change in FI, or that reduction in 
symptoms, although statistically significant, was insufficient for patients to lead a 
normal life. Indeed it may be that changes in quality of life take some time to achieve 
and it is not until patients are completely symptom free and have been for some time, 
that they have the confidence to report normalised activities. There is also the 
possibility that due to the unpredictable nature of FI, quality of life in this condition 
will never improve whilst there is always the possibility of an unexpected episode 
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occurring i.e. that fear continues to influence QOL reporting in some domains even 
after symptoms have started to resolve.  
PTNS is also used to treat overactive bladder (OAB). There are two double-blinded 
RCTs that compare PTNS with sham electrical stimulation in the treatment of OAB, and 
both showed a statistically significant improvement in urinary frequency and urge 
urinary incontinence in the active PTNS arm compared to the sham arm (71% vs. 0% 
responders in the smaller study (n=35) p<0.001268, and 54.5% vs. 24.9% p<0.001 in 
the larger pivotal trial257 (n=174)). Both of these studies reported a higher treatment 
effect of PTNS than seen in the CONFIDeNT trial, and one that is significantly beneficial 
compared to sham. 
4.5.3 Limitations 
Despite the controlled design of this study, limitations are acknowledged. As discussed 
in detail in Chapter 3, there is no perfect or universally accepted outcome measure for 
FI269. The categorical measure of a ≥50% reduction in weekly FIE was chosen as the 
primary outcome measure. Although subject to criticism, this outcome was chosen 
since it is widely used to assess SNS, thus allowing comparisons to be drawn between 
the two treatment modalities. Also, the 50% criterion has been applied as the primary 
endpoint in both the pivotal trials of contemporary treatments in FI270, 271. It is accepted 
that the choice of another, perhaps less stringent primary outcome measure may have 
resulted in a different conclusion, however if other treatments for the same condition 
are assessed using this outcome, and meet it, it is important that PTNS is assessed 
against this benchmark.  
Consideration of patient selection is important. As is the nature of faecal incontinence, 
there was heterogeneity in the population of patients selected to take part in the trial. 
This heterogeneity encompassed patients with urge, passive or a mixed picture of 
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faecal incontinence, and included some patients who suffered with frequent loose 
stools, and a significant proportion (approximately 40%) who had concomitant 
problems with rectal evacuation (see Chapter 5).  In addition to this, all patients 
received prior conservative therapy but this was not formally standardised reflecting 
the lack of consensus on what constitutes a minimum standard in the UK. Thus a 
pragmatic view was adopted that balanced some heterogeneity in baseline 
characteristics (e.g. type of faecal incontinence symptoms and degree of treatment 
refraction) with exclusion of other specific patient subgroups that might have differing 
response rates. These exclusions included patients with inflammatory bowel disease, 
who would be more likely to suffer, for example, with uncontrolled diarrhoea. This 
pragmatic design was important to adequately assess PTNS as a first line treatment for 
FI, for example in GP surgeries or nursing homes, where rigorous patient selection 
would not be feasible or possible. Some efficacy was demonstrated in reducing urge FI 
episodes, and this has been previously documented 235,251 and is akin to the approved 
indication for PTNS to treat overactive bladder.257 However to determine whether 
targeted selection of patients with this baseline characteristic (or others) would lead to 
a different conclusion would require validation in an appropriately designed study. 
Overall, it is acknowledged that results can only be considered valid for the population 
studied at the point of intervention in the algorithm of care.  
For similar pragmatic reasons, anti-diarrhoeal medication use was not prohibited 
(concern that unrecorded usage would continue). Consideration has to be given to the 
fact that a differential change in anti-diarrhoeal medication between the two groups 
may have reduced the effect size of PTNS. The decision was made to record patients’ 
Loperamide usage throughout the trial, rather than restrict it. Patients were asked each 
week about Loperamide usage, however following the first meeting of the TSC and 
DSMC, it was felt this was not accurately recalled by patients, and a decision was made 
to instead ask patients at the end of the trial whether their usage had remained the 
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same, increased or decreased. Since this decision was made partway into the trial, this 
information was not collected from all patients. The question on Loperamide usage was 
answered by 144/227 patients (64%), and this was in the main due to 55 patients 
having completed the trial prior to implementation of the new questionnaire. Those 
who did answer the question were evenly balanced between treatment arms. Of those 
who were taking Loperamide, almost three times as many patients in the PTNS arm 
reduced this compared to the sham arm. Post-hoc Chi-square testing found weak 
evidence of a difference in Loperamide use (p=0.06). Although this could have 
confounded the effect size this would have been unlikely to affect the overall trial 
conclusion based on the primary endpoint. This calculation should however be 
interpreted with caution as the numbers using Loperamide at baseline 
were comparatively small, and, since they are not the full randomised samples, may 
differ systematically. 
Another criticism of this study could be that patients were not excluded on the basis of 
having ‘zero’ faecal incontinence episodes reported on their baseline bowel diary, so 
long as the principal investigator was convinced of the fact that the patient had ‘faecal 
incontinence significant enough to warrant intervention’. This decision was taken as 
faecal incontinence is often a problem which happens in ‘bouts’ and it is not impossible 
for a patient to experience 2 symptom free weeks by chance. The alternatives would 
have been either to exclude these patients (an ethical issue in patients with significant 
FI), or to give patients another chance to complete the bowel diary. The latter would 
have risked the introduction of bias i.e. first, enthusiastic patients might fabricate a 
second bowel diary to merit inclusion and secondly, the randomness of baseline 
observations would have been compromised by selection bias. Sensitivity analysis was 
done removing the 16 patients to whom this applied, who did happen to be spread 
evenly across the two arms, and this made no difference to the overall results.   
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Quality assurance measures aimed to minimise variation in intervention performance 
but this could have contributed to differences from previously published experience in 
single expert centres. 235, 251 However, although disparity existed amongst centre 
recruitment rates (range 1-45 patients), sensitivity analysis excluding low-volume 
centres did not change the primary outcome. In addition, no significant centre effect 
was observed in analysis of the primary outcome.  
A final limitation is the short follow-up period. It is fully acknowledged that 
effectiveness of FI treatments cannot be judged adequately without a longer interval of 
follow-up e.g. 1 year. The longer-term effectiveness of PTNS was not an objective of this 
trial, however a further study following up all patients in this study, has been 
performed, and is presented in Chapter 6.  
4.5.4 Interpretation of results in context of previous published literature 
There is disparity between the CONFIDeNT Trial findings and the published literature 
on PTNS in the treatment of FI. No double blind RCT of PTNS vs. sham had been 
performed before CONFIDeNT, and it is likely that the disparity may be accounted for 
by study design.  
The CONFIDeNT Study included a sham group to negate the effect of natural change in 
disease status over time and the well-recognised effect of nurse-led face-to-face 
intervention.272 It is widely acknowledged that placebo responses are 
disproportionately high in patients with chronic debilitating GI conditions due to a high 
level of expectation.260 Meta-analyses of 45 published trials estimates the placebo 
response rate in functional dyspepsia at between 6% and 72%273, 274, and that of 50 
placebo controlled irritable bowel syndrome trials between 3% and 84%275-277. A 
recent multicentre phase II double blind randomised placebo controlled investigation 
of NRL001 (an alpha1-adrenoceptor agonist), demonstrated treatment success (using 
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both FIE and CCIS as outcomes) in 35% of the placebo arm (i.e. much higher than the 
25% they had anticipated), drawing the conclusion that any studies without a placebo 
or comparator arm should be interpreted with caution. The CONFIDeNT Study 
correctly estimated the placebo response at 35% (vs. 31% found).  
Selection bias in case series is a problem unless subjects are truly selected 
consecutively. In addition to this, case series are often subject to attrition bias as 
patients may be lost to follow up or researchers may selectively report only in subjects 
with positive findings. In case series, both the patient and the observer are often 
unblinded. This can introduce bias from both perspectives: patients may experience a 
high level of expectation, which may influence reporting; and in addition to this, bias 
may be introduced from the observers’ perspective, since clinicians often have a vested 
interest in treatment and publication. Without the rigour of an independently managed 
trial, bowel diaries can also introduce bias if they are unmasked and subject to 
investigator interpretation269.  
The CONFIDeNT Study represents Oxford Level Ib evidence278, likely reflecting more 
reliable data than the Level IV literature published before. This would not represent 
the first time a small body of low-level literature indicates a treatment to be successful, 
only for a definitive trial to contradict this. Indeed, a handful of case series intimated 
that SNS may be useful in the treatment of constipation, however a recently published 
definitive trial has shown this not to be the case279.  
The disparity of The CONFIDeNT trial findings with the randomised controlled trials of 
PTNS to treat OAB could be due to a number of reasons. Firstly, it could simply be due 
to PTNS having efficacy in OAB but not FI. Alternatively it could be due to these studies 
selecting purely patients who had overactive bladder (OAB) i.e. who experience 
bladder urgency (more akin to faecal urgency or urge faecal incontinence), which may 
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account for the CONFIDeNT trial showing no overall benefit in patients, but significant 
reductions in urge faecal incontinence episodes.  
The disparity could also be a factor of primary outcome measure selection. Peters et al. 
used a subjective primary endpoint involving number of patients who graded their 
overall bladder symptoms as moderately or markedly improved on a global response 
assessment (GRA)257.  
Both published urological RCTs also reported a significantly lower treatment effect of 
the sham. The placebo effect in trials of functional bowel disease is well-acknowledged 
to be high, as mentioned previously. This may indicate the 0% placebo effect in the 
Finazzi-Agro268 trial is a product of a small sample size, inadequate blinding, or both. 
The apparently lower sham response in both studies may also have resulted from a less 
realistic sham. The sham stimulation used was different between these urological 
studies and also different from that used in the CONFIDeNT trial. In one study, the 
needle was placed in the medial head of gastrocnemius muscle and electrical 
stimulation only activated via the needle for 30 seconds prior to the stimulator being 
turned off268 and in the other, the ankle was chosen but a Streitberger needle used, 
which does not pierce the skin, and electrical stimulation delivered via TENS. The sham 
chosen in the CONFIDeNT trial was designed to give a very similar feeling to that 
produced by the active treatment, by giving the sensation of the skin being pierced by 
the needle and by providing a constant electrical sensation. This sham was a 
modification of that used in the Peters et al. study of OAB but notably improved on the 
Streitberger approach by using the supplied Uroplasty needle and piercing the skin so 
to give the same sensation as the PTNS arm (the only difference was the needle was not 
advanced beyond the superficial subcutaneous tissue). The sham was shown not to 
stimulate the tibial nerve during neurophysiological testing.  
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4.5.5 Other interpretive consideration 
4.5.5.1 Placebo responses 
The first published work on the therapeutic effects of placebo reported up to 35% of 
1082 patient having symptomatic pain relief280. This paper was subsequently criticised, 
with the view that true study of the placebo effect should not compare the before and 
after treatment in the placebo arm of a randomised controlled trial, but the difference 
between a group randomly allocated to placebo and a group randomly allocated to no 
treatment, since observed differences may be due to natural history of the disease 
(spontaneous improvement or fluctuation of symptoms in a chronic disease) or 
regression to the mean i.e. the tendency for extreme measurements to become closer to 
the mean when repeated281   
Following a Cochrane review282 of randomised controlled trials including a placebo 
group and a non-treatment group, where very different placebo response rates were 
obtained, a recommendation was made that studies into the placebo effect should be 
studied in a disease or group of diseases283. 
The most powerful documented placebo effect is in chronic pain syndromes. In one 
study, the cholecystokinin antagonist proglumide was a better analgesic than placebo, 
which in turn was better than no treatment at all. Hidden injection of proglumide 
(which the patient was unaware of) however, was a completely ineffective analgesic. 
Thus the interpretation for the mechanism of action of proglumide was that it acts on 
expectation pathways and enhances the placebo analgesic response, rather than acting 
on pain pathways284. A better method of conducting a trial to define the efficacy of a 
pain medication has been suggested; this involves an ‘open–hidden paradigm’285 where 
medical treatments are given covertly so that the true response can be observed, 
eliminating the chance of an enhancement of the ‘expectation pathway’.  
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Unfortunately, adoption of an ‘open-hidden paradigm’ methodology would not be 
possible in a trial of an intervention, since administration would not be possible 
without patient awareness.   
Work reporting the placebo effect in Parkinson’s disease raises the concept of 
‘expectation and the subsequent neurobiological changes’285. A double-blind study on 
human fetal mesencephalic transplantation for Parkinson’s disease found that the 
patients’ perceived allocation (either active treatment or placebo) had a more powerful 
impact on both quality of life and motor function than did the actual treatment. A study 
on pain subsequently found perceived assignment in an acupuncture trial had a greater 
impact on the analgesic outcome than did the actual treatment286.  
Post hoc analysis of treatment success (using the primary outcome) is possible for the 
CONFIDeNT Study data by grouping patients by ‘perceived outcome group’ rather than 
actual treatment group i.e. analysing the outcome of those patients who thought they 
had PTNS vs. the outcome of those patients who thought they had sham. 
Eighty nine patients of the 227 in the trial thought they had received PTNS. Of these 89 
patients, 40 had treatment success. This gives a success rate of 45% in the treatment 
arm. One hundred and nineteen of the 227 patients in the trial thought they had been 
allocated to sham. Of these 119 patients, 28 had treatment success. This gives a success 
rate of 24% in the sham arm. No formal statistical analysis was done on this, since it is 
a post hoc analysis, however this is highly likely to be significant given there is almost 
double the success rate in the ‘perceived PTNS arm’ compared to the ‘perceived sham 
arm’. 
Specificity of a placebo depends on the verbal cues given to the recipient e.g. placebos 
can have opposite effects on heart rate and blood pressure depending on what the 
recipient is told the effect will be272. Several authors have highlighted the importance of 
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the doctor-patient relationship in the placebo effect, specifically communication skills, 
time spent with the patient and the doctor’s enthusiasm or attitude towards the effect – 
all of which produce a heightened placebo effect272. 
This is relevant to the CONFIDeNT Trial, since there was significant interaction with 
each patient and the practitioner delivering the treatment, as each patient attended for 
12 consecutive weeks. The trial set-up aimed to ensure, however, that practitioner-
patient interaction was identical in each group, by prescribing how the interaction was 
to take place. In this way, any effects of such interaction should be similar in both 
groups. Nevertheless, this could have had an effect in both groups, which had the 
mathematical effect of reducing the proportional difference in effect size between 
active intervention and sham 
 The nature of the placebo itself is also recognised to affect its efficacy. For example, 
‘operative interventions’ have a larger placebo effect than do ‘procedures’ than in-turn 
do ‘medications’. Intravenous medications evoke a larger placebo response than do 
oral medications. Also, the setting in which a procedure is carried out carries an effect 
on the placebo effect, e.g. a white coat or a hospital setting make a difference272. Again 
this finding is relevant to the CONFIDeNT Study, being an invasive (albeit minimally) 
intervention carried out in a hospital setting. 
Consideration of the placebo effect in the CONFIDeNT Trial is slightly easier than some 
of the trials reported above, since 1) this trial was not designed to identify or quantify a 
placebo effect, and 2) this trial did not demonstrate a positive effect of the active 
treatment.  
The inclusion of a ‘no treatment’ group in The CONFIDeNT Study would have been 
interesting, and would have allowed us to further analyse the placebo effect in FI, 
however it would not have helped in achieving the study aim, which was to assess 
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whether electrical stimulation of the tibial nerve resulted in an increased treatment 
effect in patients with faecal incontinence. In addition to this, there may well have been 
ethical issues with this trial design, since patients at this stage are already some way 
through the treatment algorithm. 
4.5.5.2 Inclusion criteria and choice of outcomes 
The CONFIDeNT Trial inclusion criteria were broad, including patients with FI from 
any cause; and with any combination of symptoms i.e. urge and/or passive FI, mixed 
FI/evacuatory dysfunction. Had we selected specific patient subgroups, the results may 
have been different. Subgroup selection, however, would have limited recruitment and 
if based on robust criteria would also have mandated more expensive and invasive 
testing e.g. formal anorectal physiology. A further factor would be generalisability of 
results had specific subgroups been selected. As discussed in Chapter 4.5.3 above, in 
the limitations of the CONFIDeNT Trial, a pragmatic approach to inclusion criteria was 
chosen. 
The results of this trial could have reflected the primary outcome measure chosen. By 
this, I refer first to the use of bowel diaries as an outcome measure, and secondly to the 
way the bowel diary was used to select a primary outcome. Whilst the bowel diaries 
were completed well in this trial, they are subjective and rely on a patient completing 
them honestly and accurately (there is no reason, however, to suspect that they would 
not do this). Unfortunately, there is no objective outcome measure available for FI since 
all outcome measures are self-reported. To improve the accuracy and ease of using 
bowel diaries, an ‘App’ to record bowel diary information may make it more reliable 
and less open to interpretation. Such technology is not however currently available, 
and to have developed and provided this in a trial would have required user testing, 
validation and additional cost.  
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The chosen outcome of at least a 50% reduction in weekly FIE may have had an effect 
on the trial results. Had we based the primary outcome on the presence of a significant 
reduction in weekly FIE, this trial would have yielded a statistically positive result 
(total and urge FIE). However for the reasons explained above, it was decided that a 
percentage reduction was a more clinically meaningful result. In addition, this outcome 
could be used to ‘benchmark’ the effect of PTNS against other FI treatments, for 
example SNS. This target is obviously achievable, since studies of SNS show treatment 
success. 
4.5.6 Clinical impact  
The clinical implications of this trial merit discussion. The pragmatic design, including 
patients with FI due to any aetiology (excepting specific exclusions) and with any 
symptom pattern i.e. urge, passive or both, aimed to make results generalisable. Based 
on the evidence presented, it would be hard to recommend the use of PTNS as a 
treatment for such unselected patients; indeed this could not be justified.  
PTNS does, however, seem to offer a treatment effect in almost 40% of patients, and 
what is unclear is whether this is a genuine biological effect not seen due to limitations 
in the study. Indeed, there are some people for whom their treatment response has 
been nothing short of miraculous. 
In addition to this, PTNS is already embedded within the FI management algorithm in 
many UK and EU centres, and whilst this is only within the context of audit or 
research,287 there are many patients for whom this treatment is highly successful 
(Figure 21). A relevant question is whether it is morally or ethically acceptable to 
withdraw this treatment based on the evidence presented here? Conversely, is it 
appropriate to continue funding a treatment whose effect size may be conferred largely 
by placebo? Could we exchange the costly PTNS with cheaper ‘sham’ delivered via 
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TENS since this has similar efficacy and much less cost? A compromise may be to judge 
treatment effect at six weeks, and only continue therapy in those who are successful at 
this time point. 
Figure 21: Daily Mail Article288 
 
Results do indicate efficacy of PTNS in reducing weekly FIE and preferentially weekly 
urge FIE. This has been previously documented235,251 and is akin to the approved 
indication for PTNS to treat overactive bladder.257 It may be that there are 
characteristics about those who are experiencing treatment effect, which could help 
improve patient selection and therefore improve treatment results. Further analysis of 
the CONFIDeNT Trial data is undertaken in the next chapter. What is certain, however, 
is that further studies are required to determine the efficacy of PTNS within subgroups 
e.g. those with urge FI. Health service research could also usefully determine how PTNS 
promotes or contributes to other mixed packages of nurse-led care.  
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5 Predictors of outcome in the CONFIDeNT Study 
5.1 Introduction 
The CONFIDeNT Study yielded a negative overall result i.e. for the population studied 
and with the primary outcome chosen, there was no significant benefit of PTNS over 
sham electrical stimulation in the treatment of faecal incontinence. However, 38% of 
patients did have successful treatment with PTNS. As discussed in the previous chapter 
(Section 4.5.1) this study was pragmatic and included all patients with FI regardless of 
aetiology. There is a possibility that specific sub-groups of patients could benefit 
significantly from PTNS, this requires further exploration. 
The results of the CONFIDeNT Study, along with previous literature indicate patient 
subgroups which may demonstrate increased benefit with PTNS treatment. Given that 
there were some positive secondary outcomes, namely a greater reduction in mean 
total weekly FIE in the PTNS group compared to the sham group, which included a 
greater reduction in urge rather than passive faecal incontinence episodes, it may be 
that the presence of urge FI is predictive of a successful outcome. Since the majority of 
patients presented with both urge and passive FI, the possibility that isolated urge FI or 
faecal urgency are predictive is also a possibility and a previous study supports this 
theory 251.  
There are factors generally relevant to the selection of FI patients, namely sex, age and 
severity of FI, and these warrant investigation. Indeed, many clinicians believe those 
patients with severe FI will not benefit from non-invasive treatments, and should 
advance directly to surgical management strategies. Many people use a cut-off of at 
least daily episodes of FI (i.e. ≥7 FIE per week) to denote severe disease, and it seems 
logical to test this. 
      
 
 
148 
 
There is a high prevalence of rectal evacuatory dysfunction amongst the FI patient 
population151, 289, and this was also apparent in the CONFIDeNT Study.  The effect of 
problematic rectal evacuation on the efficacy of PTNS in the treatment of FI is 
unknown. Whilst one study has shown PTNS to be effective in the treatment of chronic 
constipation290, a recent trial of SNS has refuted the effectiveness of this 
mechanistically similar therapy in the treatment of constipation279. It is therefore 
important to include this as a factor in the sub analysis of the CONFIDeNT Trial results.  
5.1.1 Study Aims 
The aim of this study was to identify baseline predictors of PTNS outcome at the 14 
week assessment. 
5.1.2 A priori hypotheses 
As discussed in the introduction, there are several reasonable hypotheses that merit 
testing as predictors of PTNS outcome based on the primary outcome measure of 
treatment success as defined in the CONFIDeNT Trial (i.e. ≥50% reduction in weekly 
FIE), at the 14 week assessment. These include: 
FI symptom characteristics that may have a beneficial outcome: 
 Urge faecal incontinence 
 Isolated urge faecal incontinence 
 Faecal urgency 
Other baseline characteristics whose effect on outcome is not apparent from primary 
CONFIDeNT analysis: 
 Sex 
 Age  
 Severity of FI  
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 Co-existent rectal evacuatory difficulty based on symptom reporting 
 
There were a number of other recorded baseline characteristics which could be 
predictive of outcome to PTNS treatment, but which were either too infrequent to 
enable analysis or inadequately captured in baseline assessments:  
 Lack of intractability to previous treatments 
 Absence of irritable bowel syndrome 
 Absence of psychological morbidity 
 Ability of patient to defer defaecation (measured in minutes) 
 Co-existent rectal evacuatory disorder based on objective radio-physiological 
testing 
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5.2 Methods 
5.2.1 Study population 
Data from all patients who received PTNS in the CONFIDeNT Study formed the study 
population.  
5.2.2 Methods 
Based on the above hypotheses, the following variables were investigated: 
 Urge faecal incontinence (presence or absence) 
 Isolated urge faecal incontinence (presence or absence) 
 Faecal urgency (presence or absence) 
 Rectal evacuatory difficulty (presence or absence) 
 Sex (male or female) 
 Age (≥ or < 58 years) 
 Severity of FI (≥ or < 7 weekly FIE) 
The presence of rectal evacuatory difficulty was defined as presence of any of the 
following symptoms during structured interview at baseline: patient perceived 
difficulty in rectal evacuation, excessive straining, the requirement of regular digitation 
or the sensation of incomplete emptying. These factors relate to questions from 
validated scoring systems for constipation and/or obstructive defaecation, including 
Longo’s ODS scoring system291 (straining, incomplete emptying and digitation) and 
Cleveland Clinic Constipation Score292 (incomplete evacuation, digitation).  
Patients’ age was categorised around the median age in the trial population of 58 years. 
The patients were divided into those under the age of 58, and those aged 58 or older. FI 
severity was categorised into those with at least daily episodes of FI compared to those 
with less than 7 FIE per week. 
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5.2.3 Statistical analysis 
 
Preliminary univariate logistic regression analysis was performed for each of the 
selected baseline variables. A p-value of <0.1 was selected to indicate a significant 
relationship.     
To analyse the presence of co-linear relationships between the above factors, 
multivariate logistic regression analysis, using all the variables listed above, was 
subsequently performed. 
Data were presented as odds ratios (OR) with 95% CI. A p-value of <0.05 was 
considered to indicate statistical significance.  All analyses were performed with 
proprietary software (IBM SPSS Statistics Version 22, NY, USA). 
 
.  
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5.3 Results 
5.3.1 Univariate analysis 
Univariate logistic regression analysis of the baseline characteristics of patients who 
received PTNS in the CONFIDeNT Trial included 103 patients. The number of patients 
with each baseline characteristic, along with rates of treatment success, and results of 
the univariate logistic regression analysis are presented in Table 26. 
Table 26: Univariate analysis of CONFIDeNT Trial results 
Symptom N (%) 
Succes
s n 
(%) 
Failur
en (%) 
p 
value 
Odds 
ratio 
Lowe
r 95% 
CI 
Uppe
r 95% 
CI 
Urge FI 
Present 
83 
(80.6) 
33 
(84.6) 
50 
(78.1) 
0.42 0.65 0.23 1.86 
Absent 
20 
(19.4) 
6 
(15.4) 
14 
(21.9) 
Isolated 
urge FI 
Present 
25 
(24.3) 
11 
(28.2) 
14 
(21.9) 
0.47 1.40 0.56 3.50 
Absent 
78 
(75.7) 
28 
(71.8) 
50 
(78.1) 
Faecal 
Urgency 
Present 
89 
(89.0) 
34 
(91.9) 
55 
(87.3) 
0.48 0.61 0.15 2.45 
Absent 
11 
(11.0) 
3 (8.1) 
8 
(12.7) 
Rectal 
evacuatory 
difficult 
Present 
53 
(53.0) 
15 
(39.5) 
38 
(61.3) 
0.03 0.41 0.18 0.94 
Absent 
47 
(47.0) 
23 
(60.5) 
24 
(38.7) 
Sex 
Male 
9 
(8.7) 
4 
(10.3) 
5 (7.8) 
0.67 0.74 0.19 2.95 
Female 
94 
(91.3) 
35 
(89.7) 
59 
(92.2) 
Age 
<58 
53 
(51.5) 
18 
(46.2) 
35 
(54.7) 
0.71 0.32 1.58 0.71 
≥58 
50 
(48.5) 
21 
(53.8) 
29 
(45.3) 
Severity of 
FI 
< 7/wk 
57 
(55.3) 
21 
(53.8) 
36 
(56.3) 
0.81 0.81 0.92 0.41 
≥7/wk 
46 
(44.7) 
18 
(46.2) 
28 
(43.8) 
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The only predictor of an unsuccessful outcome with PTNS from the characteristics 
selected, was the presence of any form of rectal evacuatory disorder (odds ratio 0.41, 
95% confidence interval 0.18-0.94, p=0.03).  
5.3.2 Multivariate analysis 
Subsequent multivariate logistic regression analysis was performed to explore the 
possibility of co-linear relationships between the selected baseline characteristics. 
Multivariate logistic regression analysis of the baseline characteristics of patients who 
received PTNS in the CONFIDeNT Trial included 97 patients (who had complete data 
sets for all chosen variables). The presence or absence of each characteristic at baseline 
is presented in Table 27 and the results of regression analysis in Table 28. 
Table 27: Presence of baseline characteristics in PTNS group 
Symptom N  
Urge FI Present 80 
 Absent 17 
Isolated urge FI Present 25  
 Absent 72 
Faecal Urgency Present 86 
 Absent 11 
Rectal evacuatory difficulty Present 51 
 Absent 46 
Sex Male 9 
 Female 88 
Age <58 51 
 ≥58 46 
Severity of FI < 7/wk  54 
 ≥7/wk 43 
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Table 28: Results of multivariate logistic regression analysis of PTNS group 
Sympton P-value Odds ratio 95% CI 
   Lower Upper 
Urge FI 0.85 0.86 0.20 3.80 
Isolated urge FI 0.18 0.47 0.16 1.41 
Faecal Urgency 0.57 0.61 0.11 3.47 
Rectal Evacuatory Difficulty  0.03 0.38 0.16 0.92 
Sex 0.35 0.46 0.09 2.31 
Age 0.20 0.56 0.23 1.37 
Severity of FI 0.45 0.70 0.27 1.79 
Constant 0.45 2.23   
 
The findings from multivariate logistic regression analysis confirm that the only 
baseline characteristic which affects the outcome of PTNS at 14 weeks the presence of 
rectal evacuatory symptoms (odds ratio 0.38; 95% confidence interval 0.16 – 0.92, 
p=0.03).  
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5.4 Discussion 
5.4.1 Summary 
Of the baseline characteristics selected for logistic regression analysis, only one was 
predictive for the outcome of PTNS in the treatment of FI at 14 weeks. In the 
population studied in the CONFIDeNT Trial, the presence of urge faecal incontinence, 
isolated urge faecal incontinence, and faecal urgency were not predictive of outcome 
for PTNS treatment. Age (≥ or <58 years), sex and FI severity (≥ or < 7 FIE/wk) 
similarly were not predictive of PTNS outcome. The absence of any rectal evacuatory 
difficulty at baseline, however, was highly predictive of a successful outcome with 
PTNS at 14 weeks in both univariate and multivariate analyses. 
5.4.2 Predictors of outcome 
 
The absence of any association between age, sex, severity of FI, presence of urge FI, 
isolated urge FI and faecal urgency with outcome of PTNS in the treatment of FI could 
be correct i.e. there is no association, or it could represent a type II error i.e. it may 
represent a false negative result. This finding may be a result of the number of patients 
in the analysis, since the logistic regression was only based on a maximum of 115 
patients (those in the PTNS arm of the trial). To resolve this would require properly 
designed trials including patients on the basis of presence or absence of each of these 
factors, conducted in a similar way to the CONFIDeNT Study.  
 
The association between co-existent rectal evacuatory difficulty and a negative 
outcome of PTNS in the treatment of adults with FI is very interesting and merits 
further discussion since it appears to significantly prejudice the outcome of the active 
intervention in the PTNS arm of the CONFIDeNT study. To assess whether this effect is 
one that was specific to the active intervention, we performed a further post hoc 
analysis of the sham arm of the trial using only this variable with the possibility that 
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patients with such symptoms either perform generally poorly to any intervention or 
that rectal evacuatory dysfunction has a specific biological effect making patients 
resistant to neuromodulation. The results of this analysis were also very interesting 
and confirm the widely held view that such patients, like those with other functional 
disorders e.g. IBS, have disproportionately high placebo responses. 
Univariate logistic regression analysis was thus performed on those patients who had 
sham treatment in the CONFIDeNT Trial, to further analyse the effect of rectal 
evacuatory dysfunction. The analysis included 102 patients who had sham treatment in 
the CONFIDeNT trial. Results can be seen in Table 29. 
 
Table 29: Univariate logistic regression analysis of sham group in CONFIDeNT Trial 
Symptom N (%) 
Success 
n (%) 
Failure
n (%) 
p- 
value 
Odds 
ratio 
Lowe
r 95% 
CI 
Uppe
r 
95% 
CI 
Rectal 
evacuator
y 
difficulties 
Present 
58 
(56.9) 
24 
(75.0) 
34 
(48.6) 
0.15 3.18 1.26 8.03 
Absent 
44 
(43.1) 
8 (25.0) 
36 
(51.4) 
 
Although the odds of ‘success’ with sham were not statistically significant, the presence 
of rectal evacuatory difficulty confers a high odds ratio (over 3) of response to sham 
electrical stimulation. Taken together with the negative effect in the active treatment 
arm, the reporting of rectal evacuatory difficulty is predictive both of a poor outcome 
to PTNS and a good outcome to sham electrical stimulation.  
This finding reasonably prompts a re-analysis of the CONFIDeNT Trial results, 
excluding all patients with significant rectal evacuatory problems. Results of the re-
analysis of the primary outcome are shown in Table 30. 
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Table 30: Re-analysis of CONFIDeNT trial data excluding patients with significant rectal 
evacuatory difficulty: Results of primary outcome 
 PTNS, n=47 Sham, n=44 p-value 
≥50% reduction 
weekly FIE 
23 (48.9%) 8 (18.2%) <0.01 
≥25% reduction 
weekly FIE 
30 (57.7%) 14 (31.8%) <0.01 
≥75% reduction 
weekly FIE 
18 (38.3%) 5 (11.4%) <0.01 
100% reduction 
weekly FIE 
8 (17.0%) 2 (4.5%) 0.06 
 
Re-analysis of the results excluding patients with any rectal evacuatory difficulties 
demonstrates almost 50% of patients had successful treatment with PTNS compared to 
18% with sham electrical stimulation. When compared to the 38% success rate with 
PTNS vs. 31% success rate with sham in the main CONFIDeNT Study, these results are 
clearly very different. Re-analysis of the categorical reductions using the ≥25%, ≥75% 
and 100% reduction cut-offs yields similar results (Table 30). Post hoc chi squared 
testing of these outcomes has been added to the table acknowledging the post hoc 
nature of such analyses and the fact that these were not adjusted as in the primary 
CONFIDeNT analysis.  
Further analysis of other secondary outcomes, including reduction in mean total 
weekly FIE, mean weekly urge FIE, mean weekly passive FIE and SMCS are shown in 
Table 31. 
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Table 31: Re-analysis of CONFIDeNT trial data excluding patients with significant rectal 
evacuatory difficulty: Results of secondary outcomes 
 PTNS Sham 
 Baseline 14 weeks 
p-
value Baseline 14 weeks 
P-
value 
Total 
FIE/wk 
5.0 (1.6 – 
14.0) 
2.0 (0.5 – 
5.5) 
<0.001 
7.3 (2.2 – 
16.3) 
7.0 (2.0 – 
16.4) 
0.82 
9.3 (10.4) 4.2 (5.4) 
10.9 
(12.4) 
11.2 (11.6) 
Urge 
FIE/wk 
3.0 (1.0 – 
5.5) 
1.1 (0.0 – 
3.0) <0.001 
2.8 (0.0 – 
7.0) 
1.5 (0.5 – 
11.8) 0.41 
4.7 (5.9) 2.1 (2.8) 5.2 (7.4) 6.2 (8.2) 
Passive 
FIE /wk 
2.0 (0.01- 
7.5) 
0.0 (0.0 – 
4.0) <0.001 
2.3 (0.0 – 
8.3) 
2.5 (0.5 – 8.8) 
0.68 
4.6 (5.8) 2.1 (3.2) 5.6 (7.6) 5.1 (6.0) 
SMCS 
14.0 (12.0 – 
17.0) 
14.0 (11.0 – 
17.0) 
0.82 
16.0 
(13.3 – 
18.0) 
15.0 (10.0 – 
18.0) 
0.12 
14.2 (4.0) 13.8 (4.0) 15.4 
(3.8) 
14.5 (4.6) 
 
There was a significant reduction in mean total weekly FIE, mean weekly urge FIE, and 
mean weekly passive FIE after PTNS treatment, but not after sham treatment. There 
was however still no significant reduction in mean SMCS in either treatment group.  
5.4.3 Limitations of these findings 
One limitation to performing logistic regression analysis to predict the patients in 
whom a successful outcome may be more likely is the small sample size and resulting 
underpowered statistical analysis. Whilst the sample size calculation performed in the 
CONFIDeNT Study ensured the main trial was adequately powered, far fewer patients 
were included in the logistic regression analysis. Interpretation of the results must 
therefore be viewed in context i.e. that this is in effect a selective post hoc analysis of a 
study designed with a different hypothesis.  
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5.4.4 Implications of these findings 
The implications of these findings merit some discussion in the context of the primary 
study results but do not invalidate CONFIDeNT, the results of which remain applicable 
in the population studied. While noting the limitations, it must still be acknowledged 
that the analyses performed, based on reasonable a priori hypotheses do yield a single 
clear and very important result. This is, put simply, that re-analysis of the subgroup of 
patients who have pure FI with no difficulty in rectal evacuation completely changes 
the interpretation of the CONFIDeNT trial outcomes. This has important potential 
implications on the future of the therapy, since if these patients were carefully selected 
it might be deemed premature to withdraw patient access to PTNS for all patients on 
the basis of the findings of the CONFIDeNT Trial.  
The only way to definitively confirm this association would be to perform a further 
trial of PTNS in the treatment of patients with FI, in which all patients with any form of 
rectal evacuatory dysfunction were excluded either on formal symptom evaluation or 
perhaps on objective radio-physiological testing, or a stratified medicine design was 
adopted where the presence of RED was a primary stratum for therapy direction.  This 
finding might also affect the design of all further trials of neuromodulation in the 
treatment of FI in that patients with a significant problem with rectal evacuation 
should perhaps be excluded. Of note, in the SaFaRI trial, a randomised trial comparing 
SNS with FENIX magnetic sphincter augmentation for FI, patients with significant 
obstructed defaecation, defined as an inability to satisfactorily evacuate the rectum and 
an Obstructed Defaecation Score (ODS)>8, are excluded. Though this trial design was to 
avoid risks associated with one of the treatments (Fenix, Shoreview, MN, USA) this will 
likely make for a more clinically relevant trial outcome. 
It seems that rectal evacuatory problems are not only a predictor of a negative outcome 
with PTNS in the treatment of FI, but they are a factor for improved outcomes with 
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sham stimulation. The presence of rectal evacuatory problems seems to increase the 
placebo effect, and this finding alone has very important implications for the 
understanding of the placebo effect and for the future of trials not only in FI but also in 
rectal evacuatory dysfunction and maybe constipation as a symptom in general.  
These findings throw into sharp focus the fact that FI represents a symptom and not a 
disease. The ‘traditional’ way of considering FI is to categorise symptoms into 
predominant passive incontinence, urge incontinence or both. What may, however, be 
more useful is to consider whether the FI occurs in the presence or absence of a 
significant problem with rectal evacuation.  
At this point, I make reference back to the original algorithm of care for patients with FI 
shown in Chapter 1.8. Level II (Figure 22). This algorithm highlights the importance of 
excluding any form of rectal evacuatory problem prior to embarking on any surgical 
procedure for FI.    
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Figure 22: Algorithm for the treatment of FI 
 
 
 
 
What is unclear is the reason that these two problems often co-exist. One explanation 
for patients suffering concomitant FI and RED is that overflow FI is a secondary 
symptom. This has been reported as a common phenomenon in the geriatric and 
paediatric literature 293, and more recently this finding has also been documented in 
men 294.  Indeed, this may be due to severe constipation causing faecal impaction, may 
be secondary to a structural abnormality (e.g. rectocoele or intussusception) or a 
functional problem of rectal emptying (e.g. paradoxical contraction or inadequate 
relaxation of the pelvic floor muscles during attempted defaecation and/or inadequate 
propulsive forces during attempted defaecation). Alternatively, it may be that there is 
an over-arching pathophysiology encompassing the whole pelvic floor, resulting in a 
symptom array which manifests in some patients as predominantly FI and some as 
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predominantly RED, but with all patients suffering symptoms of both.  It seems logical, 
therefore, that whilst all patients present with FI, those with significant problems with 
rectal evacuation may represent a very different disease process and to expect a 
treatment such as PTNS to successfully treat both is ambitious. It is likely that patients 
who suffer with isolated FI require a different management strategy than those with 
concomitant FI and rectal evacuatory dysfunction. 
It would have been very interesting to have performed anorectal physiology studies 
including a defaecating proctogram on all patients in the CONFIDeNT Trial, in order to 
further categorise their rectal evacuatory dysfunction. Unfortunately, due to factors of 
available expertise and cost, this step was not included in the protocol.  
5.4.5 Conclusion 
In conclusion, the only predictor of PTNS outcome for FI as determined at 14 weeks is 
the presence of any form of rectal evacuatory difficulty, which confers a statistically 
significant negative effect. For the interpretation of CONFIDeNT, this finding is 
compounded by the positive effect that this explanatory covariate has on outcome from 
sham electrical stimulation. Taken together there is strong motivation to revisit the 
efficacy / effectiveness evaluation of PTNS based on a starting cohort that excludes 
such patients.  
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6 The CONFIDeNT Follow-up Study 
6.1 Introduction 
The aim of the CONFIDeNT Study was to ascertain efficacy of PTNS vs. sham 
stimulation in the treatment of patients with FI. Whilst this study is pivotal in 
ascertaining the short-term efficacy of PTNS, it does not examine the long-term results 
for these patients. Following up all patients for 1-year after completion of the 
CONFIDeNT Study, would provide useful data regarding the ongoing efficacy of PTNS 
and the efficacy of PTNS in those patients who initially had sham in the trial. It would 
also inform requirement and timing of top-up treatments, effects on quality of life, 
acceptability of PTNS and requirement for further treatments.   
6.1.1 Study Aims 
The aim of this 1-year observational study was to follow up all CONFIDeNT Trial 
patients, including PTNS and sham arms, at 6 months and 1 year, to inform about: 
 long-term effectiveness of PTNS in those who had successful treatment 
 requirement for and timing of ‘top-up’ treatments in those with initial 
treatment success 
 outcome of sham patients: including both sham successes and sham failures 
 requirement of other treatments following unsuccessful PTNS or following the 
treatment effect subsiding  
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6.2 Methods 
6.2.1 Overview: Study Design 
The CONFIDeNT Follow-up Study was a 1-year observational study, conducted by the 
lead centre of the CONFIDeNT Trial, Queen Mary University London. All patients who 
completed the CONFIDeNT Trial were followed up at 6 months and 1 year following 
their PTNS or sham treatment by post and telephone.  
6.2.2 Study outcomes 
Clinical outcomes:  
Outcomes were assessed at two time-points, 6 months and 1 year following PTNS or 
sham treatment in the CONFIDeNT Trial. Clinical outcomes were derived from 1-week 
bowel diaries and investigator-administered questionnaires.    
Primary outcome:  
The pragmatic primary outcome of this study is binary i.e. continued success or failure, 
with treatment success defined as achieving ≥ 50% reduction in total FI episodes per 
week. 
Secondary outcomes:  
 Change in total FI episodes per week as a continuous measure; 
 Change in urge FI episodes per week as a continuous measure; 
 Change in passive FI episodes per week as a continuous measure; 
 Change in symptom severity score: St Mark’s Continence Score (SMCS). A score 
from 0 (best) -24 (worst) with >5 indicating significant symptoms 252; 
 Likert scale of patients global impression of success (scale 0-10); 
 Length of effectiveness of PTNS 
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 Requirement and timing of PTNS ‘top-up’ treatments 
 Requirement for other treatments or surgery for FI 
 Qualitative data: 
o Patient perceived impression of change in use of incontinence pads and 
constipating medications; 
o Patient perceived impression of change in urinary symptoms; 
6.2.3 Plan of analysis 
Analyses were performed comparing data collected at baseline and after the 
CONFIDenT Trial with those collected in the follow-up study i.e. 6 months and 1 year 
following the CONFIDeNT Trial.  Analysis was performed on three separate groups: 
 Group 1: Patients who had PTNS in the CONFIDeNT Trial 
 Group 2: Patients who had PTNS either in the CONFIDeNT Trial or following 
sham in the CONFIDeNT Trial 
 Group 3: All patients in the follow-up study 
 
Analysis was conducted using IBM SPSS Statistics Version 21. All data are presented as 
descriptive statistics, with no formal statistical analysis between groups. 
6.2.4 Study population 
All patients who completed the CONFIDeNT Trial were eligible for inclusion into the 
follow-up study. Since ethical approval for this study was granted after the CONFIDeNT 
Trial, only patients who were finishing treatment on or after 1st October 2012, or those 
who were contacted subsequently, were included.  The inclusion and exclusion criteria 
were otherwise the same as for the CONFIDeNT Trial. 
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6.2.5 Data collection  
Each eligible patient from the CONFIDeNT Study was approached to seek agreement 
for enrolment in the CONFIDeNT follow-up study. Events were as follows: 
Visit 13 CONFIDeNT Study: Patients were invited to be involved in the follow-up study 
and given a Patient Information Sheet at this visit if interested.  
Visit 14 CONFIDeNT Study: At Visit 14, two weeks later, patients were consented for the 
follow-up study, and their details passed on securely to the lead centre where the 
follow-up study was co-ordinated. 
6-months following CONFIDeNT Study completion: Patients were contacted by telephone 
to complete the questionnaires, and were posted a 1-week bowel diary, which was 
returned in a stamped, addressed envelope. 
12-months following CONFIDeNT Study completion: Patients were again contacted by 
telephone to complete the questionnaires, and were posted a 1-week bowel diary, 
which was returned in a stamped, addressed envelope. 
6.2.6 Loss to follow-up 
Three attempts were made to contact each patient at 6-months and 1-year by 
telephone and post or email. If these were unsuccessful, the patients were presumed 
lost to follow-up. 
6.2.7 Withdrawal from study 
If patients wished to withdraw from the follow-up study, they were free to do so at any 
time without giving a reason.  
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6.2.8 Ethical arrangements and research governance 
This trial was granted ethical approval in October 2012 (REC Reference: 
10/H0703/25- Substantial Amendment 4). The trial was conducted in compliance with 
the principles of the Declaration of Helsinki (1996), and in accordance with all 
applicable regulatory requirements including but not limited to the Research 
Governance Framework, Trust and Research Office policies and procedures and any 
subsequent amendments. The trial was compliant with the approved protocol and REC 
conditions of approval, and in line with Good Clinical Practice Guidelines. 
6.2.9 Trial oversight  
The trial was under the auspices of the Chief Investigator and was sponsored by Queen 
Mary University London. It was funded by the Chief Investigator’s department through 
a donation from Uroplasty. 
The project was overseen by a Trial Steering Committee (TSC). The TSC included an 
independent chair, and met 6 monthly throughout to provide overall supervision and 
ensure the trial was conducted to the rigorous standards set out in the Medical 
Research Council’s (MRC) Guidelines for Good Clinical Practice.  
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6.3 Results 
6.3.1 Patient flow 
The flow of patients through the trial is shown in the CONSORT diagram below (Figure 
23). This figure also demonstrates the three groups in which analysis of the 
CONFIDeNT Follow-up study was performed.  Group 1 included patients who had PTNS 
in the CONFIDeNT Study; Group 2 included patients who either had PTNS in the 
CONFIDeNT Study or had PTNS following sham in the CONFIDeNT Study; Group 3 
included all patients in the CONFIDeNT Follow-up study (i.e. also including those 
patients who had sham in the CONFIDeNT Study but did not go on to have PTNS 
afterwards). Inclusion of Group 3 was justified to avoid reporting bias.  
Figure 23: CONSORT diagram for CONFIDeNT Follow-up Study  
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6.3.2 Trial recruitment 
110 patients from 12 centres were recruited to the study between 1st October 2012 
and 23rd February 2014. The trial centres were: Barts Health NHS Trust, London; 
Aintree University Hospital, Liverpool; University Hospital Southampton NHS 
Foundation Trust; Sandwell General Hospital, Birmingham; Sheffield Teaching 
Hospital; Ching Way Medical Centre, London; Queen’s Medical Centre, Nottingham; 
Castle Hill Hospital, Hull; University College Hospital, London; St Thomas’ Hospital, 
London; Pilgrim Hospital, Lincolnshire; University Hospital of South Manchester. The 
number of patients per centre ranged from 1 to 22. Of the 117 patients who did not 
enrol on the CONFIDeNT Follow-up study, 23 were not eligible since ethical approval 
for this study had not yet been granted, 7 were un-contactable, and the remaining 87 
were either not approached for participation or did not consent. At 6 months, 109 
patients were available for follow-up (one patient was un-contactable at 6 months), 
and at 12 months, 102 patients were available for follow-up.  Between the 6 month and 
1 year time point 6 patients were lost to follow-up. 
6.3.3 Data return 
A bowel diary was returned at 6 months by 75 (68%) patients and at 12 months by 69 
(63%) patients. Questionnaires were completed at 6 months by 109 (99%) patients 
and at 12 months by 102 (93%) patients.  
6.3.4 Patient demographics and clinical data 
Demographic data for the three groups analysed in the CONFIDeNT Follow-up Study 
can be seen in Table 32. In all groups 93% of the patients were female and the median 
age was 57 years. This corresponds with baseline data from the CONFIDeNT Study. 
Mean symptom duration was 115.9 months (S.D. 122.3), and this corresponds with 
baseline data from the CONFIDeNT Study. Demographics of the three groups were 
similar in terms of obstetric history, bowel function history, bladder function history 
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and previous treatments for FI, and this was similar to the baseline demographic data 
of all CONFIDeNT Study patients. 
Table 32: Baseline demographic and clinical data of CONFIDeNT Follow up study 
 
All CONFIDeNT 
patients 
Group 1 Group 2 Group 3 
N 227 59 103 110 
Sex (female) 205 (90%) 55 (93.2%) 96 (93.2%) 103 (93.6%) 
Age (years) 
57.2 (12.2) 
58.0 (49.0, 66.0) 
57.4 (11.1) 
57.0 (49.0 – 
67) 
57.2 (10.4) 
57.0 (50.0 – 
66.0) 
56.6 (11.1) 
57 (49.0 – 
65.3) 
Duration of symptoms  
(months) 
96.3 (105.2) 
58.0 (49.0, 66.0) 
129.8 (130.3) 
72.0 (36.0 – 
186.0) 
119.4 (125.5) 
68.0 (36.0 – 
177.0) 
115.9 (122.3) 
64.0 (36.0 – 
168.0) 
6 month follow-up NA 
6.5 (0.9) 
6.4 (5.8 – 7.0) 
6.6 (1.0) 
6.5 (6.0 – 7.4) 
6.6 (1.0) 
6.5 (6.1 – 7.4) 
12 month follow up NA 
12.5 (0.7) 
12.4 (12.0 – 
12.9) 
12.5 (0.7) 
12.3 (12.0 – 
12.9) 
12.5 (0.7) 
12.4 (12.0 – 
13.0) 
Obstetric history     
Parous* 191 (93%) 49 (89.1%) 87 (90.6%) 94 (91.3%) 
Vaginal deliveries only* 186 (97%) 46 (93.9%) 84 (96.6%) 91 (96.8%) 
Caesarean sections 
only* 
5 (3%) 3 (6.1%) 3 (3.4%) 3 (3.2%) 
Episiotomies or tears* 160 (86%) 41 (74.5%) 73 (83.9%) 78 (85.7%) 
Faecal incontinence 
history 
    
Passive FI 174 (77%) 44 (74.6%) 71 (68.9%) 77 (70%) 
Urge FI 187 (82%) 51 (86.4%) 88 (85.4%) 93 (84.5%) 
Flatus incontinence 157 (69%) 35 (59.3%) 63 (61.2%) 70 (63.6%) 
Evacuatory difficulties 93 (41%) 25 (42.4%) 46 (44.7%) 51 (46.4%) 
Straining 71 (31%) 20 (33.9%) 36 (35%) 37 (36.6%) 
Digitation 27 (12%) 7 (11.9%) 14 (13.6%) 15 (13.6%) 
Urinary symptom 
history 
    
Urinary symptoms 142 (63%) 45 (76.3%) 74 (71.8%) 79 (71.8%) 
Urinary urgency 99 (44%) 30 (50.8%) 49 (47.6%) 53 (48.2%) 
Urinary urge 
incontinence 
81 (36%) 26 (44.1%) 45 (43.7%) 49 (44.5%) 
*females only 
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6.3.5 Analysis for Group 1  
At 6 months, Group 1 comprised 59 patients, which reduced to 53 patients by 12 
months. Median time to 6 month follow-up was 6.5 months (IQR 5.8 – 7.0). Median 
time to 12 month follow-up was 12.4 (IQR 12.0 – 12.9) months.  
6.3.5.1 Primary outcome 
In those patients in whom it could be calculated (the subset who completed bowel 
diaries), the percentage of patients achieving treatment success at 6 and 12 months 
follow up, according to the primary outcome (at least a 50% reduction in weekly FIE) 
was slightly higher than the percentage that achieved this outcome directly after the 
CONFIDeNT Trial (42.1% after CONFIDeNT Trial vs. 54.3% at 6 months and 54.8% at 
12 months) (Table 33). 
Table 33: Primary outcomes for CONFIDeNT Follow-up Study – Group 1 
 14 weeks 6 months 12 months 
N N = 57 N = 37 N=31 
≥ 50% reduction in FIE, n (%) 24 (42.1%) 19 (54.3%) 17 (54.8%) 
≥25% reduction in FIE, n (%) 27 (47.4%) 25 (67.6%) 19 (61.3%) 
≥75% reduction in FIE, n (%) 17 (29.8%) 16 (43.2%) 15 (48.4%) 
100% reduction in FIE, n (%) 7 (12.3%) 14 (37.8%) 9 (29.0%) 
 
6.3.5.2 Secondary outcomes 
The proportion of patients who achieved a ≥25%, ≥75% and 100% reduction in weekly 
FIE was also higher at 6 and 12 months than after the CONFIDeNT Trial. The 
proportion of patients achieving a ≥25% reduction in weekly FIE rose by 20% from 
after the CONFIDeNT Trial to 6 months (47.4% vs. 67.6%), which was sustained at 12 
months (61.3%). The increase in the proportion of patients achieving a ≥75% 
reduction in weekly FIE was not so marked, however the proportion of patients who 
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achieved a 100% reduction in weekly FIE was three times higher at 6 months than 
after the CONFIDeNT Trial (37.8% vs 12.3%).  
The weekly total FIE at baseline, after the CONFIDeNT Study and at 6 and 12 months 
follow-up can be seen in Table 34 and Figure 24. In Group 1, the reduction in weekly 
total FIE after the CONFIDeNT Trial was sustained at 6 and 12 months follow-up.  
Urge faecal incontinence episodes and passive faecal incontinence episodes at baseline, 
after the CONFIDeNT Study and at 6 and 12 months follow up can be seen in Table 34, 
Figure 25 and Figure 26. The initial reduction in mean weekly urge and passive FIE 
after the CONFIDeNT Trial was sustained at 6 months or 12 months follow-up.  
 
Table 34: Secondary outcomes for CONFIDeNT Follow-up Study – Group 1 
 Baseline 14 weeks 6 months 12 months 
Bowel diary data 
N N = 58 N = 58 N = 37 N=33 
FI episodes/week [median 
(interquartile range)] 
5.0  
(1.9 – 14.0) 
3.5  
(0.53 – 10.0) 
1.0  
(0.0 – 8.5) 
2.0 
(0.0 – 5.0) 
[mean (standard deviation)] 9.3 (10.8) 6.3 (7.8) 5.8 (10.1) 5.6 (14.1) 
Urge FI episodes/week 
3.0  
(1.0 – 7.5) 
1.0  
(0.0 – 4.0) 
0.0  
(0.0 – 4.0) 
0.0  
(0.0 – 3.0) 
 4.5 (5.4) 3.2 (4.5) 3.4 (6.3) 2.8 (7.2) 
Passive FI episodes/week 
1.5  
(0.0 – 8.1) 
1.8  
(0.0 – 4.9) 
0.0  
(0.0 – 3.0) 
0.0  
(0.0 – 3.5) 
 4.8 (6.3) 3.1 (4.1) 2.5 (5.0) 2.8 (7.7) 
St. Mark’s Continence Score (0 [best]-24 [worst]) 
N N = 57 N = 54 N = 59 N=53 
Median (IQR) and mean (SD) 
15.0 (12.5 – 
17.0) 
14.0 (11.8 – 
17.0) 
11.0 (7.0 – 
13.0) 
12.0 (6.5-
14.0) 
14.9 (3.5) 14.1 (4.0) 10.6 (3.9) 10.4 (4.6) 
SMCS >5 57 (100%) 54 (100%) 55 (93.2%) 38 (71.7%) 
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Figure 24: CONFIDeNT Follow-up Study: Weekly total FIE: Group 1 
 
*Baseline: n=58; After CONFIDeNT Trial: n=58; 6 months: n=37; 12 months: n=33 
Figure 25: CONFIDeNT Follow-up Study: Weekly urge FIE: Group 1 
 
*Baseline: n=59; After CONFIDeNT Trial: n=58; 6 months: n=37; 12 months: n=33 
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Figure 26: CONFIDeNT Follow-up Study: Weekly passive FIE: Group 1 
 
*Baseline: n=59; After CONFIDeNT Trial: n=58; 6 months: n=37; 12 months: n=33 
 
 
The SMCS at baseline, after the CONFIDeNT Study and at 6 months and 12 months 
follow up can be seen in Table 34 and Figure 27. Though there was not a significant 
reduction in SMCS after the CONFIDeNT Trial, there was a 4 point reduction in SMCS at 
both 6 month and 12 month follow-up.  
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Figure 27: CONFIDeNT Follow-up Study: SMCS: Group 1 
 
*Baseline: n=57; After CONFIDeNT Trial: n=54; 6 months: n=59; 12 months: n=53 
 
6.3.6 Analysis for Group 2 
At 6 months, Group 2 comprised 103 patients, which reduced to 95 patients at 12 
months. Median time to 6 month follow-up was 6.5 months (IQR 6.0 – 7.4). Median 
time to 12 month follow-up was 12.3 (IQR 12.0 – 12.9) months.  
6.3.6.1 Primary outcome 
The percentage of patients achieving treatment success at 6 and 12 months follow up, 
according to the primary outcome (at least a 50% reduction in weekly FIE) was similar 
to the percentage that achieved this outcome directly after the CONFIDeNT Trial 
(35.6% after CONFIDeNT Trial vs. 40.3% at 6 months and 44.3% at 12 months) (Table 
35). 
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Table 35: Primary outcomes for CONFIDeNT Follow-up Study – Group 2 
 
After 
CONFIDeNT 
6 months 12 months 
N N = 101 N = 72 N=61 
≥ 50% reduction in FIE, n (%) 36 (35.6%) 29 (40.3%) 27 (44.3%) 
≥25% reduction in FIE, n (%) 44 (43.6%) 38 (52.8%) 33 (54.1%) 
≥75% reduction in FIE, n (%) 9 (18.8%) 23 (31.9%) 22 (36.1%) 
100% reduction in FIE, n (%) 8 (7.9%) 20 (27.8%) 13 (21.3%) 
 
6.3.6.2 Secondary outcomes 
The proportion of patients who achieved ≥25% and ≥75% reductions in weekly FIE 
increased from after the CONFIDeNT Trial to 6 months and again to 12 months. This 
increase was more marked in the ≥75% outcome and the ≥100% outcome, with almost 
three times the number of patients achieving this outcome at 12 months compared to 
after the CONFIDeNT Trial.  
The weekly total FIE at baseline, after the CONFIDeNT Study and at 6 and 12 months 
follow-up can be seen in Table 36 and Figure 28. The reduction in weekly total FIE after 
the CONFIDeNT Trial was sustained at 6 months and 12 months follow up, compared to 
baseline.  
Urge faecal incontinence episodes and passive faecal incontinence episodes at baseline, 
after the CONFIDeNT Study and at 6 and 12 months follow-up can be seen in Table 36, 
Figure 29 and Figure 30. A similar mean weekly number of urge FIE was seen at 6 and 
12 months follow-up compared to that after the CONFIDeNT trial. Similar results were 
seen for mean weekly passive FIE.  
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Table 36: Secondary outcomes for CONFIDeNT Follow-up Study – Group 2 
 Baseline 14 weeks 6 months 12 months 
Bowel diary data 
 N = 102 N = 102 N = 72 N = 66 
FI episodes/week 
[median (interquartile 
range)] 
5.5 (1.7 – 
14.0) 
4.0 (1.0 – 11.1) 3.0 (0.0 – 9.0) 3.5 (0.8-8.5) 
[mean (standard 
deviation)] 
9.4 (10.5) 7.7 (9.3) 8.3 (12.4) 7.8 (13.4) 
Urge FI episodes/week 
2.5 (1.0 – 
7.0) 
1.5 (0.5 – 6.0) 1.0 (0.0 – 5.8) 1.0 (0.0-5.0) 
 4.6 (5.3) 4.1 (6.0) 4.7 (8.5) 3.8 (7.0) 
Passive FI 
episodes/week 
1.5 (0.0 – 
7.5) 
1.5 (0.0 – 5.5) 0.5 (0.0 – 5.0) 1.0 (0.0-5.0) 
 4.7 (7.0) 3.6 (5.5) 3.6 (6.2) 4.0 (7.7) 
St. Mark’s Continence Score (0 [best]-24 [worst]) 
N N = 99 N = 95 N = 102 N=95 
Median (IQR) and mean 
(SD) 
16.0 (13.0 
– 18.0 
15.0 (12.0 – 18.0) 11.0 (8.0 – 13.25) 
12.0 (8.0 – 
15.0) 
15.5 (3.7) 14.7 (4.1) 10.8 (3.8) 11.2 (4.3) 
SMCS >5 99 (100%) 95 (100%) 97 (95.1%) 76 (91.6%) 
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Figure 28: CONFIDeNT Follow-up Study: Weekly total FIE: Group 2 
 
*Baseline: n=102; After CONFIDeNT Trial: n=102; 6 months: n=72; 12 months: n=66 
Figure 29: CONFIDeNT Follow-up Study: Weekly urge FIE: Group 2 
 
*Baseline: n=103; After CONFIDeNT Trial: n=102; 6 months: n=72; 12 months: n=66 
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Figure 30: CONFIDeNT Follow-up Study: Weekly passive FIE: Group 2 
 
*Baseline: n=102; After CONFIDeNT Trial: n=102; 6 months: n=72; 12 months: n=66 
 
The SMCS at baseline, after the CONFIDeNT Study and at 6 months and 12 months 
follow up can be seen in Table 36 and Figure 31. Though there was not a significant 
reduction in SMCS after the CONFIDeNT Trial, there was again a 4-point reduction in 
SMCS at both 6 month and 12 month follow-up.  
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Figure 31: CONFIDeNT Follow-up Study: SMCS: Group 2 
*Baseline: n=99; After CONFIDeNT Trial: n=95; 6 months: n=102; 12 months: n=95 
6.3.7 Analysis for Group 3  
At 6 months, this group comprised 109 patients, and at 12 months this reduced to 102 
patients. Median time to 6 month follow-up was 6.5 months (IQR 6.1 – 7.4). Median 
time to 12 month follow-up was 12.4 (IQR 12.0 – 13.0) months.  
6.3.7.1 Primary outcome 
The percentage of patients achieving treatment success at 6 and 12 months follow up, 
according to the primary outcome (at least a 50% reduction in weekly FIE) was similar 
to the percentage that achieved this outcome directly after the CONFIDeNT Trial 
(37.4% after CONFIDeNT Trial vs. 40.0% at 6 months and 43.8% at 12 months) (Table 
37).  
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Table 37: Primary outcomes for CONFIDeNT Follow-up Study – Group 3 
 After 
CONFIDeNT 
6 months 
 
12 months 
N N = 107 N = 75 
 
N=64 
≥ 50% reduction in FIE, n (%) 40 (37.4%) 30 (40.0%) 28 (43.8%) 
≥25% reduction in FIE, n (%) 49 (45.8%) 39 (52.0%) 34 (53.1%) 
≥75% reduction in FIE, n (%) 22 (20.6%) 23 (30.7%) 22 (34.4%) 
100% reduction in FIE, n (%) 9 (8.4%) 20 (26.7%) 13 (20.3%) 
 
6.3.7.2 Secondary outcomes 
The proportion of patients who achieved ≥25% and ≥75% reductions in weekly FIE 
increased from after the CONFIDeNT Trial to 6 months and 12 months. This increase 
was more marked in the ≥75% outcome. The number of patients who achieved 100% 
reduction in weekly FIE rose from 8.4% after the CONFIDeNT Trial to 26.7% at 6 
months, and was 20.3% at 12 months.  
The weekly total FIE at baseline, after the CONFIDeNT Study and at 6 and 12 months 
follow-up can be seen in Table 38 and Figure 32. There was a significant reduction in 
total weekly FIE after the CONFIDeNT trial compared to baseline, with similar weekly 
FIE reported at 6 month and 12 month follow-up. Urge faecal incontinence episodes 
and passive faecal incontinence episodes at baseline, after the CONFIDeNT Study and at 
6 and 12 months follow-up can be seen in Table 38, Figure 33 and Figure 34.  
The significant reduction in weekly urge FIE after the CONFIDeNT Trial seemed to be 
maintained at 6 months and 12 months follow-up. The reduction in passive FIE seen 
after the CONFIDeNT Trial was also sustained at 6 month and 12 month follow-up.  
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Table 38: Secondary outcomes for CONFIDeNT Follow-up Study – Group 3 
 
Baseline 
 
After 
CONFIDeNT  
6 months 
 
12 months 
Bowel diary data 
N N = 109 N = 108 N = 75 N=69 
FI episodes/week 
[median 
(interquartile 
range)] 
5.5 (2.0 – 
14.25) 
4.0 (1.0 – 11.0) 3.0 (0.0 – 9.0) 3.0 (1.0 – 7.5) 
[mean (standard 
deviation)] 
10.0 (11.9) 7.8 (9.7) 8.1 (12.1) 7.6 (13.2) 
Urge FI 
episodes/week 
3.0 (1.0 – 8.0) 1.5 (0.5 – 5.9) 1.0 (0.0 – 6.0) 1.0 (0.0-4.5) 
 5.1 (6.3) 4.2 (6.2) 4.6 (8.4) 3.8 (6.9) 
Passive FI 
episodes/week 
1.5 (0.0 – 7.5) 1.5 (0.0 – 5.4) 0.0 (0.0 – 5.0) 1.0 (1.0 – 5.0) 
 4.8 (7.2) 3.6 (5.6) 3.5 (6.1) 3.9 (7.5) 
St. Mark’s Continence Score (0 [best]-24 [worst]) 
N N = 105 N = 102 N = 109 N=102 
Median (IQR) and 
mean (SD) 
16.0 (13.0 – 
16.0) 
15.0 (12.0 – 18.0) 
11.0 (7.5 – 
13.5) 
12.0 (8.0 – 15.0) 
15.7 (3.7) 14.7 (4.1) 10.7 (3.8) 11.1 (4.5) 
SMCS>5 105 (100%) 102 (100%) 103 (94%) 93 (91%) 
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Figure 32: CONFIDeNT Follow-up Study: Weekly total FIE: Group 3 
 
*Baseline: n=109; After CONFIDeNT Trial: n=108; 6 months: n=75; 12 months: n=69 
 
Figure 33: CONFIDeNT Follow-up Study: Weekly urge FIE: Group 3 
 
*Baseline: n=110; After CONFIDeNT Trial: n=108; 6 months: n=75; 12 months: n=69 
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Figure 34: CONFIDeNT Follow-up Study: Weekly passive FIE: Group 3 
 
 
*Baseline: n=109; After CONFIDeNT Trial: n=108; 6 months: n=72; 15 months: n=69 
 
The SMCS at baseline, after the CONFIDeNT Study and at 6 months and 12 months 
follow-up can be seen in Table 38 and Figure 35. Whilst there was no significant 
reduction in SMCS after the CONFIDeNT Study, patients reported a mean reduction of 
5-points in the SMCS at 6 months, which was sustained at 12 months follow-up. 
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Figure 35: CONFIDeNT Follow-up Study: SMCS: Group 3 
 
*Baseline: n=105; After CONFIDeNT Trial: n=102; 6 months: n=109; 12 months: n=102 
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6.4 Discussion 
6.4.1 Summary of results 
6.4.1.1 Group 1 
After the CONFIDeNT Study the proportion of patients experiencing ‘treatment success’ 
with PTNS generally improved over time from 42% after the CONFIDeNT trial to 55% 
at 12 months follow-up. Similarly the proportions of patients achieving a ≥25%, ≥75% 
and 100% reduction in weekly FIE tended to improve over the follow-up period, with 
the greatest improvements in the proportion of patients achieving a 100% reduction in 
weekly FIE. The initial significant reduction in weekly total FIE was sustained at 6 
months and 12 months follow up, and this comprised a seemingly sustained reduction 
in weekly urge and passive FIE throughout the follow-up period. No significant 
improvement in SMCS was seen after the CONFIDeNT Study; however there was a 4-
point reduction in SMCS at 6 and 12 months compared to baseline.  
Whilst these results represent patients who had PTNS in the CONFIDeNT Trial, 
interpretation must be made in light of the small sample size (n=59) and the 
limitations of this study, which are discussed in detail in 6.4.2. 
6.4.1.2 Groups 2 and 3 
Interpretation of the results of the CONFIDeNT follow-up study in Groups 2 and 3 must 
consider the significant limitations of this study, not least as a result of the 
heterogeneous patient populations included. Notwithstanding these limitations, the 
proportions of patients experiencing ‘treatment success’ in each group were generally 
sustained over time. This was also true of the proportions of patients achieving a 
≥25%, ≥75% and 100% reduction in weekly FIE. The reduction in mean total weekly 
FIE in both groups was generally sustained over time, with sustained reductions in 
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both weekly urge and passive FIE. Comparably to Group 1, whilst there was no 
significant reduction in SMCS after the CONFIDeNT trial, there was a 4-5 point 
reduction in this score at both 6 and 12 months compared to baseline in both groups. 
Whilst treatment ‘success rates’ have been quoted, no consideration has been given to 
which patients this represents. To analyse this further, Figure 36 shows the number of 
patients with treatment success at each time point. The rate of treatment success 
obtained from the follow-up study group after the CONFIDeNT Study reflected the 
study results from the whole CONFIDeNT cohort of 227 patients (i.e. CONFIDeNT Trial 
38% success in PTNS arm and 31% success in sham arm vs. follow-up study 41% in 
PTNS arm and 31% in sham arm). At 6 months follow-up some patients have 
experienced treatment success regardless of whether they had successful treatment 
previously, however, it is interesting to note that the highest rate of continued 
treatment success at 6 months and at 12 months is in the group who had successful 
PTNS during the CONFIDeNT Trial (at 6 months 12/24 = 50% and at 12 months 9/12 = 
75%).  
Figure 36: Number of patients with ‘treatment success’ at each follow-up time point 
 
      
 
 
188 
 
6.4.2 Limitations 
Limitations of the study are acknowledged, and interpretation of the results must be 
undertaken in light of these limitations. Whilst the number of patients enrolled in the 
CONFIDeNT Follow-up study was considerable, since not all patients who were 
involved in the CONFIDeNT study were enrolled, there is inevitable attrition bias. This 
attrition is further evident between the 6 and 12 month follow-up time points and 
especially for bowel diaries which were returned only by a subset of the follow-up 
cohort. This potential reluctance for patients to be enrolled or remain enrolled on the 
CONFIDeNT Follow-up study may be a reflection of a negative result.  However, the 
baseline demographics and characteristics of the population in the CONFIDeNT Follow-
up study did mirror that in the main CONFIDeNT trial (Table 32) and in addition, the 
proportion of patients achieving treatment success in each arm was similar in both the 
CONFIDeNT Trial and the follow-up study (Figure 36). Based on this, there is no strong 
reason to suspect the patient sample from the CONFIDeNT follow-up study does not 
reflect the CONFIDeNT Trial accurately.  
Further, the CONFIDeNT Follow-up study represents an observational design - in effect 
a case series. All sources of bias accompanied by this trial design, as discussed in 
Chapter 3 above, were thus re-introduced. PTNS treatment given after sham and 
further ‘top-up’ PTNS treatments were performed on an ‘open-label’ basis (un-
blinded), and were not subject to the same strict trial conditions set out in the 
CONFIDeNT Trial protocol. Whilst there are not likely to be any significant differences 
between the treatments given within and out with the trial, this cannot be confirmed. 
In addition to this, the number and timing of top-up treatments delivered during the 
CONFIDeNT Follow-up study was not standardised or prescribed, and each centre 
delivered ‘top-up’ treatments according to local protocol. Further, some patients were 
given alternative treatments where PTNS had failed. Whilst these treatments were not 
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controlled or standardised, they were recorded in order that their effect on further 
outcomes could be estimated.  
Finally, the limitations associated with the outcome measures chosen are also present 
in this study, however, for all of the same reasons as discussed in Chapter 3 above, 
these outcome measures were selected.  
6.4.3 Interpretation of results 
Overall, within the outcomes measured and considering the limitations of the study, 
the results of PTNS seem sustained with longer follow-up, and perhaps could be 
considered slightly more favourable. The primary outcome improved with time, whilst 
the reduction in weekly FIE was sustained. In addition to this, whilst there was no 
reduction in SMCS after the CONFIDeNT Study, there was a sustained reduction in 
SMCS of between 4 and 5 points over the follow-up period.  
What is unclear is whether these findings are a result of bias, or whether there is a 
genuine delayed response to PTNS, i.e. there is something about the mechanism of 
action that means it takes longer than 14 weeks for the treatment to take effect.  
An explanation for the SMCS showing no improvement immediately after PTNS 
treatment in the CONFIDeNT Trial despite there being a significant reduction in weekly 
FIE, but then showing an improvement at 6 months which is sustained at 12 months, is 
that this may be secondary to patient behaviour. Perhaps patients do not stop using 
Loperamide or incontinence pads until they are convinced of the effects of treatment. 
In order to test this hypothesis further analysis into which domains showed significant 
improvement in the SMCS was performed. When comparing the mean score for each of 
the domains at baseline and 6 months, there was significant reduction in the score for 
the frequency of FI to solid stool (mean score 2.44 +/- 1.1 to mean score 1.72 +/- 1.3, 
p<0.01), the score for the frequency of FI to liquid stool (mean score 2.50 +/- 1.2 to 
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mean score 1.56 =/- 1.6, p<0.01), the score for how often bowel symptoms affect 
lifestyle (mean score 2.45 =/- 1.4 to mean score 2.05 =/- 1.5, p<0.01 and the need to 
rush directly to the toilet as soon as the urge arises (mean score 3.53 +/-1.3 to mean 
score 1.03 =/- 1.8, p<0.01). There was however no significant reduction in 
incontinence pad or Loperamide usage.  
Another legitimate consideration is whether results reflected patients undergoing 
other treatments for FI during the CONFIDeNT follow-up study time period. Patients 
did undergo other treatments on an open label basis, and there is no way of accounting 
for the contribution that other treatments have made. However, in the 24 patients who 
had successful PTNS in the CONFIDeNT Study, during the 12 month follow-up period, 
the only other FI treatments used were flax seed in one patient, occasional rectal 
irrigation in one patient and an increase in Loperamide in one patient. It is unlikely 
these treatments would have affected the outcome. Another consideration is that many 
centres do not use this primary outcome when considering how and when to deliver 
‘top-up’ treatments or further therapies. The usual cut off used is patients’ perception 
of success. If the patient perceives success, no further treatment is warranted, 
regardless of the 50% cut off, equally, if a patient perceives a treatment not to be 
successful, no further treatments may be offered despite them achieving a 50% 
reduction in weekly FIE.  
To re-design this study and make it methodologically sound would ideally have 
required the continued blinding of all CONFIDeNT Trial patients and withholding of all 
further treatments for FI, for a period of 12 months. Unfortunately, this study design 
would not have been ethical, and the likelihood of patients remaining compliant would 
be small. An improved but ethically acceptable design could, however, have prevented 
attrition bias. It would have been possible to have a trial design with initial double-
blinding followed by a prescribed open label period to one year follow-up. Regrettably, 
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while this design was considered and originally submitted for funding, it was rejected 
by the HTA on the basis of cost.  
6.4.4 Clinical interpretation of results 
The CONFIDeNT follow-up study indicates that there are a proportion of patients who 
do seem to respond well to PTNS, and this response is sustained for 1 year. 
Further research into this treatment is essential so that we do not ‘throw the baby out 
with the bathwater’ in terms of discrediting PTNS as a valid treatment for FI. Results 
could be used to design further studies into the efficacy of PTNS in FI.   
      
 
 
192 
 
7 Discussion 
7.1 Summary of results 
Systematic review of the literature demonstrated the evidence surrounding the use of 
PTNS in the treatment of FI to be encouraging, however of poor quality.  
The CONFIDeNT Study was therefore performed to contribute to the evidence base in 
this area. This was a multicentre, double-blind parallel group randomised controlled 
trial of PTNS vs. sham electrical stimulation in the treatment of adults with faecal 
incontinence. The primary outcome (proportion of patients who achieved ≥50% 
reduction in weekly FIE) showed no superiority of PTNS over sham electrical 
stimulation for the treatment of adults with FI. Whilst many of the secondary outcomes 
also produced a negative result, in terms of St Marks Continence Score and all quality of 
life measures, there was benefit of PTNS over sham stimulation in reducing mean total 
weekly FIE and mean weekly urge FIE.  
Following the CONFIDeNT Trial, logistic regression analysis was performed to identify 
baseline patient characteristics, which may predict treatment outcome. The only factor 
identified as predicting successful PTNS in the treatment of FI, was the absence of 
rectal evacuatory problems at baseline. Subsequent re-analysis of the CONFIDeNT Trial 
results, excluding patients with any difficulties with rectal evacuation, changed the trial 
interpretation; more than twice as many patients in the PTNS arm than the sham arm 
achieved treatment success. 
All patients in the CONFIDeNT Study were invited to participate in a 1-year follow-up 
study, the CONFIDeNT Follow-up Study. Whilst the results of this study have to be 
interpreted in light of significant limitations, there is evidence to suggest ongoing 
efficacy of PTNS in some patients, at 1 year.  
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7.2 Discussion of objectives 
7.2.1 Objective 1: To perform a systematic review of the current evidence base for 
tibial nerve stimulation to treat faecal incontinence 
In Chapter 3, the current literature has been searched methodically to investigate the 
therapeutic effect of TNS on FI in adults. Whilst a large, randomised sham controlled 
trial of TTNS in the treatment of FI demonstrates no significant benefit of the active 
treatment, a trial of similar quality in PTNS is lacking. The literature for the use of PTNS 
in the treatment of FI was limited and of poor quality, however, using the outcome 
measure chosen (treatment success indicated by at least a 50% reduction in weekly 
faecal incontinence episodes), the rates of treatment success were documented to be 
52-82%. No definitive randomised controlled trial of PTNS had, however, been 
conducted to address its clinical efficacy. 
7.2.2 Objective 2: To assess the short-term clinical efficacy of PTNS compared to sham 
electrical stimulation in the treatment of patients with significant faecal 
incontinence in the CONFIDeNT Study, a large multicentre randomised sham 
controlled trial. 
The CONFIDeNT study was a definitive randomised trial, carried out to a high standard 
with an absence of any significant methodological flaws or serious breaches. PTNS did 
not show significant clinical benefit over sham electrical stimulation in the treatment of 
faecal incontinence based on the proportions of patients who reported at least a 50% 
reduction in weekly FIE (38% in PTNS arm vs. 31% in sham arm). There was however 
a significant improvement in those patients who had PTNS in mean reduction in total 
weekly FIE, urge weekly FIE and patient centred outcomes (a derivative of the ICIQ-B), 
compared to those who had sham. 
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The study was at odds with previously reported literature and reported a considerably 
lower rate of treatment success (38% vs. the 52-82% previously reported). It confirms 
the importance of well-designed randomised controlled trials to define the clinical 
benefit of FI treatments.  
Based on this evidence presented it would be hard to justify recommending this 
therapy for the patient population in the trial. However, in view of the relatively low 
costs associated with this treatment and its high acceptability, there may be a 
justification for exploring the continued treatment of a subgroup of patients with 
troublesome urge faecal incontinence symptoms, in whom directed therapy may cause 
symptomatic improvement. Further studies of PTNS are warranted and should 
potentially be directed at those with urge FI to determine whether this approach has 
value.   
7.2.3 Objective 3: To identify factors predictive of successful PTNS from the CONFIDeNT 
Study data 
Logistic regression analysis identified the absence of any symptoms of rectal 
evacuatory difficulty as a predictor of a positive outcome with PTNS in the treatment of 
adults with FI. Conversely, the presence of symptoms of rectal evacuatory difficulty 
predicted a successful outcome with sham electrical stimulation. The presence of urge 
FI, isolated urge FI or urgency was, however, not predictive of treatment outcome. 
Interestingly, when the CONFIDeNT trial results were re-analysed, excluding patients 
with rectal evacuatory problems, the success rate in the PTNS arm was more than 
twice the rate of success in the sham arm (48.9% vs. 18.2%). 
Whilst the trial was not designed to test this hypothesis, the importance of these 
findings is not to be underestimated. They point to a high level of placebo response 
amongst patients with rectal evacuatory problems, which may be very useful when 
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designing future trials for this problem. Equally, they indicate that perhaps patients 
with significant rectal evacuatory problems should be excluded from further trials of 
neuromodulation in the treatment of FI, and indeed there may be an argument for 
excluding such patients from all trials of FI. Further, there is a wider question about the 
symptomatology of FI, and whether the traditional subdivision of symptoms into urge 
and passive FI is less helpful than the subdivision into patients who have pure FI, or 
those who have concomitant difficulty with rectal evacuation. This will prove 
important for future management algorithms of FI, where difficulties of rectal 
evacuation might be excluded prior to embarking on some invasive or costly 
treatments for FI. It also raises broader questions regarding the pathophysiology of FI, 
and the importance of overlapping symptomatology between FI and rectal evacuatory 
problems.  
7.2.4 Objective 4: To follow-up all patients enrolled in The CONFIDeNT Study, to assess 
medium-term outcomes 
The CONFIDeNT Follow-up study enrolled 48% of patients from the CONFIDeNT Study, 
and although subject to the significant limitations discussed in detail in Chapter 6, did 
produce some interesting and important results. There is evidence of ongoing efficacy 
for a small number of patients who originally had PTNS in the CONFIDeNT Trial at 1 
year follow up. Reductions in mean total weekly FIE, mean passive weekly FIE and 
mean urge weekly FIE tended to be sustained at 12 months. Interestingly however, the 
mean SMCS was apparently better at 6 and 12 months, despite this being unchanged 
immediately after the CONFIDeNT Trial. Further sub-analysis of the SMCS at 6 months 
revealed the improvement is in the areas of solid and liquid FIE, lifestyle and faecal 
urgency.  
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7.2.5 Conclusions and further researchMy experiences with this research 
The CONFIDeNT Trial has, to my mind, been an extremely successful trial of an 
intervention, and has signified a breakthrough in research collaboration between 
specialist pelvic floor units in the UK. In order to ensure successful and meaningful 
research into pelvic floor disorders in this country, structure and collaboration are 
paramount. I feel research should be inclusive not exclusive, and hope the relationships 
forged during this trial are long-lasting and productive.   
There were a few key areas which I feel contributed to the success of the trial. These 
included: the quality of the data (including bowel diaries) which was secondary to 
training of participants and trial centres with regards to compliance; effective sham 
stimulation; rigorous quality assurance, provided by the pragmatic clinical trials unit; 
patient-centred and qualitative outcome measures; and the standardised practitioner-
patient interaction.  
Conversely, there were elements of the trial design that I would have changed, if given 
the opportunity over again. Firstly, I would have considered patient weight/BMI, 
menopausal status and employment status at the outset. Whilst I do not feel these data 
would have changed results significantly, they may have provided interesting post hoc 
analyses. I would re-write the bowel diary, to include consistency of every bowel 
movement, include use of constipating medication, and generally make it slightly more 
user-friendly. As mentioned previously, the development of an app to capture these 
data would be fantastic, but costly! 
In addition to these changes, I would have asked all participants specific ‘tick box’ style 
questions about previous treatments and past medical history in order to attempt 
subgrouping of patients in an effort to reduce heterogeneity of the population. Whilst 
this may not have been helpful, it may have helped in defining where in the algorithm 
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of treatment PTNS has most efficacy. I would also have liked to reduce the 
questionnaire burden and used more up-to-date questionnaires, such as PAC-QOL and 
PAC-SYM, including those which concentrate more on the link between FI and RED. 
Finally, I also wish there had been the originally planned, robust follow up study, 
blinding patients for a longer period of follow-up. The obvious ethical, financial and 
logistical problems result in huge obstacles to this however.  
7.2.6 Future work 
I consider the term ‘future work’ has two key elements, and I should like to explore 
these separately. The first is where I consider the general key focuses in FI research 
should be; and the second is where I think the priorities lie regarding research into 
PTNS, in light of the CONFIDeNT Trial results. I describe the issues this way round, as I 
feel it would be helpful to address the more general issues prior to embarking on 
further specific work.  
International collaboration by all stakeholders in FI and/or anal incontinence should 
be established, and seek to set a few standards that all literature and research should 
conform to, to enable comparisons to be made. These include:  
A standardised global definition of faecal and anal incontinence  
Agreement on FI sub-types, specifically whether the current classification of urge and 
passive incontinence are useful, or whether new definitions based on pure FI or 
overlapping RED should be used. These definitions should be accompanied by 
anorectal physiological guidelines and definitions. 
Minimum FI symptom requirement for patient to be eligible for trial inclusion  
Choice of the ‘best’ primary and secondary endpoints for studies of FI 
Algorithm detailing rationale and order of treatments given for FI 
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Once agreement has been reached, future research into PTNS in the treatment of FI 
would be much more straightforward.  To my mind, future research priorities in terms 
of PTNS in light of the CONFIDeNT Trial results include answers to the following 
questions:  
Does PTNS have good efficacy compared to sham for patients with pure FI? 
At what follow-up time period should PTNS be assessed in studies? 
What is the optimal PTNS treatment duration? 
In order to answer these questions, I would suggest designing a further parallel group, 
sham-controlled, double blind RCT, similar to that of the CONFIDeNT Study. 
Recruitment to this study would be in line with the agreed standard definition of FI, 
with patients fulfilling the agreed minimum FI symptom requirement. Patients would 
have pure FI, as based on the agreed anorectal physiological definitions. Treatment 
would be given at the time point agreed in the algorithm, and outcome measures would 
be those agreed by the international collaboration. Trial design would be similar to the 
CONFIDeNT Trial in other respects, including measuring outcomes after 6 and 12 
weeks treatment. In addition to this, a longer period of blinded follow up, up to 1 year, 
would be added, and then a structured and monitored extended follow-up where 
patients were permitted certain other treatments also under trial conditions. Whilst 
such a trial would be extremely robust, it would unfortunately involve a large workload 
with significant cost.   
7.2.7 Key clinical messages 
The CONFIDeNT Trial has shown PTNS to have no superiority over sham electrical 
stimulation in the treatment of unselected adults with FI, based on the primary 
outcome measure chosen. There is however some evidence to suggest treatment 
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efficacy in those with urge FI, and in addition, potentially higher success rates in 
patients who experience no concomitant problems with rectal evacuation.  
Based on my experience of this thesis, I would advocate that PTNS should not be used 
as a ‘blanket first line treatment’ for all patients with FI. I feel it also very important to 
highlight however that there are clearly some patients who do receive significant 
benefit from treatment. I feel that my research should mark the beginning of a large 
body of work into which subgroups of patients benefit from PTNS, and where it best 
fits into a carefully designed algorithm of care. Allied research into a likely mechanism 
of action may also help this process significantly.   
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9 Appendices 
9.1 Appendix 1: Bowel Diary 
Day 1 2 3 4 5 6 7 
Controlled bowel movements (no incontinence: underwear, pads or pants remained clean) 
How many 
times did you 
go to the toilet 
(controlled)? 
       
Uncontrolled bowel movements (incontinence: underwear, pads or pants got dirty) 
How many 
times did you 
NOT make it in 
time to toilet 
(rush)? 
       
How many 
times did you 
not feel the 
bowel 
movement but 
only afterwards 
(passive 
leakage)? 
       
Staining/ minor soiling of underwear 
Did you 
stain/soil your 
underwear, 
pants or pad(s) 
today? 
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no 
Pad usage/Enema/ Suppository 
Pad(s) used for 
incontinence? 
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no 
Enema 
Suppository 
administrated? 
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no 
Social functioning 
Did your 
(faecal) 
incontinence 
limit you in your 
daily activities 
(e.g. leaving the 
house, 
shopping etc)? 
Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no Yes/no 
Stool consistency 
What was your 
stool 
consistency 
today? (Circle 
one) 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
Solid/ 
mushy/ 
liquid 
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9.2 Appendix 2: St Marks’ Continence Score 
 Never Rarely Sometimes Weekly Daily 
How often do you have incontinence 
(accidents) with solid stool? 
 
     
How often do you have incontinence 
(accidents) with liquid stool? 
 
     
How often do you lose control of gas/wind? 
 
     
How often do your bowel symptoms affect 
your lifestyle? 
 
     
      
    No Yes 
Do you use a Pad or anal plug? 
 
     
Do you medications to make that make you constipated? 
 
     
Do you have to rush to the toilet as soon as you have an urge to go?       
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9.3 Appendix 3: Cleveland Clinic Incontinence Score 
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9.4 Appendix 4: Supplementary tables for systematic review 
Table 39: Other outcomes in randomised trials of percutaneous and transcutaneous tibial nerve stimulation 
Reference Outcome Results 
Leroi et al. (2012) FIQL score No significant differences between the two groups* 
Patient-perceived 
success 
No difference in patient-perceived treatment efficacy between groups: TTNS 30% (0–100) vs. sham 20% (0–
100) success (P = 0.024) 
Physician-perceived 
success 
Physician-estimated treatment efficacy significantly higher in TTNS group: TTNS 59% vs. sham 35% improved 
(P = 0.01) 
Anorectal manometry  No significant difference between two groups in anorectal manometry at 3 months compared with baseline 
George et al. (2013) St Mark’s 
incontinence score 
All groups demonstrated improvement in incontinence score, but no significant difference between groups 
(P = 0.201) 
FIQL score All groups demonstrated improvement in FIQL score, but no significant difference between groups in any 
domain 
SF-36® QoL score All groups demonstrated improvement in SF-36® score, but significant difference between groups only in 
vitality domain (P = 0.008) 
Anorectal manometry  No anorectal physiology assessments showed any significant difference between groups 
Thomas et al. (2013) 
 
St Mark’s 
incontinence score 
No comparison made between groups 
Percentage reduction 
in weekly FIE 
No comparison made between groups 
Weekly frequency of 
defaecation 
No comparison made between groups 
Ability to defer 
defaecation  
No comparison made between groups 
FIQL Score No comparison made between groups 
SF-36® QoL score No comparison made between groups 
Time taken to return 
to baseline FI 
episodes 
No comparison made between groups 
*In terms of median relative changes compared with baseline. FIQL, Faecal Incontinence Quality of Life Scale; TTNS, transcutaneous tibial nerve stimulation; SF-
36®, Short Form 36 (QualityMetric, Lincoln, Rhode Island, USA). 
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Table 40: Characteristics of RCTs (publication order)  
Study  Characteristic Description 
Leroi et al. 2012  
 
Methods Study Design: Multi-centre double-blind randomised sham-
controlled trial.  
Follow-up: 3 months after treatment commencement i.e. 
immediately after cessation of treatment. Total study duration: 4 
months. 
Participants 144 patients selected from consecutive patients referred for FI to 
the nine centres. (F=131, M=13). Age 30-82 years. 
Inclusion criteria: FI lasting > 3 months, with FI defined as more 
than one incontinent episode (or urgency episode causing the 
patient to remain at home to avoid incontinent episode) on average 
per week; failure of conservative treatments; not a candidate for 
conservative treatments and ≥ 18 years of age.  
Exclusion criteria: Congenital anorectal malformation; previous 
colorectal resection; pelvic irradiation; rectal prolapse; faecal 
impaction; external anal sphincter defect exceeding 90 degrees in 
circumference; implanted pacemaker or defibrillator; pregnant or 
intention to become pregnant; complete peripheral or central 
neurological lesion; rapidly progressive neurological disease (in <6 
months); anatomical limitations preventing the successful 
placement of an electrode; previous experience with therapeutic 
electrical stimulation such that the patient did not suspect that he or 
she was being treated with a sham stimulation; and chronic 
diarrhoea resistant to medical treatment.  
TTNS Group: n=73 (M=5, F=68). Median age 60 years (range: 30-80 
years). Median duration of symptoms 5 years (range: 1–36 years). 
Sham group: n=71 (M=8, F=63). Median age 59.3 years (range: not 
reported). Median duration of symptoms 8.8 years (range: not 
reported). 
Groups similar with no significant difference in sex, age and 
duration of symptoms.   
Interventions Randomisation performed using a random number table stratified 
based on the CCIS score. No other details given.  
Intervention Group: Electrical stimulation performed with TENS Eco 
Program P3 stimulator applied over tibial nerve using method 
described by Qualtero et al. Negative electrode behind internal 
mallelous positive electrode 10cm above negative electrode. Correct 
position of negative electrode detrmined by observing rhythmc 
flexing of toes. Intensity level set just under threshold causing motor 
contraction. Stimulation applied in continuous mode at 10Hz with a 
200 μs pulse width. Patients shown how to operate stimulator and 
requested to perform 20-minute stimulation sessions twice daily for 
3 months at home. 
Sham group: Equipment set up identically to treatment group. Sham 
stimulations performed with a placebo stimulator that physically 
resembled the active stimulator but did not deliver a current. 
Patients were shown how to operate stimulator and requested to 
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perform 20-minute stimulation sessions twice daily for 3 months at 
home.  
Outcomes Bowel diaries regarding episodes of FI and urgency for 3 weeks 
prior to treatment and throughout the 3 month treatment duration. 
CCIS at baseline and following 3 months treatment. Delay in 
postponing defaecation at baseline and following 3 months 
treatment. FIQL at baseline and following 3 months treatment. 
Patients opinion regarding efficacy of the treatment using graduated 
100mm vertical line ranging from “0 = no efficacy at all” to “100 = 
complete efficacy with cure”. Evaluating physician also asked 
whether they felt treatment was effective or not. 
Anal manometry at baseline and after 3 months treatment.  
George et al. 
2013 
 
Methods Study Design: Single centre single blind randomised controlled trial 
with 3 arms.  
Group 1: Percutaneous tibial nerve stimulation 
Group 2: Transcutaneous tibial nerve stimulation 
Group 3: Sham transcutaneous tibial nerve stimulation 
Follow-up: 6 months. Total study duration: 8 months. 
Participants Thirty patients recruited into 3 arms of study. 
Inclusion criteria: Age>18 years with at least two or more episodes 
of FI per week.  
Exclusion criteria: Previous congenital or acquired spinal injury, 
spinal tumour or spinal surgery, presence of neurological diseases 
(such as diabetic neuropathy, multiple sclerosis and Parkinson’s 
disease), peripheral vascular disease, uncontrolled diabetes 
mellitus, congenital anorectal malformations, recent rectal surgery 
(rectopexy or resection within 24 months), presence of external full-
thickness rectal prolapse, inflammatory bowel disease, chronic 
diarrhoea uncontrolled by drugs or diet, previous use of tibial nerve 
stimulation, stoma in situ, bleeding complications, and pregnancy or 
attempting to conceive. 
Group 1: n=11. Sex not stated. Age not stated. 
Group 2: n=11. Sex not stated. Age not stated.   
Group 3: n=8. Sex not stated. Age not stated.   
No comment on similarities between groups. 
Interventions Randomisation via sealed-envelope technique. 
Group 1: PTNS using Uroplasty Urgent PC on either leg. Current 
increased until both motor and sensory responses noticable. 
Current set at the highest level tolerable by patient. Patients treated 
with twice-weekly 30-minute sessions for 6 weeks.   
Group 2: Using the NeuroTrac Continence Neurostimulator by 
Premiere Medical Products. Two self-adhesive surface electrodes 
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placed with the negative behind the medial malleolus and the 
positive 10cm above it. Current increased until motor and sensory 
responses obtained. Current at the highest level tolerable to patient. 
Stimulation was given in twice-weekly 30-minute sessions for 6 
weeks.  
Group 3: Using same equipment as described for group 2. 
Equipment set up as above but stimulator only briefly switched on 
for 30 seconds to induce a minor electrical sensation in the skin and 
then turned off for the remaining treatment duration. Patients 
attended for twice-weekly 30-minute sessions for 6 weeks.  
Outcomes Bowel diaries recording weekly episodes of faecal incontinence, St 
Mark’s Continence Score, Rockwood Quality of Life Score and SF-36 
Quality of Life score were recorded before and after treatment. 
Thomas et al. 
2013 
Methods Study design: Single-centre single blind (assessor only) randomised 
study to compare daily with twice-weekly transcutaneous tibial 
nerve stimulation. 
Follow-up: 6 weeks after commencement of treatment, i.e. 
immediately after cessation of treatment.  
Participants 29 patients from a single centre (from 30 originally recruited). 26 
females.  
Inclusion criteria: Signed consent form; 18-80 years of age; FI 
defined as at least 2 episodes per week of involuntary loss of either 
liquid or solid stool; previous unsuccessful biofeedback; willingness 
to attend for the study; willing and able to complete the 
questionnaires and bowel diaries; no previous neuromodulation. 
Exclusion criteria: Congenital or acquired spinal injury, tumour or 
surgery; peripheral vascular disease; peripheral neuropathy or 
neurological disorder; anorectal surgery within the last year; full 
thickness rectal prolapse; active inflammatory bowel disease; 
psychological or physical inability to cope with the study protocol; 
pregnancy or attempting to become pregnant.  
Daily TTNS: 14 patients (all female). Median age 54.5 IQR (8.5) 
years. Median duration of symptoms 6 years (IQR 4.13).  
Weekly TTNS: 15 patients (12 females). Median age 51 IQR (29) 
years. Median duration of symptoms 5 years (IQR 9).  
Interventions Randomisation, performed by a third party who did not take part in 
analysis of results, was by random selection of a sealed opaque 
envelope, which contained group allocation. No other details given. 
Treatment: All patients performed treatments at home for 6 weeks 
following one to one instruction on the use of TTNS, written 
instructions and a photograph demonstrating the electrode pad and 
lead position. TTNS was given using a NeuroTrac TENS 
transcutaneous electrical nerve stimulator (Verity medical Ltd, 
Hampshire, UK) via two 50 mm x 50 mm electrode pads. The live 
pad was placed posterior and superior to the medial malleolus and 
the ground pad was placed 10cm cephalad to this. Continuous 
stimulation at pulse width 200 microseconds and frequency 10Hz 
was used. Amplitude was set to produce a sensory stimulus in the 
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ipsilateral foot, at a tolerable intensity. All treatments were given for 
30 minutes. 
Twice weekly: Patients randomised to this group self-treated at 
home twice weekly. 
Daily: Patients randomised to this group self-treated at home daily.  
Outcomes Primary outcome: Frequency of faecal incontinence episodes per 
week. These were measured from 2-week bowel diaries before and 
after treatment.   
Secondary outcomes: Ability to defer defaecation (measured in 
minutes), the frequency of defaecation, changes in St Marks 
Continence Score and changes in FIQL score. The SF-36 survey was 
also conducted and a visual analogue scale assessing patient 
response to ‘how happy are you with the way your bowels have 
been functioning’ on a scale of 0 (very unhappy) to 100 (very 
happy).  
All outcomes were assessed prior to and immediately following a 6-
week course of treatment in both arms. 
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Table 41: Other outcomes in studies of percutaneous tibial nerve stimulation 
Reference Outcome Results 
Shafik et al. (2003) Rectometrogram No clear result shown 
Recurrence of symptoms Recurrence of symptoms in 30% patients who originally had success, and with further treatment 
75% had improved symptoms again 
De la Portilla et al. (2009) FIQL score FI no longer affected QoL 6 months after treatment in 12.5% patients (reduction from 37.5% of 
patients to 25%) 
Significant improvement in FIQL score in depression, coping/behaviour and embarrassment 
domains, but not in lifestyle 6 months after treatment versus baseline (P < 0.004, P < 0.02, 
P < 0.005 and P = 0.086 respectively)* 
VAS for QoL Significant improvement at 3 months and after 6 months without treatment (P = 0.002 and 
P = 0.001 respectively)* 
Anorectal manometry Significant improvement found in mean squeeze pressure between baseline and 6 months after 
treatment (P < 0.007), but not in resting pressures or rectal sensation 
Govaert et al. (2009) SF-36® SF-36® improved significantly in all domains apart from vitality at 1 year (P < 0.005)* 
FIQL score FIQL improved significantly in coping/behaviour and embarrassment domains after treatment, 
and in lifestyle and coping/behaviour domains at 1 year (P < 0.005)* 
Boyle et al. (2010) Time to defer defaecation Deferment of defaecation time improved in 65% patients from a median of 1 (range 0–15) to 5 (0–
25) min (P < 0.001) 
Duration of effect Duration of effect data not collected or reported systematically 
Outcome versus physiological 
parameters 
No correlation found between outcome and physiological parameters 
Findlay et al. (2010) HAD score Significant improvements seen in ICIQ-B score bowel control and quality of life domains 
(P = 0.001 and P = 0.007 respectively), and in FIQL score lifestyle domain (P = 0.028)*. All other 
parameters showed non-significant improvements 
ICIQ-B score 
FIQL score 
Hotouras et al. (2012) Time to defer defaecation Improved significantly from 1 (range 0–30) min before treatment to 5 (0–60) min after treatment 
(P < 0.001) 
George et al. (2012) St Mark’s incontinence score Improvement in continence score seen, but no comment on significance* 
FIQL score Improvement in FIQL score, but no comment on significance* 
SF-36® QoL score Improvement in SF-36® score, but no comment on significance* 
Anorectal manometry Significant improvement in mean peak squeeze pressure from baseline to post-treatment from 
mean (s.d.) 50(29) to 68(34) cmH2O (P = 0.043) 
Arryo et al.(2014) VAS for faecal incontinence Significant improvement from baseline 6 to 7.5 at 6 months (p=0.001) 
Time to defer defaecation Improvement from 2 minutes at baseline to 4 minutes at 6 months (p=0.008) 
Anal manometry Significant improvement in maximum resting pressure from 41 ± 26 mmHg to 51 ± 31 mmHg 
(p<0.001) at 6 months and in maximum squeeze pressure from 83 ± 35 mmHg to 94  ± 52 mmHg 
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(p<0.001) 
Al Asari et al. (2014) FIQL score Significant improvement in score from baseline to 6 months (mean 2.1 to 3.1, p<0.001) and 
baseline to 12 months (mean 2.1 to mean 3.1, p<0.001) 
PTNS vs. SNS No difference in proportion of patients achieving >50% improvement in CCIS between PTNS and 
SNS at 6 months or 12 months. 6 months 47% vs. 50% (p=0.53). 12 months 30.7% vs. 57.5% 
(p=0.09). 
No significant difference in FIQL score at baseline between groups. No significant difference in 
FIQL score between PTNS and SNS groups at 6 months (p=0.79) or 12 months (0=0.37). 
Hotouras et al.(2014) Time to defer defaecation Improved from median of 1 minute (range 0-60 minutes) to 5 minutes (range 0-60).  
PTNS vs. SNS in ‘pseudo’ 
case-control model 
Significantly more incontinence episodes in SNS group prior to treatment (p=0.02). No significant 
difference in incontinence episodes between groups following treatment (0.27). No significant 
difference in deferment time between groups. 
De la Portilla et al.(2014) VAS for QOL Improved significantly from mean (s.d.) 15 (±3.6) to 10 (±5.6) after treatment (p=0.005), 9 (±6) 
after 9 months (p=0.005) and 8.6 (±6) after 27 months (p=0.001)  
FIQL score Significant improvement at 27 months from baseline in three of the four domains; lifestyle 
(p=0.013), behaviour (p=0.005) and embarrassment (p=0.002) 
Anorectal manometry Significant improvement in squeeze pressure (p=0.019) and threshold volume for desire to 
defaecate (p=0.043) at 27 months compared to baseline 
Hotouras et al. (2014) Time to defer defaecation Significantly improved from a median of 1 minute to 5 minutes at 3 months (p<0.001) and from a 
median of 1 minute to 4 minutes after a median of 29 months follow up (0<0.001). 
Univariate and multivariate 
analysis 
No effect of age, sex, incontinence type, intact IAS, intact EAS, anal resting and squeeze pressures 
on mean reduction in CCIS. 
FIQL A significant improvement from baseline to both follow-up periods (3 months and median 29 
months) in all domains; lifestyle, coping, depression and embarrassment.  
Lopez-Delgado et al.(2014) Time to defer defaecation At baseline 75% patients had urgency <1 minute. This fell to 12.5% by 3 months and to 0% at 6 
months. At 6 months 75% patients had urgency of 1-5 minutes. No statistical analysis performed. 
VAS of perception of degree 
of incontinence. 
VAS for perception of degree of incontinence improved from 2.5 to 2.4 however this was not 
statistically significant.  
FIQL There were no differences in the domains of FIQL score before and after 3 or 6 months treatment. 
No raw data or analysis shown. 
Incontinence episodes Incontinence diaries showed a ‘slight improvement’ with a trend towards improvements in 
patients with between three and seven episodes per week at 6 months, however this was not 
statistically significant.  
Associations A frequency of incontinent episodes of <3 per week was associated with a better response to 
PTNS (OR=2, 95% CI 1-3.97; P=0.027). Previous episiotomy and baseline CCIS>12 were negative 
predictors of response to PTNS (OR=5.78, 95% CI 1.77-21.53; P=0.007) and (OR=2.9, 95% CI 1.09-
6.72; P-0.035). 
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Anal manometry When patients with negative outcome were excluded, significant improvements in mean resting 
pressure and mean squeeze pressures were seen at 3 months (p=0.043 and p=0.049 respectively) 
and at 6 months (p=0.021 and p=0.045 respectively). Significant inverse correlations were seen at 
6 months between CCIS and both mean resting and mean squeeze pressures.  
*Mean values reported in study. FIQL, Faecal Incontinence Quality of Life Scale; QoL, quality of life; VAS, visual analogue scale; SF-36®, Short Form 36 
(QualityMetric, Lincoln, Rhode Island, USA); HAD, Hospital Anxiety and Depression Scale; ICIQ-B, International Consultation on Incontinence Questionnaire – Bowel 
module. 
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Table 42: Characteristics of PTNS studies (publication order)  
Study Characteristic Description  
Shafik et al.  2003  Methods Study design: Non-randomised prospective case series with control 
group.  
Study duration: 4 weeks. Follow-up: 16-30 months (mean 22.3 
months +/-4.6). 
Participants 32 patients with idiopathic FI (M=10, F=22)  
Intervention group: Mean age 38.2 +/- 6.7 years.  Mean duration FI 
8.6 +/- 2.7 years.  
“Control” group: ‘Twenty patients with FI who matched the treated 
group in age, duration of symptoms and investigative results acted 
as controls.’  F=14; M=6. 
Inclusion: FI (incontinent of solid stools) with normal EMG activity 
of EAS, puborectalis and levator ani and normal anorectal 
sensitivity, anal pressure, defecography and endoanal USS.  Failure 
of medical therapies, pelvic floor stimulation, Kegel exercise and 
biofeedback. 
Exclusion: Not mentioned 
Interventions Intervention group: PTNS using Stoller Afferent Nerve Stimulator. 
Unilateral stimulation. Parameter recognised by flexion of big or 
other toes. 30-minute stimulations every other day for 4 weeks (14 
treatments). In case of symptom recurrence, stimulation repeated 
twice per week for 4 weeks.  
Control group: Equipment attached but no stimulation given. 
Outcomes Bowel incontinence questionnaire (Solid, liquid and flatus 
incontinence, pad usage, daily social functioning)  
Rectometrogram measuring rectal volume, pressure and 
compliance at the first rectal and urge sensation (twice in each 
patient to ensure reproducibility) 
De la Portilla et al. 
2009 
Methods Study Design: Non-randomised prospective case series.  
Follow-up: Immediately after 3-months treatment. Those with 
treatment success continued therapy and were followed up until 6 
months after treatment cessation.  
Total study duration: 14 months. 
Participants Sixteen patients (11 female) mean age 59 +/- 7.9 years.  
Inclusion criteria: Age 18-80,  CCIS score 10 or higher, >4 fecal 
leaks within 28 days as well as duration >6 months, failure of 
conservative treatment and integrity of external anal sphincter.  
Exclusion criteria: severe cardiopulmonary disease, lesion of the 
tibial nerve, severe distal venous insufficiency, cardiac pacemaker 
or implantable defibrillator, inflammatory bowel disease, 
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uncontrolled diabetes with peripheral nerve involvement, 
immunosuppression, active anal fissure, fistula or abscess, or 
pregnancy. 
Interventions PTNS using Uroplasty Urgent PC. Amplitude increased until 
plantarflexion or fanning of toes and kept at level where sensation 
was available. 30 minute stimulations weekly for 12 weeks. If good 
response achieved (CCIS score decrease to <40% of original score) 
treatment continued at every two weeks for 2 months, every three 
weeks for 2 months and then a final treatment a month later. Total 
20 treatments. 
Outcomes CCIS score and FIQL questionnaire at all time-points (before 
treatment; after 3 months treatment; after 8 months treatment and 
after 6 months without treatment). Visual analogue scale of success 
before treatment and after 3 months initial treatment. Bowel diary 
before treatment, after 8 months treatment and after 6 months 
without treatment. 
Govaert et al. 
2009  
 
Methods Study Design: Multicentre non-randomised prospective case series.  
Follow-up: Immediately after 6-weeks treatment. Those with 
treatment success continued therapy and were followed up at 3 
months, 6 months and 1 year. Total study duration: 12 months. 
 
Participants 22 patients (16 female) mean age 60.4 +\-11.7 years.  
Inclusion criteria: Age>/= 18, FI with solid or liquid stool causing 
disruption to lifestyle, psychological stability and suitability for 
intervention as determined by the investigator, willing to commit 
to a rigid follow-up schedule, failed conservative therapy, intact 
peripheral neurosensory nervous system as determined by clinical 
investigation, adequate motor and/or sensory response during 
treatment, able to read and write.  
Exclusion Criteria: Major internal or external anal sphincter defect 
(>120 degrees of circumference), faecal impaction, implanted 
pacemaker, defibrillator, cardiopathy or bleeding disorder, 
pregnancy or intention to become pregnant, neurogenic or 
congential disorders resulting in fecal incontinence (multiple 
sclerosis and spina bifida) unable to travel to the hospital to 
receive the treatment.   
Interventions PTNS using Uroplasty Urgent PC on either leg. Amplitude increased 
until sensory and/or motor responses were evident.  30 minute 
stimulations twice weekly for 6 weeks. If patients had sufficient 
subjective reduction in symptoms, maintanence therapy was 
started. This consisted of weekly sessions for 6 weeks, fortnightly 
sessions for 8 weeks and monthly sessions for 6 months. Total 
treatment duration: 11 months. 
Outcomes CCIS at all time-points (before treatment; after 6-weeks, 3-months, 
6-months and 1-year). 
Bowel diaries at baseline, after 6 weeks treatment and after 1 year.  
SF-36 and FIQL questionnaires at baseline and after 6 weeks 
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treatment.  
Boyle et al. 2010  Methods Study Design: Single centre non-randomised prospective case 
series. 
Follow-up: Median 9 months (range 3-14 months).   
Participants 33 patients (32 female) median age 58 (range 34-77). 
Inclusion criteria: All patients referred for conservative 
management of urge FI. 
Exclusion criteria: Pregnancy or intended pregnancy, implanted 
pacemaker or defibrillator, history of ischemic heart disease, 
peripheral neuropathy, any medication affecting coagulation and 
patients with mixed symptoms (e.g. concomitant passive 
incontinence, constipation, and rectal evacuatory disorder). 
Interventions PTNS using Uroplasty Urgent PC on either leg. Stimulation was 
gradually increased until sensation was perceived in the foot, or 
motor flexor response was seen at the great toe.  
Treatment involved 12 weekly sessions of 30 minutes duration, 
followed by 2 sessions at 2-week intervals, and one a month later. 
Outcome were assessed in March 2009 at a median follow-up of 9 
months (range, 3–14) from the end of treatment. 
Outcomes Bowel diaries recording weekly FI episodes, CCIS and degree of 
faecal urgency (recorded as patients perceived ability to defer 
defaecation) recorded prior to and after treatment.    
Findlay et al. 2010  Methods Study Design: Single centre non-randomised retrospective case 
series.  
Follow-up: Conducted at month 4 (i.e. one month after treatment 
cessation). 
Participants Thirteen consecutive patients with FI. Age and sex of patients not 
detailed. 
Inclusion Critria: FI of at least 6 months’ duration, failure of 
medical and non-invasive interventions (including pelvic floor 
physiotherapy and biofeedback).  
Exclusion criteria: Age under 18 years, coagulopathy, neuropathy, 
implanted pacemaker or cardiac defibrillator, and pregnancy or 
intention to become pregnant. 
Interventions PTNS using Uroplasty Urgent PC using either leg. Successful 
placement confirmed by elicitation of digital plantar flexion or 
abduction. PTNS undertaken for 15 min at the highest current (0–9 
mA) not causing a motor response, at frequency of 20 Hz. After 15 
min, current was increased by 1 mA for a further 15 min. Weekly 
30-min sessions for 12 consecutive weeks. 
Outcomes Bowel diaries recording monthly episodes of FI to flatus, liquid and 
solid. Hospital Anxiety and Depression (HAD) Score, the 
International Consultation on Incontinence Questionnaire Anal 
Incontinence Symptoms and Quality of Life Module (ICIQ-B), and 
      
 
 
232 
 
FIQOL, completed 4 weeks before and after treatment. 
Hotouras et al. 
2012  
Methods Study Design: Single centre non-randomised prospective case 
series.  
Follow-up: 3 months i.e. immediately following cessation of 
treatment. 
Participants 88 female patients. Mean age 58.0 +/- 13.6 years.  
Inclusion criteria: Female patients with FI over a 3-year period 
(2008-2011). 
Exclusion criteria: none listed.  
Interventions PTNS using Uroplasty Urgent PC on either leg. Current gradually 
increased until sensation elicited in foot or motor flexor response 
seen in great toe. Twelve 30-minute treatment sessions once or 
twice weekly over a 6–12 week period. If treatment successful two 
further treatments 2 weeks apart and one a month later. 
Outcomes Bowel diaries recording weekly episodes of faecal incontinence. 
CCIS score. All data were collected prior to treatment and 
immediately after the final treatment visit. 
Arroyo et al. 2014 Methods Study Design: Two centre non-randomised prospective case series.  
Follow-up: 6 months 
Participants 16 patients (15 female). Mean age 56.5 +/- 10.9 years. 
Inclusion criteria: Patients with faecal incontinence of a diverse 
cause, who were refractory to medical treatments. Patients were 
selected on the basis of a 90-180 degree sphincter lesion. 
Exclusion criteria: Inability to communicate (e.g. patients with 
Alzheimer’s disease, among others), acute anatomical problems 
with possible surgical resolution (less than 3 months) and 
unwillingness to consent to participate in the study. 
Interventions PTNS using Uroplasty Urgent PC. Leg not mentioned. Successful 
placement was confirmed by presence of electric sensation 5cm 
above and below the insertion site or by plantar flexion of toes. 
PTNS was undertaken at the highest setting which did not cause a 
motor response or pain. Twelve weekly 30-minute treatments 
were undertaken. If clinical improvement occurred, patients 
received an additional six sessions every 2 weeks. 
Outcomes At 6 months: Median CCIS had decreased from 10 to 5 (p=0.006). 
Retention time had improved from <1min in 75% patients at 
baseline to only 2 patients (p=0.008)./ VAS increased from 6 to 7.5 
(p>0.05). Maximum resting and squeeze pressures increased 
significantly. 
Al Asari et al. 
2014 
Methods Study Design: Single centre non-randomised prospective case 
series (PTNS and SNS patients over same time period) 
Follow-up: 1 year 
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Participants 78 patients (71 female). PTNS: 21 (21 female) mean age 62.3 +/- 
15.3. SNS 29 (32 female) mean age 60.1 +/-12.  
Inclusion criteria: Patients who had failed to respond to 
conservative treatment, including dietary modification, anti-
diarrhoeal drugs and biofeedback therapy for 3-12 months.  
Exclusion criteria: Cardiac pacemaker, neurological disease, 
diabetes, psychiatric disease, coagulopathy, unable to attend 
repeated weekly sessions, local skin disease at site of puncture.  
Interventions PTNS using Uroplasty Urgent PC. Leg not mentioned. Correct 
stimulation parameters were seen by plantar flexion of ipsilateral 
toes but without any sensation or contraction of the pelvis. 
Unilateral stimulation performed twice per week for 6 weeks then 
once per week for 3 weeks. Thereafter patients received one 
session every 15 days, followed by one every 3-4 weeks and then 
once every 5-6 weeks as required.  
Outcomes Assessments at 6 weeks, 3 months, 6 months and 12 months. 
Primary outcome was statistically significant reduction in Wexner 
FI score at 6- and 12-month periods compared to baseline. 
Secondary outcomes included improvement in quality of life rated 
by FIQL questionnaire and treatment-related complications. 
Hotouras et al. 
2014 
Methods Study Design: Single centre non-randomised prospective case 
series of PTNS and SNS, including a sub-group analysis using a 1-1 
‘pseudo-case control model’.  
Follow-up: 3 months. 
Participants 146 patients (128 female). Median age 56 (range 15-83).  Sub-
group analysis included 37 SNS patients and 37 selected PTNS 
patients from above group. 
Inclusion: Not specified. 
Exclusion: Not specified. 
Interventions PTNS delivered with Uroplasty Urgent PC, which was performed 
over 12 nurse-led outpatients sessions, according to the previously 
published departmental protocol. 
Outcomes All patients had the following outcomes assessed at baseline and 3 
months: CCIS score, ability to defer defaecation, number of weekly 
FI episodes. A 10 year treatment cost comparison was also 
documented.  
De la Portilla et al. 
2014 
Methods Study Design: Single centre non-randomised prospective case 
series. 
Follow-up: 3 months, 8 months, 14 months, 27 months.  
Participants 30 patients (21 female). Median age 56 +/- 11.2 years. 
Inclusion: Age 18-80, severe FI with CCIS at least 10, more than 
four FI episodes per 28 days, duration of FI longer than 6 months, 
failure of conservative treatments (fibre plus loperamide, 
biofeedback or bulking agents and integrity of the external anal 
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sphincter.  
Exclusion: severe cardiopulmonary disease, severe venous 
insufficiency of lower limbs, cardiac pacemaker or implantable 
defibrillator, inflammatory bowel disease, irritable bowel 
syndrome, uncontrolled diabetes with peripheral neuropathy, 
immunosuppression, anal fissure, anal fistula or abscess, 
pregnancy. 
Interventions PTNS delivered with Uroplasty Urgent PC unilaterally. Amplitude 
was slowly increased until plantar flexion of the large toe or 
fanning of the other toes occurred. The intensity of stimulation was 
set at a well-tolerated level.  Patients underwent 12 weekly 
outpatient treatment sessions, each lasting 30 minutes (first 
phase). Further treatment was given to patients who achieved a 
40% or more decrease in CCIS. This consisted of treatments every 
other week for 2 months followed by every 3 weeks for 2 months 
and finally one session in 1 month.  
Outcomes Outcomes were measured before treatment, immediately after 3 
months treatment, after 8 months, after 14 months and after 27 
months. Outcomes included CCIS, FIQL and a VAS for overall 
quality of life.  Anorectal manometry was performed pre treatment 
and after 8 months treatment. 
Hotouras et al. 
2014 
Methods Study Design: Single centre non-randomised prospective case 
series. 
Follow-up: 3 months, median 29 months (range 15-45 months). 
Participants 115 patients (103 female). Median age 56 (range 30-83 years).  
Inclusion: Not specified 
Exclusion: Not specified 
Interventions PTNS delivered with Uroplasty Urgent PC according to published 
departmental protocol. Treatments generally delivered as 12 half-
hour treatments over a period of 3 months, followed by 3 ‘weaning’ 
sessions and then 6-monthly maintenance ‘top-up’ sessions.  
Outcomes CCIS, bowel diaries, deferment time and FIQoL scores all obtained 
pre-treatment, at 3 months and at final follow-up.  
Lopez Delgado et 
al. 2014 
Methods Study Design: Single centre non-randomised prospective case 
series.  
Follow-up: 3 months and 6 months 
Participants 24 patients (19 female). Mean age 62.1 +/- 10.1 years. 
Inclusion: Patients with FI due to various causes who were 
refractory to medical and surgical treatment. 
Exclusion criteria: Inability to communicate, dementia, acute 
trauma for which surgery was possible and refusal to enter the 
study.   
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Interventions PTNS using Uroplasty Urgent PC. No mention of leg. Successful 
placement was confirmed by presence of electric sensation 5cm 
above and below the insertion site or by plantar flexion of toes. 
PTNS was undertaken at the highest setting which did not cause a 
motor response or pain. Twelve weekly 30-minute treatments 
were undertaken. If clinical or anal manometric improvement 
occurred, patients received an additional six sessions every 2 
weeks.  
Outcomes CCIS. Time to deferment of defaecation. Fecal Incontinence Quality 
of Life score. Incontinence diary dividing patients into groups: <3 
weekly faecal incontinence episodes (mild), 3-7 weekly faecal 
incontinence episodes (moderate) and >7 weekly faecal 
incontinence episodes (severe). Perception of the degree of 
incontinence using a visual analogue scale (0 worst to 10 best). 
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Table 43: Other outcomes in trials of transcutaneous tibial nerve stimulation 
Reference Outcome Results 
Queralto et al. Anorectal manometry No change from baseline to post-treatment 
Vitton et al. VAS for symptoms 42% reported symptomatic improvement at 3 months 
VAS for QoL Improved by 50% in same 42% of patients as above 
Time to defer defaecation Improvement reported in 25% of patients 
Vitton et al. VAS symptom improvement 54% reported symptomatic improvement at 3 months 
GIQOL Not predictive of treatment success. No other data presented 
Eleouet et al. VAS for subjective improvement Mean VAS: 63% perceived improvement at 1 month with mean improvement of 25% (±30%) 
FIQL score Mean FIQL improved significantly in all areas at 3 months but only coping/behaviour and general 
at 6 months 
KESS score Mean KESS score improved significantly at 3 months but not at 6 months 
ADS score Mean ADS anxiety score improved significantly at 3 months but not at 6 months 
Leroi et al. FIQL score Marked improvement in all four domains 
Anorectal manometry Significant improvement in maximum squeeze pressure after 3 months treatment (but not resting 
pressure, squeeze duration or rectal sensitivity) 
George et al. St Mark’s Continence Score Improvement in incontinence score from mean(s.d.) 18.5(3.1) to 14.7(6.7) after 3 months; 
reduction in bowel movements from 2.6(1.4) to 2.4(1.3) per 24 h; increase in deferment to 
defaecation time from 1.9(0.9) to 2.2(2.4) min (no statistical analysis reported) 
FIQL score 
SF-36® QoL score Improvements in all domains of SF-36® (no statistical analysis reported) 
Anorectal manometry Improvement in peak squeeze pressure after 3 months treatment (but not resting pressure, rectal 
or anal sensitivity) 
Thomas et al. Bowel diaries Percentage reduction in frequency of incontinent episodes: Median of 60% in the daily group and 
median of 50% in the twice-weekly group. 
Weekly frequency of defaecation: No significant changes in either group. 
Ability to defer defaecation: No significant change in either group. 
St Mark’s Continence Score Twice weekly group showed significant improvement from 21 (4) to 17 (7) (p=0.012). No 
significant reduction was seen in the daily group 18 (5.25) to 18 (4.50) (p=0.07).  
VAS for bowel satisfaction Improved significantly in both groups. Daily group: 10 (21) to 30 (23.25) (p=0.01). Twice-weekly 
group: 10 (39) to 30 (40) (p=0.004). 
FIQL No significant improvement in any domain in the twice-weekly group. Significant improvement in 
the daily group in the lifestyle and embarrassment domains only. 
SF-36 No improvement in any domain in the twice-weekly group. Improvement in the physical 
functioning domain only in the daily group. 
Effect of body mass index and 
ankle circumference 
Neither had any effect upon the change in incontinent episodes. 
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Thomas et al. Bowel diaries Median percentage reduction in FI episodes for the group was 66%. 
Ability to defer defaecation was significantly improved from median (SD) of 3 (4) minutes to 5 (8) 
minutes (p=0.03).  
Patients who experienced a reduction in FI episodes returned to baseline in a median (SD) of 3 (1) 
weeks.  
VAS for bowel satisfaction Improved significantly from median 10 (25) to 20 (52.5) (p=0.02).  
FIQL Significant improvement in lifestyle domain from median (IQR) 2.1 (0.6) to 2.5 (1.6) (p=0.01). 
SF-36 Significant improvement in the general health domain from median (IQR) 41.5 (15.7) to 46.2 (14.9) 
(p=0.04).  
Effect of body mass index and 
ankle circumference 
No effect of body mass index or ankle circumference on change in incontinent episodes.  
VAS, visual analogue scale; QoL, quality of life; GIQOL, Gastrointestinal Quality of Life Index; FIQL, Faecal Incontinence Quality of Life Scale; KESS, ADS, Anxiety and 
Depression Scale; SF-36®, Short Form 36 (QualityMetric, Lincoln, Rhode Island, USA); IQR, Interquartile Range. 
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Table 44: Characteristics of TTNS studies (by publication date) 
Study Characteristic Description  
Qualtero et al. 
2006  
 
Methods Study Design: Single-centre prospective case-series.   
Follow-up: 1 month and 4 months after treatment cessation. 
Total study duration: 4 months. 
Participants 
 
10 female patients referred for idiopathic anal incontinence.    
Inclusion criteria: No sonographic sphincter defect, no anatomical 
rectal prolapse, and clinical failure of medical treatments and 
biofeedback rehabilitation or trans sacral neuromodulation. 
Exclusion criteria: None listed. 
Interventions
  
TENS provided via a Cefar Primo stimulating TENS unit. Negative 
electrode placed on ankle skin behind internal malleolus and 
positive electrode 10cm above this. Adequate position of electrode 
determined by visualisation of rhythmic flexion of toes during 
stimulation. Intensity level selected as that immediately under the 
threshold of motor contraction. Applied daily for 4 weeks at the 
patient’s home. 
Outcomes assessed after 4 weeks, and patients discontinued 
treatment in case of failure, or continued for 2 months, 5 days per 
week, if benefit was observed. 
Outcomes CCIS score at baseline compared to after 4-weeks treatment and at 
4 months for those who continued treatment.  
Anal manometry before compared to after 4-weeks treatment. 
Vitton et al. 2009  
 
 
 
 
 
 
  
Methods Study Design: Single-centre prospective case-series.   
Follow-up: 3 months i.e. immediately after treatment cessation.  
Total study duration: 3 months. 
Participants 12 (F=9) with inflammatory bowel disease and FI. Median age 51 
years (range 29-64).   
Inclusion criteria: Age >18 years, IBD stable for 3 months with no 
treatment modification, FI symptoms for >6 months (involuntary 
passage of stool and CCIS score>5/20).  
Exclusion criteria: Pregnancy, active IBD (Harvey-Bradshaw index 
>8), pouchitis or anastomotic stenosis in case of ileoanal 
anastomosis, uncontrolled diabetes, neurological diseases or spinal 
cord lesion. 
Interventions TENS provided using a TENStem Eco stimulating TENS unit. 
Negative electrode placed on the ankle skin behind internal 
malleolus and positive electrode 10cm above this. Intensity level 
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set just below intensity inducing a sensitive perception from the 
patient. Treatment applied by the patient for 20 minutes every day 
for 3 months at the patients home. 
Outcomes CCIS score and Harvey-Bradshaw Index questionnaires at baseline 
and following 3 months of treatment. Analogue scales for 
symptoms and quality of life collected following 3 months 
treatment. 
Vitton et al. 2010  
 
Methods Study Design: Single-centre prospective case-series.   
Follow-up: 3 months i.e. immediately after treatment cessation. 
Those experiencing treatment success continued treatment and 
were followed up after a mean period of 15 months (range 9-35 
months). Total study duration: 35 months.  
Participants 24 (F=22) consecutive patients referred to the department due to 
FI. 
Inclusion criteria: Age >18 years, FI symptoms for >6 months, 
previous failure of medical treatment and/or biofeedback therapy.  
Exclusion criteria: Pregnancy, severe distal venous insufficiency, 
severe cutaneous local lesion, active anal lesion, inflammatory 
bowel disease, use of a cardiac pacemaker or implantable cardiac 
defibrillator. 
Interventions TENS provided using a TENStem Eco stimulating TENS unit. 
Negative electrode placed on ankle skin behind internal malleolus 
and positive electrode 10cm above this. Intensity level set just 
below the intensity inducing a sensitive perception from patient. 
Stimulation parameters 200 μs,  10-Hz and 10-30mA, and 
treatment applied by patient for 20 minutes every day for 3 
months at patient’s home. For those patients experiencing 
improvement in symptoms, treatment continued with same 
parameters though duration not noted.   
Outcomes CCIS score and GIQOL Index at baseline, following 3 months 
treatment and at final follow up for those continuing therapy.  
Analogue scales for symptom improvement collected at 3 months 
and final follow-up. 
Eleouet et al. 2010 
 
Methods Study Design: Single-centre prospective case-series.   
Follow-up: 1 month i.e. immediately after treatment cessation. 
Those experiencing treatment success continued treatment and 
were followed up again at 3 months, after which those with no 
benefit stopped treatment, and the remainder were followed up at 
6 months. Total Study Duration: 6 months. 
Participants 32 (F=30) consecutive patients referred to the department due to 
FI. Age 61 +/-13 years. 
Inclusion criteria: Severe incontinence to faeces with CCIS from 11-
20, failure of previous conservative therapy (i.e. biofeedback, diet 
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modification laxatives or anti-diarrhoeal drugs).  
Exclusion criteria: Soiling as a unique symptom (i.e. without any 
flatus incontinence), overt rectal prolapse, faecal impaction, total 
proctectomy, local inflammation, inflammatory bowel disease and 
insulin-dependent diabetes. 
Interventions TENS provided using a TENStem Eco Program P3 stimulating TENS 
unit. Negative electrode placed on the ankle skin behind internal 
malleolus and positive electrode 10cm above this. Correct position 
of negative electrode determined by visualisation of rhythmic 
flexion of the toes. Intensity level set just below threshold 
determining motor contraction. Stimulation frequency applied at 
10Hz and pulse width of 200 μs in continuous mode. Patients 
asked to apply treatment at least 20 minutes twice daily in their 
own home. For those patients experiencing improvement in 
symptoms after 1 month of treatment, treatment was continued.  
Outcomes Level of subjective improvement for each patient following 1 
month of treatment was the main endpoint with a 10cm visual 
analogue scale. 
CCIS score and FIQL Index KESS score and anxiety and depression 
scale (ADS) were performed at baseline, following 1 month of 
treatment and 3 and 6 months for those who continued therapy. 
Thomas et al. 
2013 
Methods Study Design: Single-centre prospective case-series.   
Follow-up: 6 weeks (1.5 months) i.e. immediately after treatment 
cessation. 
Participants 17 (15 females) patients consecutively recruited (20 originally 
however 3 excluded from analysis due to pregnancy (n=1) and 
unknown (n=2).  Age median (IQR) 61 (24.5). 
Inclusion criteria: Age 18-80 years, FI defined as at least 2 episodes 
per week of involuntary loss of either liquid or solid stool as 
defined by a baseline bowel diary, completed biofeedback and 
conservative therapy, no previous neuromodulation. 
Exclusion criteria: Spinal pathology, recent surgery, peripheral 
vascular disease, previous anorectal surgery within the past year, 
external rectal prolapse, active inflammatory bowel disease, 
pregnancy, inability to apply the device independently. 
Interventions All patients performed treatments at home following one to one 
instruction on the use of TTNS, written instructions and a 
photograph demonstrating the electrode pad and lead position. 
TTNS was performed on both ankles simultaneously for 30-
minutes daily, for a 6-week period. TTNS given using NeuroTrac 
Continence device (Verity Medical Ltd, United Kingtom) via two 
50mm x 50mm electrode pads. The live pad was placed posterior 
and superior to the medial malleolus and the ground pad was 
placed 10cm cephalad to this. Continuous stimulation at pulse 
width 200 microseconds and frequency 10Hz was used. Amplitude 
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was set to produce a sensory stimulus in the ipsilateral foot, at a 
tolerable intensity.  
Outcomes Outcomes were measured at baseline and immediately following 
the 6-week course of treatment. These included two 2-week bowel 
diaries, which recorded frequency of FI episodes, frequency of 
defaecation time and the deferral time to defaecation; a visual 
analogue scale asking patients ‘how happy are you with the way 
your bowels have been functioning’ (range 0, very unhappy to 100, 
very happy); Faecal Incontinence Quality of Life Score (FIQL); 
SMCS (St Mark’s Continence Score) and SF-36. The body mass 
index and ankle circumference were also measured.   
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9.5 Appendix 5: CONFIDeNT subgroup analyses 
 
Results of sub-groups analysis on primary outcome (N = 227) 
 Main treatment effect  Interaction term(s)    
Moderator PTNS vs. 
sham 
95% CI p-
value 
Interaction 
Term 1 
95% CI Interaction 
Term 2 
95% CI Interaction 
term global 
p-value 
 
Sex (M vs. F) OR = 1.143 0.629 to 
2.078 
0.661 OR = 5.418 0.451 to 
65.065 
n/a n/a 0.183 
 
>= 7 FI episodes p/w 
base vs. < 7 
OR = 1.177 0.535 to 
2.590 
0.686 OR = 1.212 0.389 to 
3.776 
n/a n/a 0.740 
 
Age groups (years):    40-60 vs. < 
40 
 60+ vs. < 40  
   <40, 40-60, 60+ OR = 1.575 0.205 to 
12.106 
0.662 OR = 0.745 0.075 to 
7.371 
0.857 0.088 to 
8.385 
0.957 
 
Type of incontinence    Urge only vs. urge & 
passive 
Passive only vs. urge & passive 
Urge or passive or both OR = 1.589 0.730 to 
3.456 
0.243 OR = 0.824 0.185 to 
3.675 
0.424 0.090 to 
1.995 
0.554 
Notes:  
OR (odds ratio) corresponds to the adjusted odds ratio for PTNS vs. sham from a logistic mixed effects model, adjusted for baseline mean FI episodes per week, sex 
and includes a random effect for study centre. 
Missing data were multiply imputed using multilevel multiple imputation to create 10 complete datasets for analysis, the results of which were combined using 
Rubin’s rules. 
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9.6 Appendix 6: CONFIDeNT sensitivity analyses 
Results of sensitivity analysis 1(excludes 16 patients with no FI episodes in baseline bowel diary) 
Outcome Type N Estimate Lower 
CI 
Upper 
CI 
P-value Model 
based ICC 
>= 50% reduction in FIE  OR 211 1.325 0.736 2.385 0.348 <0.001 
        >= 25% reduction in FIE OR 211 1.314 0.747 2.311 0.344 <0.001 
>= 75% reduction in FIE OR 211 1.643 0.775 3.484 0.195 0.212 
100% reduction in FIE OR 211 1.670 0.596 4.674 0.330 0.008 
        Change in FIE beta 211 -2.468 -4.533 -0.403 0.019 <0.001 
Change in urge FIE beta 211 -1.557 -2.881 -0.232 0.021 <0.001 
Change in passive FIE beta 211 -0.736 -1.850 0.378 0.195 0.1 
        FI QoL embarrassment beta 211 0.049 -0.149 0.247 0.630 <0.001 
FI QoL coping beta 211 0.021 -0.172 0.214 0.831 0.116 
FI QoL lifestyle beta 211 0.105 -0.070 0.280 0.236 <0.001 
FI QoL depression beta 211 0.025 -0.294 0.344 0.873 <0.001 
        SF36 physical 
functioning beta 211 -2.025 -7.515 3.464 0.469 <0.001 
SF36 role-physical beta 211 1.646 -8.860 12.152 0.758 n/a 
SF36 bodily pain beta 211 -1.039 -7.114 5.036 0.737 <0.001 
SF36 general health beta 211 0.159 -4.759 5.076 0.949 <0.001 
SF36 vitality beta 211 -2.930 -8.194 2.334 0.273 n/a 
SF36 social functioning beta 211 6.343 0.010 12.676 0.051 0.017 
SF36 role emotional beta 211 -5.461 
-
15.881 4.959 0.302 n/a 
SF36 mental health beta 211 0.031 -4.477 4.540 0.989 0.065 
        St. Mark's continence 
score beta 211 -0.139 -1.163 0.885 0.790 <0.001 
Patient centred 
outcomes beta 211 -0.562 -1.123 -0.001 0.050 <0.001 
EQ-5D index score beta 211 -0.017 -0.081 0.048 0.610 0.019 
GI QoL beta 211 -1.558 -5.566 2.449 0.442 n/a 
Likert scale of success beta 211 0.786 -0.123 1.694 0.091 0.009 
OR (odds ratio) corresponds to the adjusted odds ratio for PTNS vs. sham from a logistic mixed effects 
model, adjusted for baseline mean FI episodes per week, sex and includes a random effect for study 
centre. beta corresponds to the adjusted difference in means for PTNS vs. sham from a linear mixed 
effects model, adjusted for baseline level of outcome (except Likert scale of success), sex and includes a 
random effect for study centre. n/a indicates that the unconditional ICC (intracluster coefficient) was < 0 
and the corresponding outcomes were modelled using linear regression without an adjustment for study 
centre. Missing data were multiply imputed using multilevel multiple imputation to create 10 complete 
datasets for analysis, the results of which were combined using Rubin’s rules. 
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Results of sensitivity analysis 2: excluding centres that recruited <5 patients (2 centres, 4 patients). 
Outcome Type N Estimate Lower 
CI 
Upper 
CI 
P-
value 
Model 
based ICC 
>= 50% reduction in FIE OR 223 1.234 0.693 2.196 0.476 <0.001 
        >= 25% reduction in FIE OR 223 1.220 0.698 2.132 0.485 <0.001 
>= 75% reduction in FIE OR 223 1.634 0.776 3.438 0.196 0.214 
100% reduction in FIE OR 223 1.690 0.609 4.693 0.315 0.006 
        Change in FIE beta 223 -2.158 -4.034 -0.283 0.024 <0.001 
Change in urge FIE beta 223 -1.501 -2.752 -0.25 0.019 <0.001 
Change in passive FIE beta 223 -0.592 -1.637 0.453 0.267 0.094 
        FI QoL embarrassment beta 223 0.020 -0.166 0.206 0.83 <0.001 
FI QoL coping beta 223 0.017 -0.168 0.203 0.855 0.1 
FI QoL lifestyle beta 223 0.092 -0.072 0.257 0.27 <0.001 
FI QoL depression beta 223 0.010 -0.301 0.321 0.945 <0.001 
        SF36 physical functioning beta 223 -1.479 -6.674 3.717 0.576 <0.001 
SF36 role-physical beta 223 1.462 -8.684 11.608 0.777 n/a 
SF36 bodily pain beta 223 -0.844 -6.712 5.024 0.778 <0.001 
SF36 general health beta 223 -0.021 -4.676 4.634 0.993 <0.001 
SF36 vitality beta 223 -3.857 -8.875 1.161 0.131 n/a 
SF36 social functioning beta 223 5.419 -0.585 11.423 0.078 0.012 
SF36 role emotional beta 223 -5.297 15.405 4.811 0.303 n/a 
SF36 mental health beta 223 -0.877 -5.237 3.483 0.693 0.031 
        St. Mark's continence 
score beta 223 0.052 -0.928 1.032 0.917 <0.001 
Patient centred outcomes beta 223 -0.575 -1.121 -0.029 0.039 <0.001 
EQ-5D index score beta 223 -0.020 -0.082 0.042 0.524 0.017 
GI QoL beta 223 -1.269 -5.182 2.643 0.521 n/a 
Likert scale of success beta 223 0.856 -0.016 1.728 0.055 0.02 
OR (odds ratio) corresponds to the adjusted odds ratio for PTNS vs. sham from a logistic mixed effects 
model, adjusted for baseline mean FI episodes per week, sex and includes a random effect for study 
centre. 
beta corresponds to the adjusted difference in means for PTNS vs. sham from a linear mixed effects 
model, adjusted for baseline level of outcome (except Likert scale of success), sex and includes a random 
effect for study centre. 
n/a indicates that the unconditional ICC (intracluster coefficient) was < 0 and the corresponding 
outcomes were modelled using linear regression without an adjustment for study centre. 
